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 Summary 
 
It is widely accepted that the ultimate response to antigen-specific signals is also 
influenced by accessory receptors-ligand engagements that deliver costimulatory signals 
while strengthening the interaction between the cells. CD6, a type I cell surface 
glycoprotein, whose expression is largely restricted to peripheral T lymphocytes and 
medullary thymocytes, has been known to play a role in T cell activation. We have cloned 
by PCR the rat homologue of CD6 and biochemical analysis showed that CD6 interacts 
with CD5 at the surface of T lymphocytes and that the fraction of CD5 associated with 
CD6 was highly phosphorylated in kinase assays, in marked contrast with the low level of 
phosphorylation of CD5 associated with either TCR or CD2. Examination of protein 
kinases associating with CD6 showed the involvement of Lck, Fyn, and ZAP-70, and 
additionally the Tec family kinase Itk, which is absent from CD2, CD5 and TCR 
complexes. Together these results suggest that CD6 has an important role in the 
regulation of CD5 tyrosine phosphorylation, probably due to its unique feature of 
associating with kinases of different families. While cloning the rat homologue we 
discovered a novel isoform of the accessory molecule CD6 which lacks the CD166-
binding domain, CD6∆d3. Subsequently, four novel human extracellular isoforms were 
identified and cloned, including isoforms lacking domain 1 or domain 3. Ensuing studies 
showed that the differential expression of the SRCR domain 3 resulted in a remarkable 
functional difference: whereas full-length CD6 targeted to the immunological synapse, 
CD6∆d3 was unable to localize at the T cell:APC interface during antigen presentation. 
This new finding constitutes a rare example of an alternatively splice-coded isoform with a 
distinct physiological function. Moreover, CD6∆d3 is markedly up-regulated upon 
activation of T lymphocytes, partially substituting full-length CD6, as evaluated by 
immunoblotting and by flow cytometry using antibodies recognizing SRCR domains 1 and 
3 of human CD6. This isoform is considerably expressed in a significant number of 
thymocytes, constituting the sole species in a small percentage of cells, suggesting that 
CD6 switching between full-length and ∆d3 isoforms may be involved in thymic selection 
as well. We have also focused our attention in the accessory receptor CD2 and have 
addressed the mechanisms that control the localization of rat CD2 at the plasma 
membrane, as well as its redistribution induced upon activation. We found no evidence 
that rat CD2 was subjected to lipid modifications that could favor the translocation to lipid 
rafts, preferred sites for signal transduction. On the other hand, using Jurkat cells 
expressing different CD2 and Lck mutants, we showed that the association of CD2 with 
the rafts fully correlates with its capacity to bind to Lck. As CD2 physically interacts with 
both Lck and Fyn, preferentially inside lipid rafts, and reflecting the increase of CD2 in lipid 
 
 rafts following activation, CD2 can mediate the interaction between the two kinases and 
the consequent boost in kinase activity in lipid rafts. These results are in agreement and 
contribute to the current view that the raft localization of cell surface molecules is mainly 
driven by protein-protein interactions. 
 
 Sumário 
 
A resposta específica resultante do reconhecimento do antigénio pelo receptor dos 
linfócitos T é influenciada por co-receptores que, quando associados aos respectivos 
ligandos, fornecem sinais co-estimulatórios e fortalecem a interacção entre os linfócitos T 
e as células apresentadoras de antigénio. O CD6 é uma proteína transmembranar que 
está envolvida em processos de activação de células T e cuja expressão está largamente 
restringida a linfócitos T periféricos e a timócitos da zona medular do timo. Nesta 
investigação, clonou-se a proteína homóloga de CD6 de rato e demonstrou-se que este 
co-receptor se associa ao CD5, à superfície de linfócitos T. Verificou-se também que a 
fracção de CD5 associada ao CD6 se apresentava fortemente fosforilada, contrastando 
assim com os baixos níveis de fosforilação do CD5 associado ao TCR e ao CD2. O CD6 
tem a capacidade de se associar com diferentes cinases de tirosinas, tais como, a Lck, 
Fyn, ZAP-70 e Itk. Os resultados obtidos sugerem que o CD6 tem um papel importante 
na regulação da fosforilação de tirosinas do CD5 e que este facto se deve, 
provavelmente, à capacidade do CD6 de se associar com estas diferentes cinases. Nos 
trabalhos que se seguiram à clonagem da proteína CD6 de rato, verificou-se a existência 
de uma isoforma, resultante de “splincing” alternativo, que não possui o domínio de 
ligação ao ligando-CD166, que se denominou CD6∆d3. Posteriormente, identificaram-se 
e clonaram-se quatro novas isoformas extracelulares de CD6 humano, entre as quais 
isoformas sem domínio 1 ou domínio 3. A expressão diferencial do domínio 3 resulta 
numa função alternativa: enquanto a molécula de CD6 completa se encontra na sinapse 
imunológica, a isoforma CD6∆d3 não é recrutada para a zona de contacto entre as 
células T e as células apresentadoras de antigénio. Este resultado constitui um raro 
exemplo de uma molécula resultante de “splicing” alternativo com uma função fisiológica 
distinta. Verificou-se, usando técnicas de imunodetecção e de citometria de fluxo com 
anticorpos específicos para os domínios 1 e 3, que a expressão da isoforma CD6∆d3 
está aumentada em linfócitos T activados. Mais ainda, esta isoforma é consideravelmente 
expressa em linfócitos, sendo a única presente num número significativo de células, 
sugerindo um papel na selecção tímica. Neste trabalho investigou-se outro co-receptor, o 
CD2. Foram determinados os mecanismos que controlam a localização do CD2 de rato 
na membrana celular, assim como a sua redistribuição após activação. Não foram 
encontradas evidências de que o CD2 de rato seja sujeito a modificações lipídicas que 
favoreçam a sua translocação para os “rafts”, locais preferenciais de transdução de sinal. 
Utilizando células T humanas Jurkat, que expressavam diferentes mutantes de CD2 e de 
Lck, foi possível demonstrar que a associação do CD2 com os “rafts” é determinada pela 
capacidade do CD2 de se associar com a Lck. O CD2 associa-se com a Lck e a Fyn, 
 
 preferencialmente nestes locais da membrana facilitando a interacção entre as duas 
cinases. Assim sendo, o aumento do CD2 nos “rafts” verificado após activação pode 
induzir a amplificação da actividade das cinases nos “rafts”. Estes resultados estão em 
conformidade e fortalecem a visão corrente de que a localização de determinadas 
proteínas nos ”rafts” é fundamentalmente determinada por interacções entre proteínas. 
 
 Sommaire 
 
Le concept que plusieurs molécules accessoires influencent la réponse des lymphocytes 
T déclenchée par la reconnaissance de l’antigène est largement accepté. CD6, une 
glycoprotéine de surface de type I dont la expression est spécifique des lymphocytes T et 
des thymocytes médullaires, joue un rôle méconnu dans la activation des lymphocytes T. 
Nous avons cloné CD6 de rat par PCR et ensuite montré que le CD6 interagit avec le 
CD5 à la surface des lymphocytes T. En plus, nous avons démontré que la fraction de 
CD5 en association avec le CD6 présente des forts niveaux de phosphorylation dans des 
essais kinase, contrairement à la fraction associé avec le TCR ou le CD2. L’analyse des 
différentes kinases associées avec le CD6 a démontré l’implication de Lck, Fyn, ZAP-70 
et Itk, une kinase de la famille des Tec protéine kinases, absente des complexes CD2, 
CD5, et TCR.  L’ensemble de ces résultats suggère que le CD6 a un rôle clé dans la 
régulation des niveaux de phosphorylation du CD5, possiblement en raison de son 
association avec des protéines kinases de différentes familles. Nous avons aussi 
découvert une nouvelle isoforme du CD6, CD6∆d3, dont le domaine de liaison au ligand 
CD166 est absent. Ensuite, nous avons identifié et cloné quatre nouvelles isoformes du 
domaine extracellulaire chez l’homme, notamment des isoformes sans les domaines 1 et 
3.  Des études qui ont suivi ont montré que l’expression différentielle du domaine SRCR 3 
produit des effets fonctionnels importants : seule la forme entière du CD6 est localisé à la 
synapse immunologique lors du contact cellule T : APC en présence d’antigène. Ceci est 
un exemple rare de divergence fonctionnelle entre produits d’épissage alternatif du même 
transcrit. L’expression de CD6∆d3 augmente de forme significative après activation des 
lymphocytes T, substituant partiellement  la forme entière de la molécule, comme le 
démontrent des expériences de western blot et cytométrie en flux. Cette isoforme est 
aussi présent dans un nombre significatif de thymocytes et c’est la seule isoforme détecté 
dans une fraction de thymocytes, ce que suggère l’existence d’un mécanisme de 
remplacement de la molécule de CD6 entière par la forme tronquée au cours de la 
sélection thymique. Nous avons aussi étudié les mécanismes impliqués dans le contrôle 
de la localisation de la molécule accessoire CD2 de rat dans la membrane cellulaire et au 
cours de l’activation des lymphocytes T. Nos résultats montrent que le CD2 n’est pas 
sujet à des modifications favorisant la translocation vers les rafts lipidiques. Au contraire, 
la localisation du CD2 dépende entièrement de sa capacité à lier Lck dans les rafts. 
Comme le CD2 interagit avec Lck et Fyn préférentiellement à l’intérieur des rafts 
lipidiques, le CD2 pourrait y jouer un rôle dans l’interaction entre les deux kinases et ainsi 
contribuer au  renforcement de l’activité kinase après activation des lymphocytes T par 
l’antigène dans les rafts. Nos résultats contribuent au concept que des interactions du 
 
 type protéine-protéine jouent un rôle majeur dans le repositionnement des molécules de 
surface dans les rafts lipidiques.   
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I. Introduction
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Chapter I - Introduction 
 
 
The vertebrate immune system recognizes infectious agents and then uses innate 
and adaptive responses to eradicate them. The adaptive immune response, which plays a 
critical role in this process, relies on diverse antigen-specific B and T cell receptors (BCRs 
and TCRs). Together these receptors can discriminate essentially the total world of 
potential foreign antigens. 
T lymphocytes play a key role in controlling the adaptive immune response by 
producing cytokines and in some cases acting as cytotoxic cells to kill infected host cells. 
Activation of T lymphocytes involves the recognition of microorganism-derived peptides 
bound to major histocompatibility complex (MHC) molecules on the surface of antigen 
presenting cells (APCs) by the TCR. The tight regulation of this recognition process is 
thus critical to prevent inappropriate and potentially harmful responses to self-antigens. 
Productive stimulation or positive TCR engagement leads to a succession of events that 
include activation of protein kinases and phosphorylation of many substrates, including 
the TCR, and the formation of protein complexes containing adaptors and enzymes. 
These “proximal” events culminate in cellular responses such as proliferation, 
differentiation and secretion of cytokines and growth factors. 
The ultimate response to antigen-specific signals is also influenced by accessory 
receptor-ligand engagements that deliver costimulatory signals while strengthening the 
interaction between the cells. How can such complexity and specificity be achieved 
through the stimulation of a single class of receptors? How are the decisions made? The 
answer must depend on the different biochemical activation pathways. Although the TCR 
signal transduction pathways have been extensively studied there are still critical 
questions that remain unanswered and conflicting data that should be reconciled. 
In this chapter a brief description of current knowledge and recent advances 
towards the understanding of basic events that regulate T lymphocyte activation is 
presented. It is now well documented that initiation and propagation of the TCR-generated 
signal is critically dependent on the transient assembly and spatial reorganization of 
specific components used by T cells. These include accessory cell surface receptors and 
associated enzymes that will be described here in more detail. 
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1. Signal transduction in T lymphocytes 
 
1.1. TCR/CD3 complex 
 
The T cell receptor is a multicomponent structure that comprises two functional 
subunits. The antigen-binding subunit, that recognizes peptide-MHC complex (pMHC), is 
a highly polymorphic heterodimer of clonotypic α and β chains [1, 2], or γ and δ in 2-5% of 
T lymphocytes [3]. These membrane-spanning chains show great similarity to the domain 
structure of the immunoglobulins (Igs) displaying one variable and one constant 
extracellular domain [4]. The variable region domains of α and β or γ and δ come together 
to form the antigen binding cleft and the mechanisms for generating the vast TCR 
diversity and antigen specificity involve rearrangements of the multiple germline variable 
(V), diversity (D) and joining (J) gene segments. The TCR β and δ chain are assembled 
from V, D and J segments while TCR α and γ chain are assembled from V and J 
segments (reviewed in [5]). The affinity of αβ TCRs binding to pMHC is relatively low 
(Kd∼1–100 µM) and this binding occurs through complementarity-determining regions 
present in their variable domains [6]. 
TCR heterodimers are non-covalently associated with the non-polymorphic 
transmembrane proteins CD3γ, δ and ε chains and a ξ homodimer [7, 8], which form the 
signal transducing subunit. A coordinated expression of the ligand-recognizing and signal-
transducing subunits is required to achieve full expression of the TCR/CD3 complex on 
the cell surface. However, despite precedent efforts, the stoichiometry of the TCR/CD3 
complex is still unclear. The complex is formed in the endoplasmic reticulum (ER) and is 
assembled after a series of pairwise interactions involving the formation of dimers of CD3ε 
with either CD3γ or CD3δ. These dimers assemble with TCR α and TCR β chains, and 
finally, the ξ homodimer is added to allow export of the full complex from the ER [9-12]. As 
a result, a typical TCRαβ is associated with at least six signaling subunits, including 
CD3εγ and CD3εδ heterodimers and CD3ξξ homodimer. 
Despite the extensive work performed in the attempt of unravelling TCR/CD3 
complex assembly, the enormous amount of conflicting data on this subject reflects the 
experimental difficulties of examining such a complex receptor structure in the available 
cellular systems. There have been two major models of different stoichiometry and 
valency proposed for the TCR/CD3 complex assembly. A model in which a single TCR 
heterodimer associates with all signaling components [11, 13, 14], in contrast to the model 
in which two TCRαβ heterodimers form two hemicomplexes containing either CD3εγ or 
CD3εδ dimers which become associated via the ξ homodimer [15, 16]. More recent data 
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from Call et al., using direct biochemical approaches instead of transgenic mice, support 
the model were the TCR/CD3 complex is monovalent, with a stoichiometry of 
TCRαβ−CD3εγ−CD3εδ−ξξ [13]. 
The TCR α and β chains have very small cytoplasmic tails and are unable to 
communicate signals produced by antigen recognition. Therefore, the CD3 and ξ 
components of the receptor are accountable for transmitting the signal into the cell. They 
do so via a conserved amino acid motif present in their cytoplasmic tails, consisting of the 
sequence YXX(L/I)X6-8YXX(L/I) and known as immunoreceptor tyrosine based activation 
motif (ITAM) [17-19]. Given the current structural model of the TCR complex a total of 10 
ITAMs are present in a single receptor complex: each ξ chain contains three ITAMs in 
tandem while each of the CD3 chains has only one of these modules [20].  
Two non-exclusive models incorporating previous results were put forward by 
Pitcher et al. to argue the contribution of the ten ITAMs to T-cell signaling [21]. The ITAM 
multiplicity model describes a functional redundancy for distinct ITAMs. In fact, several 
reports support this view: a CD8/ξ chimera was able to induce early and late signaling 
events that were undistinguishable from those elicited by the intact TCR, in the absence of 
CD3 chains [18]. Later on the same authors have also established that trimerization of the 
ξ ITAMs yielded more intense intracellular signals than single ITAMs, implying that ξ 
ITAMs functioned in a cumulative manner and induce a similar pattern of tyrosine 
phosphorylation [17]. Moreover, chimeric receptors comprising the cytoplasmic domains 
of TCRξ versus CD3ε were equally capable of restoring thymopoeisis [22] implying 
functional redundancy between the TCRξ and CD3ε ITAMs. 
The differential signaling model, which proposes distinct functions for the CD3γ, δ 
and ε and TCRξ modules is also supported by other studies which report that activation of 
T cells through either TCRξ or CD3ε results in a distinct pattern of tyrosine 
phosphorylation and in specific interactions with a number of intracellular proteins [23-26]. 
The authors suggested that T-cell development, signal transduction and effector functions 
incorporate both ITAM multiplicity and differential signaling, the relative contributions may 
depend on the avidity of the TCR for its particular cognate antigen, the developmental or 
differentiation state of a T cell, and/or the environmental context in which a T cell is 
activated.  
A number of mechanisms can be envisaged for how information is transferred 
upon TCR triggering. Several models were proposed even though they converge to the 
idea that ligand engagement results in a perturbation of the extracellular region of the 
TCR/CD3 complex through either a rigid body or intermolecular conformational change. 
Also, multimerization of TCR/CD3 complex into dimers or higher order complexes is 
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suggested as a common model for TCR triggering  [27]. Although different models 
invoking aggregation, conformational changes and segregation of the TCR/CD3 complex 
are proposed they are not mutually exclusive and triggering may involve a combination of 
all mechanisms.  
Full activation through the T cell receptor results in the phosphorylation of multiple 
ITAMs that become high-affinity binding sites for intracellular proteins that couple antigen 
recognition to the subsequent cascade of downstream intracellular signals. These events, 
essential requirements for the cellular effector functions of T cells, particularly, the 
signaling pathways and the signaling machinery will be briefly described in this chapter. 
 
 
1.2. Signaling pathways 
 
1.2.1. Ca2+/PLCγ signaling pathway in T cells 
 
Activation of T cells triggers the recruitment of tyrosine kinases that initiate a 
signaling cascade that transmits the stimulus across the membrane giving rise to the 
phosphorylation and activation of phospholipase C-γ (PLCγ) [28, 29]. Hydrolysis of inositol 
phospholipids, mainly phosphatidylinositol-4,5-bisphosphate due to the activity of PLCγ, at 
the inner leaflet of the plasma membrane [30-32] generates the second messengers 
inositol-1,4,5-trisphosphate (IP3), which causes entry of Ca2+ to cytosol from the ER and 
the extracellular space; and 1,2-diacylglycerol (DAG), which activates a protein kinase C 
(PKC) dependent pathway [33].  
 
 
1.2.1.1. Calcium signaling: triggering, release and influx 
 
The rise of intracellular free calcium ([Ca2+]i) is recognized as a crucial triggering 
signal for T cell activation and the nature of this signal is though to be strongly influenced 
by factors such as T cell type and maturation state as well as APC and antigen 
characteristics. Because some of these factors are known to influence the outcome of 
TCR triggering towards activation, anergy or death, it is reasonable to imagine that 
together with the large number of participants in Ca2+ signal generation they add 
complexity for signal modulation [34].  
The T cell Ca2+ response begins with the binding of IP3 to its receptors in the ER 
and plasma membranes causing the opening of Ca2+ channels which leads to the rising of 
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[Ca2+]i [35, 36]. Multiple IP3 molecules bind to the tetrameric receptor illustrating a highly 
cooperative mode of binding of the ligand. The outcome is that the release generates a 
rapid transient peak in [Ca2+]i with half of the stored Ca2+ being released within 200ms 
after addition of saturating (1µM) IP3 [37]. Although the role of IP3 in the initial Ca2+ 
release is evident, it is still not clear how Ca2+ stores are maintained depleted for long 
periods, sustaining activation of Ca2+ influx. Indeed, Putney showed that if Ca2+ stores 
were kept in a depleted state, Ca2+ influx was maintained even though average IP3 levels 
have returned to near basal levels [38]. One possible explanation introduced by Guse and 
colleagues, was that cyclic adenosine diphosphoribose (cADPR) takes over IP3 in keeping 
the stores empty by activating the ryanodine receptor (RyR), another ER Ca2+ release 
channel. While IP3 acts in the initial phase of Ca2+ signaling, cADPR is involved in both 
initial and subsequent sustained phases [39]. An alternative possibility is that local IP3 
generation remains sufficiently high to keep the IP3 receptor channel open. It is also 
possible that once depleted by IP3, the Ca2+ stores cannot refill, due to a massive Ca2+ 
leak, as was demonstrated during adhesion-induced T cell priming [40].  
Moreover, a role for nicotinic acid adenine dinucleotide phosphate (NAADP+) as a 
Ca2+ mobilizing compound in T cells, has been described [41]. The experiments 
established that NAADP+ acts as a first messenger to provide a Ca2+ trigger which then 
activates both IP3- and cADPR -mediated Ca2+-signaling, in a Ca2+-induced Ca2+-release 
mechanism. More recently, Langhorst and colleagues, using combined microinjection and 
single cell calcium imaging, show data that demonstrate that in T cells RyRs are 
quantitatively the major intracellular Ca2+ release channels involved in Ca2+ mobilization by 
NAADP+, and that such Ca2+ release events are largely amplified by Ca2+ entry [42].  
In resting T lymphocytes, due to the thin cytoplasmic compartment, the amount of 
Ca2+ found in intracellular stores is usually extremely low. Since the amplitude of Ca2+ 
release is small, sustaining the Ca2+ response is mainly achieved by Ca2+ influx, through 
store-operated Ca2+ channels, named CRAC (Ca2+ release-activated Ca2+ channels). 
These are highly Ca2+-selective and essential for generating the prolonged [Ca2+]i 
elevation required for the expression of T-cell activation genes. Although considerable 
efforts have been focusing on the elucidation of the molecular mechanism of store-
operated Ca2+ entry, important questions remain and the models proposed are not fully 
satisfactory (see [43] for a review). 
Lymphocyte activation does not lead to a unique outcome. There are multiple 
processes that originate from an intracellular Ca2+ increase, being enzymatic activation, 
cytoskeleton reorganization and exocytosis the nearly immediate, and gene activation the 
more delayed. A central but elusive aim is to know how different patterns of Ca2+ signaling 
can lead to such diverse and selective effects, namely the activation of different 
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transcription factors. The nuclear factor for activated T cells (NFAT), a transcription factor 
that regulates the expression of several T-cell proliferation associated genes including IL-
2 (interleukin-2), is established as the main target in sensing [Ca2+]i oscillations. Ca2+ 
activates the phosphatase calcineurin, which in turn dephosphorylates and activates 
NFAT [44].  
Studies performed in Jurkat T cell line and on rat basophilic leukaemia cells 
showed the relevance of Ca2+ oscillations on gene activation [45, 46]. The results 
suggested that for low levels of stimulation, oscillations in [Ca2+]i are more efficient in 
activating NFAT. Hence, [Ca2+]i oscillations may function to maximize the sensitivity of low 
antigen concentration. Moreover, the frequency of the oscillations appears to direct cells 
into diverse patterns of activation. 
 
 
1.2.1.2. Coupling TCR to PLCγ1 activity  
 
Mobilization of Ca2+ via activation of PLCγ1 is crucial for the activation of 
lymphocytes by antigens (Ag) and consequently the understanding of the mechanism of 
PLCγ1 activation following TCR engagement of an extreme importance. T cells 
predominantly express the PLCγ1 isoform which is ubiquitously expressed, whilst PLCγ2 
is limited to cells of hematopoietic lineage [47]. All PLC enzymes contain a split catalytic 
domain comprised of two conserved regions, termed X and Y. In PLCγ, these regions are 
separated by a regulatory domain which includes a tandem of Src-homology 2 (SH2) 
domains followed by a single Src-homology 3 (SH3) domain. PLCγ1 contains also at least 
5 potential sites for tyrosine phosphorylation [48]. All these features provide PLCγ1 with 
the ability to interact with many different intracellular proteins. 
Triggering of the TCR leads to the recruitment of PLCγ1 towards its substrate at 
the membrane to the TCR-proximal signaling complex, which is followed by PLCγ1 
phosphorylation and activation [49, 50]. Given that the TCR itself as no intrinsic kinase 
activity, a number of proteins that are involved in the formation of the TCR signaling 
complex have also been shown to be implicated in the regulation of PLCγ1. The hallmark 
of PLCγ1 recruitment is its association with the adaptor protein LAT (linker for activation of 
T cells), through the interaction of PLCγ1 N-terminal SH2 domain with phosphotyrosine 
132 of LAT [51]. SLP-76 (SH2-domain containing leukocyte protein of 76 KDa), another 
adaptor protein is constitutively associated with Gads and after TCR engagement Gads 
binds to tyrosine-phosphorylated LAT through its SH2 domain [52]. The presence of a 
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trimolecular SLP-76-Gads-LAT complex generates a platform for the recruitment of 
multiple signaling molecules, such as PLCγ1, Grb2, Nck, Vav, c-Cbl and Itk [48]. 
Recently, a model summarizing the current knowledge of PLCγ1 recruitment and 
activation was put forward. Braiman and colleagues [48], propose that upon TCR 
triggering, PLCγ1 is recruited to the SLP-76-Gads-LAT complex but, this binding through 
the N-terminal SH2 domain of PLCγ1 is not sufficient for PLCγ1-LAT association to be 
kept. The SH3 or the C-terminal SH2 domain of PLCγ1, with the participation of Vav, c-Cbl 
and SLP-76 are required to stabilize PLCγ1 recruitment, as shown in figure 1. 
Furthermore, they report that all three PLCγ1 SH domains are necessary for an efficient 
phosphorylation and activation of PLCγ1 in T cells. These findings are in contradiction with 
the previous current model, which suggested that the N-terminal SH2 domain of PLCγ1 
was both necessary and sufficient for its recruitment and phosphorylation. The molecules 
and their signaling modules described above will be dealt with in more detail in the 
following sections. 
 
Figure 1. Schematic model of PLCγ1 recruitment and activation. Taken from [48]. 
 
 
1.2.2. Protein Kinase C-θ (PKCθ) functions 
 
The importance of PKCθ in T-cell biology stems from the fact that pharmacological 
agents, such as phorbol esters synergize with calcium ionophores that respectively 
activate PKCθ and elevate calcium levels, are able to mimic many aspects of antigen 
receptor triggering. Another relevant aspect is that upon TCR activation the DAG 
produced, resulting from PLCγ1 activity, is a PKC-activating second messenger [53]. T 
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cells express several PKC isotypes, but PKCθ found in T cells and in muscle cells, has an 
expression profile that is unique and distinct from all other PKC [54].  
PKCθ is a crucial serine/threonine kinase which as been implicated in the 
regulation of important transcription factors involved in T cell activation and the production 
of T cell survival factors such as IL-2. The transcription factor activator protein-1 (AP-1) is 
composed of two protein components: Jun and Fos. Jun proteins are in the cytoplasm of 
resting cells and translocate to the nucleus after being phosphorylated by c-Jun N-
terminal kinase (JNK) where they bind Fos to form AP-1 complex. It was shown that PKCθ 
is able to activate AP-1, which has an important role in the induction of genes such as the 
IL-2 gene. More specifically, it was reported that PKCθ is capable of activating JNK 
leading to AP-1 activation, but the physiological significance of this activation is unclear 
given that PKCθ-deficient mice show normal TCR/CD28-induced JNK activation. Another 
transcription factor activated by PKCθ is NFAT; this conclusion came from the observation 
that in one of the two knockout mice for PKCθ shows a deficient mobilization of NFAT. 
The final pathway in which PKCθ is reported to be involved is that of NF-κB activation. 
Both PKCθ-deficient mouse strains show a deficient stimulation of both AP-1 and NF-κB 
leading to a severe defect in TCR/CD28-induced IL-2 production and proliferation [53, 55]. 
PKCθ is therefore an essential regulator of several pathways critical to T cell activation 
ultimately affecting IL-2 production. 
 
 
1.2.3. Ras regulation in T cells 
 
 The general interest in Ras stems from the fact that is was early on recognized as 
an oncogene, regulating pathways that lead to cellular proliferation and survival. 
Lymphocytes are among the cells in which the function of Ras has been extensively 
studied [56]. In fact, the guanine nucleotide binding protein, Ras, was shown to 
accumulate in its active GTP-bound form after TCR engagement [57]. Ras as also been 
shown to be required for thymocyte development, T cell proliferation and IL-2 production 
[58]. Like for all GTPases, the binding cycle of Ras is controlled by two main classes of 
regulatory proteins: guanine nucleotide exchange factors (GEFs) that promote the 
formation of active GTP-bound Ras complexes, and GTPase activating proteins (GAPs) 
which stimulate GTPase inactivation [59]. The Ras GEF Sos, the mammalian homologue 
of the Drosophila “Son of Sevenless” protein, associates constitutively with the SH3 
domain of an adaptor molecule Grb2 [60]. In activated T cells, tyrosine-phosphorylated 
LAT interacts with SH2 domain of Grb2, thereby forming complexes that regulate the 
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membrane localization and catalytic activity of Sos. Phosphorylated LAT also acts as the 
scaffold of other signaling pathways: it can bind the SH2 domain of PLCγ1, possibly 
coupling the two pathways [51, 59]. The recognition of another Ras GEF in lymphocytes, 
Ras guanyl nucleotide-releasing protein (GRP), which has a DAG/phorbol-ester binding 
domain, supports a model where Ras is activated via DAG recruitment of Ras GRP. 
Several lines of evidence suggest that this model is not completely satisfactory and it may 
be that depending on the cell type, either DAG/GRP or Gbr2/Sos pathways are more 
relevant [59].  
 Once Ras is activated it couples to several effector signaling pathways, the best 
characterized being Raf-1/MEK/Erk1,2 pathway. Raf-1, a serine/threonine kinase, is 
recruited to the plasma membrane where it is activated and subsequently activates MEK 
(MAPK/Erk kinase) that triggers the mitogen-activated protein kinases (MAPKs) Erk1 and 
Erk2 [56]. However, the Raf-1/MEK/Erk pathway is not the only Ras effector signaling 
pathway. Activated Ras also couples to signaling pathways controlled by the Rac/Rho 
GTPases [59]. Moreover, several Ras effectors, proteins whose function is regulated by 
the binding of GTP-Ras, have been described. This is the case of phosphatidylinositol 3-
kinase (PI3K), which activates Akt thus promoting cell survival [56]. 
 In peripheral T cells, the ultimate Ras function is to activate transcription factors 
that are involved in cytokine gene induction, including AP-1 and NFAT. It is know evident 
that the plasma membrane is not the only platform for Ras/MAPK signaling. This signaling 
pathway has also been viewed on endosomes, the ER, the Golgi apparatus and 
mitochondria but it appears that the Golgi apparatus is the primary platform for signaling. 
Studies with a spatiotemporal fluorescent probe revealed that the pathway of activation on 
the Golgi involves PLCγ and Ras GRP1 and thereby differs from the Grb2/Sos-mediated 
pathway for Ras activation on the plasma membrane. Thus, compartmentalized signaling 
can be accomplished by using distinct upstream pathways [56].  
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Figure 2. T cell receptor signaling events leading to activation of transcription factors. This 
figure presents an overview of some of the key signaling events triggered by the binding 
of peptide- MHC to the T cell receptor (TCR/ CD3). Taken from [61]. 
 
 
1.3. Non-receptor molecules and modules involved in signal transduction in T 
cells 
 
Proximal events that immediately follow TCR triggering include the activation of 
protein kinases and phosphorylation of many substrates, including the TCR/CD3 complex 
itself, and the assembly of signaling pathways and networks, that involve numerous 
enzymes and adaptor proteins. It is now indisputably accepted the idea that specific 
protein-protein interactions control numerous cellular processes. Other than temporal and 
spatial factors, the specificity of pairwise binding events and the subsequent protein 
networks established, largely determine the specificity of signal transduction.  
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1.3.1. Protein interaction domains: Src homology domains 
 
 Generally, regulatory proteins are composed of domains, in a cassette-like fashion, 
that have enzymatic activity or mediate molecular interactions. The latter, the modular 
interacting domains, are conserved regions specialized in mediating interactions between 
proteins or between proteins and other molecules such as lipids or nucleic acids. By doing 
so, they can target proteins to a specific subcellular location, confer a means for 
recognition of protein posttranslational modifications, centre the establishment of 
multiprotein complexes and control the conformation, activity and substrate specificity of 
enzymes, hence directing specific cellular responses to external signals [62]. Among all 
protein interaction modules, the Src homology domains are one of the best characterized 
members. These domains were first recognized as regions of sequence similarity between 
the non-catalytic domains of the Src family of tyrosine kinases and the divergent signaling 
proteins Crk and PLCγ1 [63, 64]. Since these modules were first noted in proteins of the 
Src family they were designated Src-homology 2 (SH2) and Src-homology 3 (SH3) 
domains [65].  
SH2 domains are modules of about one hundred amino acids that in addition to 
their common ability to bind to phosphotyrosine recognize between 3–6 residues C-
terminal to the phosphorylated tyrosines in a fashion that differs from one SH2 domain to 
another. The SH2 domain comprises a central anti-parallel β-sheet flanked by two α-
helices which form a positively charged pocket on one side of the β-sheet for binding of 
the phosphotyrosine moiety of the ligand and an extended surface on the other for binding 
residues C-terminal to the phosphotyrosine [66]. Indeed, specificity of SH2 domains 
seems to be determined by the recognition of these C-terminal residues. For instance, it 
was shown by Songyang and collegues [67] that the SH2 domains of the PI3K bind 
preferentially to phosphorylated YMXM motif, while the Src SH2 domain bound to an 
optimal phosphopeptide with a YEEI motif. The same author also demonstrated that Grb2 
SH2 domain binds phosphorylated YXN sequences [68]. The specificity can also be 
increased if proteins have two SH2 domains in tandem, such is the case of ZAP-70 (zeta-
chain-associated protein 70), SHIP2 and PLCγ1 [66]. 
After TCR engagement, tyrosine phosphorylation of receptor tyrosine kinases 
(RTK) acts as a switch to recruit SH2-containing targets. These targets can function by 
simply binding to the receptor, and therefore, juxtaposing them next to membrane 
associated substrates. Illustrating this re-location is PLCγ1, PI3K and Ras GAP, that after 
binding through their SH2 domains to the cytoplasmic tail of RTK come closer to the 
membrane, where their substrates are located [69]. In addition, SH2 domains can function 
to regulate enzymes activity through intramolecular interactions. In the case of 
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autoinhibited Src-family kinases, the SH2 domain binds to a C-terminal phosphotyrosine 
site, positioning the SH3 domain to recognize the linker sequence between the SH2 and 
kinase domains [70-72]. One more function of the SH2-containing protein once bound to 
the receptor is simply to become a substrate for phosphorylation, resulting either in a 
conformational change or in the creation of docking sites for additional SH2 proteins. 
SH3 domains are a group of small interaction modules of about sixty amino acids 
that are ubiquitous in eukaryotes. These domains were initially shown to always bind to 
proline-rich sequences and the PXXP was identified as the core conserved binding motif 
[73]. The SH3 domains have a relatively flat hydrophobic binding surface that contains 
three shallow pockets of which two are occupied by the two hydrophobic prolines in the 
PXXP motif whereas the third is negatively charged and interacts with a basic residue 
either NH2- or COOH-terminal of the PXXP core [74]. A number of SH3 domains have 
also been shown to recognize a (R/K)XX(R/K) motif, were positively charged residues 
appear to play a dominant role. These include SH3 domains form PLCγ1, Grb2 and Nck 
[75]. 
These domains can regulate a variety of biological activities as diverse as signal 
transduction, protein and vesicle trafficking, cytoskeletal organization, cell polarization and 
organelle biogenesis [76, 77]. Their function is in several circumstances overlapping to 
those of the SH2 domains. Although the affinity of SH3 domains for their ligands is 
relatively low and selectivity is generally marginal, SH3 domains show specific biologically 
significant interactions. One of the best examples of a specific SH3-mediated 
intermolecular interaction, which is also evidence of their function as protein re-locaters, is 
the role of Grb2 in Ras activation. Grb2 has a SH2 domain flanked by two SH3 domains 
that bind to the proline-rich tail of Sos.  Sos is recruited by Grb2 to the tyrosine 
phosphorylated sites at the membrane, where Ras (the substrate) is located. For that 
reason, Grb2 couples tyrosine phosphorylation to the activation of Ras [78]. An illustration 
of the importance of intramolecular SH3-mediated interactions comes from the regulation 
of the Src family of kinases (mentioned above). In this case SH2 and SH3 domains 
together with phosphorylation of at least two regulatory sites are involved in complex 
regulatory interactions, such as a delicate conformational switch. 
Since the interaction between an SH3 and a proline-rich sequence is relatively 
weak, and that these domains are able to interact with several different ligands, is has 
been suggested that affinity and selectivity could result from the collective contribution of 
sub-optimal interactions [75]. Providing an alternative for increasing specificity are factors 
such as cellular context, co-operative events and subcellular localization. The importance 
of the latter is depicted by the CD2BP2 (CD2-binding protein). In T cells, Fyn SH3 domain 
binds to the same proline-rich motifs in CD2 cytoplasmic tail as does the GYF domain of 
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CD2BP2. However, these potential competitors are segregated since CD2BP2 associates 
with CD2 outside lipid rafts (membrane microdomains discussed latter) while Fyn is 
present only in lipid rafts to which CD2 is translocated upon its crosslinking [79]. Affinity 
and specificity can also be achieved by the recognition of residues outside the 
conventional PXXP motif and, as for SH2 domains, by the tandem organization of these 
domains. Although posing a challenge for the explanation of signaling specificity, the weak 
and promiscuous interactions of SH3 domains can be valuable in circumstances where 
the formation and dissolution of signaling complexes have to take place rapidly to favour 
the dynamic flux of protein networks [75]. 
 
 
1.3.2. The organization of membrane proximal TCR signaling: implicated 
protein tyrosine kinases and phosphatases  
 
The molecular aspects of signal transduction and cellular activation have been the 
centre of attention of many immunologists during the last decade. On the other hand, 
interconnecting a given biochemical mechanism with a physiological phenomenon is an 
essential but in many cases still elusive objective. Important questions regarding how 
molecules function within the immune cells have and will continue to be addressed with 
the use of improved research technologies. Among these questions are the functions of 
several protein tyrosine kinases (PTK) and protein tyrosine phosphatases (PTP) in the 
early T cell signaling events. 
Although much of the past work as focused on the PTK-mediated signaling, it is 
becoming obvious that many PTP play equally important roles in T cells and that the 
subtle equilibrium required for an appropriate effector function results from the fine-tuned 
regulation of tyrosine kinases and phosphatases. This balance between kinases and 
phosphatases can also be perceived from the human genome that encodes the same 
number of PTK and their counterbalanced, PTP (approximately 90 genes) [80, 81]. In T 
cells, upon antigen receptor stimulation there is a rapid wave of tyrosine phosphorylation 
that involves the coordinated action of several protein tyrosine kinases that include 
members of the Src, Syk, Csk and Tec families [28, 82]. 
 
 
1.3.2.1. Structure, function and regulation of Src family kinases 
 
The first family of PTK to be recruited and activated after TCR engagement is the 
Src family kinases, namely Lck and Fyn. These two kinases have a domain design similar 
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to the other Src family kinases: N-terminal attachment sites for saturated fatty acids 
addition, a unique region, an SH3 domain, an SH2 domain, a tyrosine kinase domain, and 
a C-terminal negative regulatory domain [83]. Lck and Fyn, are inserted into the inner 
membrane leaflet through the cotranslational fusion of myristate to the glycine at position 
2, after the start methionine is removed [84]. Besides being myristoylated these two Src 
family kinases also undergo reversible palmitoylation at cysteine 3 and at cysteine 5 in 
Lck or cysteine 6 in Fyn [85, 86]. The lipid modifications and consequent localization in 
lipid rafts, specialized plasma membrane microdomains enriched in glycosphingolipids, 
sphingomyelin and cholesterol (discussed below), seem crucial for the effective function of 
Lck, as a non-acylated form of the kinase failed to phosphorylate the TCR/CD3 complex 
[87].  
The function of the unique domain of most Src kinases is still largely unknown with 
the exception of that of Lck and Fyn. In Lck, it is responsible for a specific interaction with 
co-receptors CD4 and CD8, through a dicysteine motif (CXXC) present in Lck unique N-
terminal domain and two cysteines (CXCP motif) in the cytoplasmic tail of CD4 and CD8 
[88]. Recent data suggest that these residues direct a high-affinity binding via coordination 
of a Zn2+ ion, which is critical for creating an ordered stabilized structure [89]. The unique 
domain of Fyn has been shown to be involved in the association of the kinase with 
subunits of the TCR/CD3 complex [90]. 
The SH3 and SH2 domains of the kinases that bind to polyproline motifs and to 
specific phosphotyrosine motifs, respectively, are implicated in both intramolecular and 
intermolecular regulation of kinase functions. Nevertheless, the kinase domain also as a 
role in the regulation of kinase activity, as it contains itself two critical residues, an 
autophosphorylation site, necessary for kinase activation, and a C-terminal tyrosine that 
negatively regulates the kinase activity [91]. After being phosphorylated mainly by Csk (C-
terminal kinase), C-terminal tyrosine residues (Y505 on Lck and Y528 on Fyn) create an 
intramolecular binding motif for the SH2 domain, placing the kinase in a close/inactive 
conformation. Csk is recruited to the membrane by its interaction with the adaptor PAG 
(phosphoprotein associated with glycosphingolipid-enriched microdomains; also known as 
Cbp for Csk binding protein) and becomes itself phosphorylated by the Src kinases. Upon 
TCR stimulation PAG is transiently dephosphorylated, releasing Csk from its membrane 
anchor and form the proximity of Lck, facilitating and/or sustaining the activation of Lck 
and Fyn [82, 92-94].  
This mode of regulation likely applies to Lck and Fyn but, as mentioned above,  the 
activity of these kinases also seems to depend on the phosphorylation status of the 
activation loop tyrosine (Y394 on Lck and Y417 in Fyn) on the kinase domain [82, 95, 96]. 
LYP/PEP, a potent phosphatase with a negative regulatory role in TCR signaling, binds to 
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the SH3 domain of Csk that through its interaction with PAG is brought to the vicinity of 
Lck and Fyn in lipid rafts, where it dephosphorylates Y394 on Lck and Y417 on Fyn. Thus, 
PEP dephosphorylation of activating tyrosine concomitantly with phosphorylation of the C-
terminal inhibitory tyrosine by Csk are thought to synergize in inactivating Src family 
kinases [81, 97, 98]. 
The negative effect imposed by Csk and PEP is counterbalanced by the activity of 
a phosphatase, CD45. In this sense, it is known that in normal thymocytes and T cells, 
CD45 keeps the inhibitory tyrosine specifically dephosphorylated, rendering Lck in a 
primed state. In agreement with this evidence, it was proposed that an equilibrium state 
between conformationally different Lck molecules may exist: (1) open and activated 
(phosphorylated on Y394), (2) open and not activated or primed and (3) closed and not 
activated [99]. Together with several studies showing that CD45 was essential for tyrosine 
phosphorylation and PLC activation after TCR engagement, this phosphatase is viewed 
as a positive regulator of the Src family kinases function in T cell signaling [81].  
The specific recognition of an antigen in the context of an MHC molecule groove 
by the TCR involves a further stabilization of the complex by the binding of CD4 and CD8 
receptors to the nonvariable regions of MHC. This results in the recruitment of Lck via its 
noncovalent association with CD4 or CD8 to the complex, which positions the kinase to 
phosphorylate tyrosine residues within ITAMs [83]. This view has however been 
confronted with studies suggesting that it is Lck SH2 domain that mediates the recruitment 
of CD4 or CD8 to the TCR complex [100]. More recently, it was reported that the adaptor 
Unc119 associates with CD3 and CD4 and activates Lck and Fyn. Recombinant Unc119 
binds to the SH3 domain of Lck and Fyn, perhaps facilitating an open and active 
conformation [101]. Accordingly, CD4 and CD8 possibly in concert with Unc119 may be 
involved in the recruitment and clustering of Lck and/or Fyn with ξ and CD3 ITAMs. 
However similar in structure, several lines of evidence support the idea that Lck and Fyn 
have distinct but yet overlapping functions. Both kinases function equally well in 
phosphorylating ξ chains in TCR-mediated naïve T-cell survival, however, only Lck is 
capable of TCR-dependent homeostatic proliferation of naïve T cells. Moreover, Lck 
seems to have a greater and more specific role throughout T cell development and 
function, while Fyn appears to be less critical (reviewd in [83]).  
The function and the mechanism of activation of each kinase may also be 
regulated by their different lipid raft localization. As was recently suggested by Filipp and 
colleagues, after TCR and CD4 co-crosslinking, Lck is initially activated outside rafts and 
then translocates to lipid rafts were it activates the resident Fyn [102]. This concept is 
further supported by the observation that in resting cells the fraction of Lck found in the 
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rafts is in a close and inactive conformation, and upon cell activation the open/active form 
of Lck is most abundant in the rafts [103]. 
 
 
1.3.2.2. Structure, function and regulation of Syk family kinases 
 
The Src family kinases have two major roles in the propagation and amplification 
of T cell receptor signaling: they phosphorylate ITAM domains in the TCR/CD3 complex 
and then they phosphorylate and activate Syk family kinases that are recruited to the 
ITAMs via their tandem SH2 domains. Syk family members expressed in T cells include 
ZAP-70, whose expression is restricted to T cells and natural killer (NK) cells [104] and 
Syk, that is widely expressed in the hematopoietic lineage [105]. The crystal structure of 
the tandem SH2 domains of Syk or ZAP-70 complexed with a dually phosphorylated ITAM 
peptide revealed that each of SH2 domains of Syk can function as an independent unit 
[106], whereas for ZAP-70, the two SH2 domains bind cooperatively [107]. 
Once recruited, ZAP-70 activation requires the phosphorylation of Y493 on its 
activation loop by the Src family kinases [108]. Upon phosphorylation at Y493, the bound 
ZAP-70 molecules are able to autophosphorylate, possibly in trans, to produce docking 
sites for SH2-containig signaling proteins [109]. Syk, on the other hand, is able to trans-
autophosphorylate and activate itself, even though its activation is facilitated by Src 
kinases [110, 111]. Activation of the Syk kinases, mostly of ZAP-70 is an important step in 
instigating downstream signaling cascades [82]. In fact, a crucial substrate of ZAP-70 is 
the adaptor molecule LAT that, during T cell signaling, acts as a membrane scaffold, 
important for the assembly of numerous signaling complexes. Another adaptor that is also 
known to be a ZAP-70 substrate is SLP-76. Together these molecules couple the TCR to 
PLCγ1, Ca2+ and Ras signaling [50, 112, 113]. Besides the substrates, several SH2-
containing proteins bind phosphorylated ZAP-70 and Syk, these include Lck, Fyn, PLCγ1, 
Vav-1, Ras GAP and c-Cbl, and it is assumed these molecules produce a platform to 
create physical proximity and facilitate their tyrosine phosphorylation by the Syk and the 
Src family kinases [82].  
Dephosphorylation of ZAP-70 and Syk is thought to be achieved by the action of 
two PTP: SH2-containig SHP-1 and LYP/PEP. SHP-1, probably the most studied PTP, is 
known to have a negative role in T cell activation. In fact, the importance of this 
phosphatase comes from the observation that thymocytes from mice with motheaten 
mutation [114], which results in a homozygous loss of SHP-1, are hyperresponsive to 
TCR stimulation. This negative regulation is at least in part mediated by a direct 
dephosphorylation of ZAP-70 [115].  LYP/PEP, in addition to its role in the regulation of 
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Src family kinase activity also dephosphorylates ZAP-70 possibly through its association 
with c-Cbl. The mechanisms that regulate LYP/PEP targeting to TCR associated PTK are 
illustrated on figure 3 but remain largely unknown [81]. 
 
Figure 3. Schematic model for the three distinct ways that LYP (in green) can target TCR 
associated PTKs: (1) association with ZAP-70 through c-Cbl, (2) LYP may target PTKs 
directly, (3) after association with the SH3 domain of Csk is targeted to the PAG/Cbp, 
which is located in lipid rafts in the vicinity of Lck and other Src family PTKs. Taken from 
[81]. 
 
 
1.3.2.3. Structure, function and regulation of Tec family kinases 
 
The next step in TCR signal transduction is the activation of the Tec family 
kinases, namely three major found in T cells: Tec, Itk and Rlk. These Tec family members 
resemble Src family kinases in their domain organization, in the sense that they include a 
tyrosine kinase domain and a single SH2 and SH3 domains. However, the different 
subcellular localization of the Tec kinases is dictated by the presence of a pleckstrin 
homology (PH) domain responsible for their interaction with PI3K products. Following T 
cell activation, the phosphatidylinositol (3,4,5) triphosphate levels increase considerably 
targeting these kinases to the membrane. Rlk is an exception since it lacks a PH domain 
but in addition it contains a cysteine-string motif that after being palmitoylated targets Rlk 
to lipid rafts [116]. Once at the membrane, Lck phosphorylates the activation loop tyrosine 
of the Itk kinase domain and activates Itk kinase activity by inducing autophosphorylation 
events [117]. 
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In T cells, mice mutations affecting Itk or Itk and Rlk lead to mild perturbations of T 
cell responses namely decreased responses to TCR stimulation, including proliferation, 
IL-2 production, and production of effector cytokines. Nevertheless, these mice show 
severe defects in TCR-mediated phosphorylation and activation of PLCγ1 [116, 118, 119], 
establishing Itk as an intermediate in the pathway from the TCR to PLCγ1. Itk is able to 
directly associate with PLCγ1 [120] nevertheless, other mediators of this pathway have 
been elucidated. Specifically, Itk can directly associate with SLP-76 via cooperative 
binding of Itk-SH3 domain and Itk-SH2 domain that selectively binds SLP-76 in activated 
T cells. LAT, also known to be an essential mediator of this pathway, associates with Itk, 
although it is still not clear if this association is direct or indirectly mediated by Grb2 or 
SLP-76 [116]. ZAP-70 has been shown to be important in the regulation of Itk activation 
following TCR engagement through the phosphorylation of its substrate LAT [121]. All 
these findings are consistent with a role for Tec kinases in the formation of the 
trimolecular SLP-76-Gads-LAT complex described before in the regulation of PLCγ1 
activity [48]. 
Besides the role of Tec family kinases as regulators of PLCγ1, recent data support 
a function for Tec kinase Itk in the regulation of polymerization and polarization 
downstream of TCR triggering. T cells from Itk-deficient mice, as well as Jurkat cells 
expressing mutant forms of Itk, are defective in actin polymerization, conjugate formation 
and localized activation of Cdc42 and WASP (a key actin regulatory protein) in response 
to antigen-pulsed APCs. It has been suggested that this function of Itk in TCR-mediated 
actin polarization is kinase-independent [122, 123]. Itk appears to be involved particularly 
in signaling through CD28 and CD2 [116]. 
A potential mechanism for downregulating Itk activity functions via its requirement 
to colocalize with the LAT/SLP-76 adapter complex. It was shown that overexpression of 
the tyrosine phosphatase CD148 leads to reduced phosphorylation of LAT and PLC-γ1 in 
activated Jurkat T cells and it is expected that this pathway downregulates Itk activity, 
further attenuating the signals downstream of the TCR [124]. 
 
 
1.4. Accessory receptors involved in signal transduction in T cells   
 
 The first signal which confers specificity is provided by the interaction of the TCR 
with pMHC complex on APCs. This signal alone, although essential, is not sufficient to 
initiate transcriptional activation and mount an effective immune response [125]. The 
orchestration of accessory receptor-ligand interactions is required to direct, modulate and 
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fine-tune T cell receptor signals. These receptors may also play a role in the formation 
and stabilization of a highly organized supra-molecular signaling platform currently known 
as the immunological synapse (IS) (discussed in 2.1.). 
 
 
1.4.1. CD28 costimulatory receptor 
 
 It is well recognized that naive T lymphocytes require two distinct signals from 
APCs to be functionally activated: one provided by the TCR/CD3 complex and a second 
one generated by the engagement of costimulatory molecules [126, 127]. Several lines of 
evidence report that inhibition of costimulatory molecules at the cell surface or their 
intracellular signal transduction leads to T-cell unresponsiveness or anergy [128, 129].  
 Numerous costimulatory molecules have been described but CD28 is the 
classical illustrative example. CD28 is constitutively expressed on the surface of 95% of 
CD4+ human T lymphocytes and of 50% of CD8+ T cells [130], and on most mouse T cells 
[131]. It is a 44 KDa transmembrane protein that belongs to the IgSF (immunoglobulin 
superfamily) as do its ligands, the B7 molecules CD80 (B7-1) and CD86 (B7-2) [132, 133]. 
CD28 costimulation has been implicated in a wide variety of T-cell responses, including T 
cell proliferation, IL-2 production, prevention of anergy and induction of the antiapoptotic 
factor Bcl-xL [134, 135]. It has been suggested that CD28 induces cytokine gene 
transcription via the activation of the MAP kinase, JNK, and of the transcription factor NF-
κB, however co-engagement of the TCR is still required for this activation [136]. 
Furthermore it is proposed that CD28 crosslinking reduces the number of TCRs that need 
to be engaged, as well as the time required for T cells to interact with antigen, and 
enhances the magnitude of the T cell response to low levels of TCR occupancy [137].  
Although CD28 lacks enzymatic activity, it is capable of becoming tyrosine 
phosphorylated by Scr family kinases after its crosslinking, resulting in an increase 
association with PI3K, Itk and Grb2 [138]. CD28 receptor engagement induces tyrosine 
phosphorylation and activation of Itk [116]. A study by Michel et al. suggests that Itk 
activation downstream of CD28 is involved in the amplification of TCR-mediated signals, 
such as PLCγ1 phosphorylation, leading to Ca2+ mobilization [139]. Contrarily, and 
suggesting a negative regulatory role for Itk in CD28 signaling, is a different study showing 
increased responsiveness of Itk-deficient T cells to anti-CD28 stimulation [140]. Hence, 
the specific role of Itk in CD28 signaling awaits further elucidation. The roles of PI3K and 
Grb2 in CD28 signaling are also still not clear. The colligation of TCR and CD28 results in 
the synergistic and sustained phosphorylation and membrane localization of Vav [141] 
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that possible links to Gbr2 via SLP-76 and together will ultimately lead to IL-2 gene 
transcription [142]. 
Recently, CD28 was reported to accumulate at the IS by the selective recruitment 
of B7-2 [143, 144] and it was additionally suggested that CD28 recruits Lck to the synapse 
where it phosphorylates ξ chains of the TCR/CD3 complex and by this means sustains 
TCR signals [145-147]. 
 The CD28 homologue ICOS, which is expressed on activated T cells and binds to 
a B7 family member named ICOSL, is upregulated on T cells after activation [148-150]. 
The ICOS and CD28 have unique and overlapping functions that synergize to regulate 
CD4+ T cell differentiation. Like CD28, ICOS augments T-cell differentiation and cytokine 
production and provides critical signals for immunoglobulin production. ICOS signals are 
important for the regulation of cytokine production by recently activated and effector T 
cells: it can regulate both T helper 1 and T helper 2 effector cytokine production, and it 
has a particularly important role in regulating IL-10 production [151]. 
 CTLA-4 is another member of the CD28 family and along with its homologue, 
CD28, is a B7-binding protein. CTLA-4 functions both by scavenging CD80/86 ligands 
away from CD28 and by direct negative signaling to T cells [134], thus, playing an 
important role in the downregulation of both CD28 and ICOS mediated signaling [152, 
153]. Therefore, superimposition of inhibitory signals, such as those delivered by CTLA-4, 
leads to a complex network of positive and negative costimulatory signals, that will be 
integrated to modulate immune responses.  
 
 
1.4.2. CD4 and CD8 
 
 The assembly of a signaling competent complex involves the engagement not only 
of the TCR and pMHC but also of the CD4 or CD8 co-receptors and additional signaling 
molecules. CD4 and CD8 are expressed on mutually exclusive populations of T 
lymphocytes and recognize class II and class I MHCs, respectively, on target cells. The 
CD4 co-receptor is normally associated with helper T cells function whereas CD8 relates 
to cytotoxic T cells function [154, 155]. 
 CD4 is a 55 KDa single chain type I transmembrane glycoprotein with four 
extracellular Ig-like domains, a single transmembrane region and a short cytoplasmic tail 
[156]. CD8 can be expressed as a disulphide-linked heterodimer (αβ) or as a homodimer 
(αα) at the surface of T lymphocytes. Both isoforms are differentially expressed and have 
distinct functional behaviours [157]. The CD8αα homodimer binds primarily to the α3 
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domain of MHC molecule in an antibody-like fashion, but the position of CD8αα/MHC 
scaffold relative to the TCR is unresolved as the structure and relative conformation of the 
C- terminal stalk that attach the molecule to the T cell surface are still unclear [158, 159]. 
The crystal structure of CD8αβ heterodimer has not yet been resolved and the predicted 
models have used information from CD8αα mutational studies and take into account the 
different stalk lengths of the α and β subunits. However, to understand the structural basis 
of the different isoforms functions, the determination of the crystal structure of CD8αβ in 
complex with pMHC is essential [6, 160]. CD8 was shown to be absolutely required for 
binding of weak agonist ligands and aided the binding of strong agonist ligands, moreover 
it has been suggested that CD8 molecules may directly facilitate TCR-pMHC binding, 
since certain anti-CD8 antibodies were shown to increase TCR-pMHC interactions [161].  
 In contrast to CD8 the extremely weak pMHCII/CD4 interaction does not stabilize 
TCR-pMHCII interactions or contribute to cognate tetramer binding. For this reason it is 
assumed that CD4 does not affect pMHC binding [162, 163]. This view has recently been 
challenged by the observation that some anti-CD4 antibodies block pMHCII tetramer 
binding and that these effects have a parallel in T cell activation assays [164].  
 
 
1.4.3. CD6 
 
CD6, a monomeric 100-130 kDa type I cell surface glycoprotein, whose expression 
is largely restricted to peripheral T lymphocytes and medullary thymocytes, has been 
known to play a role in T cell activation [165]. CD6, like CD5, belongs to the scavenger 
receptor cysteine rich (SRCR) superfamily where these accessory receptors are the most 
closely related members, having similar domain organization including three extracellular 
SRCR domains [166]. The human Cd6 gene is located in chromosome 11, region 11q13, 
contiguous to the Cd5 gene, supporting the idea that both genes are likely to have arisen 
from the duplication of a common ancestral gene [167]. Human, rat and mouse Cd6 
genes contain thirteen exons: the first six exons code for most of the extracellular domain, 
exon 7 codes for the transmembrane domain and the last six code for the cytoplasmic tail. 
Different CD6 isoforms have been described arising from alternative splicing of exons 
coding for sequences within the cytoplasmic domain [167-170], but so far no specific 
physiological function has been attributed to any of these isoforms. 
Although several studies point towards a role for CD6 as a costimulatory molecule 
in T cell activation, no precise function as been clarified up to now. Treatment of T cells 
with anti-CD6 antibodies can potentiate the outcome of TCR-induced signaling [171-173]. 
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A role for CD6 in thymocyte maturation has also been suggested, as blocking CD6 
reduces the adhesion of thymocytes to thymic epithelial cells [174]. Additionally, it was 
shown that a CD6 negative sub-population of T cells displayed a lower alloreactivity in 
mixed leukocyte reactions as compared to a normal CD6+ T cell population [175], and, 
more recently, that soluble monomeric CD6 present in antigen-primed mixed leukocyte 
reactions inhibited antigen-specific T cell responses [176, 177]. On the other hand, it was 
shown that CD6 expression on immature thymocytes correlates with resistance to 
apoptosis, implying some inhibitory signaling properties for CD6 during selection [178]. 
CD6 may as well exert its function via association with CD5, as both receptors were 
shown to co-immunoprecipitate from Brij 96 lysates of normal and leukemic human T cells 
[179]. 
CD166/ALCAM is so far the only known ligand for CD6 on immune cells and the 
molecular basis of CD6-CD166 interaction has been comprehensively investigated [180]. 
CD166 is a widely expressed glycoprotein containing five immunoglobulin superfamily 
(IgSF) domains, of which the N-terminal domain has been shown to bind to the 
membrane-proximal domain (SRCR 3) of CD6 [181, 182]. Recently, thermodynamic 
analysis revealed that binding occurs with a relatively strong affinity (Kd = 0.4-1.0 µM) 
[177]. The resulting interaction between CD6 and CD166 occurs through lateral binding, 
an unusual type of interaction as most other T lymphocyte surface proteins mediating cell-
cell interactions have a top-on-top binding manner. CD6 physically associates with the 
TCR/CD3 complex and is able to concentrate in the cSMAC after T cell activation in a 
Jurkat-Raji model system [176]. More recently, in a resting T cell/dendritic cell (DC) 
model, it was shown that ALCAM and CD6 are recruited to the IS and are involved in the 
stabilization of this structure which in turn contributes to both early and later stages of DC-
induced T cell activation and proliferation, mimicking CD28 co-stimulatory behaviour [183]. 
The intracellular pathways elicited by CD6 are still largely unknown. Evidences 
have shown that CD6 is tyrosine phosphorylated after stimulation with CD3 alone or by 
crosslinking CD3 with CD2 or CD4 [184] suggesting that interactions with SH2 domain-
containing intracellular mediators may occur. In addition, CD6 cytoplasmic tail contains 
multiple potential binding sites for SH3 domain-containing proteins, Casein Kinase II, and 
Protein Kinase C-consensus binding sites [173]. The rat homologue of CD6 has indeed 
been shown to associate with protein tyrosine kinases of different families, namely Src-
family kinases Lck and Fyn, ZAP-70 of the Syk family, and the Tec-family kinase Itk [185]. 
Recently, the first intracellular partner for human CD6, syntenin-1, which functions as an 
adaptor able to bind cytoskeleton proteins and signaling effectors has been identified 
[186]. Despite the progress made, important issues regarding intracellular signaling 
partners and their functional roles remain elusive. Additional research focusing towards 
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the understanding of the molecular mechanisms underlying CD6-mediated signaling is 
necessary to establish an unambiguous role for CD6 in T cell activation. 
 
 
1.4.4. CD2 
 
The human T cell adhesion molecule CD2 is one of the most studied accessory 
receptors. CD2 is a 45-58 KDa type I integral protein expressed on virtually all T lineage 
and natural killer cells [156]. The extracellular domain is composed of two immunoglobulin 
superfamily domains [187], of which the membrane-distal V-like domain is involved in the 
binding to the ligand [188]. Engagement of CD2 to CD58 in humans, or to CD48 in 
rodents, facilitates adhesion between T cells and antigen presenting cells (APC) and 
promotes the formation of an optimal intercellular membrane spacing (~140Å) suitable for 
TCR-pMHC recognition [189]. CD48 and CD58 are structurally related to CD2, as both 
molecules have two Ig-like domains and a short stalk and with the N-terminal domain 
mediating the interaction. The crystal structure of human and rat CD2 as well as of CD2 
bound to CD58 have been determined [187, 189-191]. The interaction of CD2 with its 
ligands was shown to be of low affinity allowing transient multivalent contacts between 
cells expressing these molecules [192]. In fact, the interaction of rat CD2 with CD48 has a 
Kd of 65 µM that is largely outside the range values of 5-20 µM found for most leukocyte 
surface proteins interactions [193, 194]. It has been suggested that specificity depends 
largely on electrostatic complementarity at the binding surfaces without requiring 
increases in affinity [189, 195]. Studies on CD2-deficient mice have shown that the CD2-
CD48 interaction is not essential for the development or function of an apparently normal 
immune system [196]. Instead, CD2 has been shown to have a subtle role in setting TCR-
affinity thresholds for T cell activation, thus fine-tuning the T cell repertoire [197-199].  
Along with its function as an adhesion molecule, CD2 also has a role in the 
process of signal transduction. Intracellular CD2 signaling pathways and networks have 
been a matter of extensive research. It has long been known that stimulation of CD2 with 
combinations of monoclonal antibodies or with the physiological ligand induces T cell 
proliferation in rats and human [200, 201]. Moreover, ligation of CD2 with CD58 augments 
the interleukin-12 (IL-12) responsiveness of activated T cells [202], and can also reverse T 
cell anergy induced by B7 blockage [203]. CD2-mediated activation depends on its 
cytoplasmic domain [204-207], but as it has no intrinsic enzymatic activity, it relies on 
physical interactions with other signaling molecules to propagate the stimulus received 
upon ligand binding. CD2 associates with the Src-family tyrosine kinases Lck and Fyn 
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[208-210], and through these kinases couples to downstream signal transduction 
pathways. 
 Proline-rich sequences of the cytoplasmic domain of CD2 have also been shown 
to establish interactions with the SH3 domains of several proteins. The interaction 
between CD2 and CD2AP, mediated by the first SH3 domain of CD2AP, is induced by T 
cell activation and is required for CD2 clustering and T cell polarization. CD2AP seems to 
function as a molecular scaffold for receptor patterning and cytoskeletal polarization [211]. 
Another CD2 cytoplasmic tail-binding protein, termed CD2BP1 has been identified: upon 
CD2 clustering, the SH3 domain of CD2BP1 binds CD2 and functions as an adapter to 
recruit cytosolic PTP-PEST, thereby down-regulating adhesion [212]. CD2 additionally 
binds to the GYF domain of CD2BP2, an interaction involved in cytokine production 
following CD2 stimulation. Fyn SH3 domain can compete with CD2BP2 as it binds 
specifically to the GYF domain-binding site of CD2  [213]. The same authors 
demonstrated that CD2BP2 binds to CD2 outside lipid rafts and is replaced by Fyn after 
CD2 is translocated into lipid rafts. In contrast to rat and mouse CD2 that are raft-resident 
molecules [214], human CD2 has been shown to translocate to lipid rafts only upon CD2-
antibody crosslinking, or following binding to CD58 during conjugate formation [215]. CD2, 
like several other costimulatory molecules, has been shown to up-regulate TCR signals by 
enhancing the association of the TCR with lipid rafts [216].  
 
 
2. Spatial organization 
 
2.1. Immunological synapse 
 
The orchestration of Ag-specific immune responses, elicited by the engagement of 
the TCR with pMHC on the surface of an APC, is performed in a localized environment, 
called the immunological synapse, and requires the coordinated activities of several TCR-
associated molecules, including CD3, the co-receptors CD8 or CD4, and other accessory 
receptors.  
Despite the knowledge gathered for years that T cell activation required physical 
interaction between the T cell and the APC, the first imaging studies that examined the 
molecular organization of the contact area were only performed in the late 90’s [217-219]. 
Monks et al. (1998) first described the spatial segregation of LFA-1, talin, TCR and PKC-θ 
at the contact interface between T cells and antigen presenting B cells: TCR and PKC-θ 
are accumulated in the central region, the cSMAC (central supramolecular activation 
clusters) and are enclosed by a ring structure of LFA-1 and talin, the pSMAC (peripheral 
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supramolecular activation clusters). The authors also implied that TCR signaling was 
initiated and sustained by the cSMAC. One year latter, Dustin and colleagues [217], 
termed the bull’s eye pattern observed by Monks et al. and themselves as “immunological 
synapse”. Several studies that confirmed the formation of a cSMAC and a pSMAC have 
also helped discover other constituents of the cSMAC, such as CD2, CD28, Lck, Fyn, 
CD4 and CD8 (for review see [220]). The large molecule, CD45 shows a distinctive 
behaviour, it is recruited to the cSMAC at an early time point, possibly to activate Lck, and 
later moves to a more peripheral region than the pSMAC, termed distal SMAC (dSMAC) 
[221].  
Although initially the IS was defined as a specialized structure composed of a 
cSMAC and a pSMAC, the term know refers to a more diverse range of structures that 
present an accumulation of TCR and related signaling molecules. In fact, several studies 
show diverse synapse morphologies and suggest that T cells can be activated in the 
absence of cSMAC formation [222]. Immature CD4(+)CD8(+) thymocytes form a 
decentralized synapse with multi-focal TCR clusters and do not form a cSMAC [223]. 
Also, the IS between T cells and dendritic cells was shown to be a multi-focal structure in 
the absence of Ag and when Ag is present, the T cells are activated without the formation 
of a cSMAC [224].  
How is the kinetics of TCR signaling coupled to the dynamic nature of the 
immunological synapse formation? It has long been accepted that TCR signaling was 
initiated well before cSMAC formation and it has been hypothesized that the cSMAC was 
involved in sustaining signaling. In contrast, Lee and collaborators [225] have shown that 
early phosphorylation of Lck and ZAP-70 occurs in the peripheral region of the contact 
area and before the formation of a mature IS in normal T cells. Moreover, the first 
suggestion that T cell activation can be augmented in the absence of cSMACs came from 
studies using T cells from mice deficient in CD2AP. These T cells do not form cSMACs 
and show a defective TCR down-regulation [226]. These authors suggest that the cSMAC 
acts as an adaptive controller that enhances weak signals and attenuates signals by 
strong ligands. 
It has long been recognized that small TCR clusters are formed prior to the IS, but 
it was only very recently that the precise behaviour of these microclusters (MCs) was 
analyzed. Using supported bilayer membranes and nanometer-scale structures to contain 
movement of molecules, Mossman et al. [227] demonstrate that the TCR MCs 
mechanically trapped in the peripheral regions of the synapse had long-lasting TCR 
signaling and calcium mobilization. There observations suggest a three-step process to 
form a mature IS: TCR engagement of pMHC; TCR-pMHC assembly into MCs and 
transport of MCs to form the cSMAC. They suggest that the main role of cSMAC is the 
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internalization of the engaged TCRs while the pSMAC shows to have a role in initiating 
and sustaining TCR signaling.  
The application of TIRF (total internal reflection fluorescence) microscopy to the IS 
led to the discovery that TCR-pMHC clusters are continuously forming at the periphery of 
the IS [228]. This study shows that microclusters, at the periphery of the contact interface 
between T cells attached to the pMHC-containing bilayer, include the TCR, ZAP-70 and 
SLP-76. Throughout the translocation of these initial MCs to the centre of the contact, to 
form the cSMAC, ZAP-70 and SLP-76 dissociate from the TCR MCs, supporting the idea 
that the initial MCs initiate and sustain T cell activation (figure 4). In the future, 
characterizing the influence of antigen quality in processes such as microcluster formation 
and the role of the synapse will be of extreme importance. Furthermore, the precise role of 
the cSMAC should be clarified. 
 
                    
Figure 4. Dynamic formation of microclusters and immunological synapse during the 
  
 
processes of antigen recognition and T-cell activation. In the figure, MCs are represented 
by three components: the kinase, red; the receptor, dark blue; and the adaptor, light blue. 
(a) After a T cell is placed on a planar bilayer containing peptide-loaded MHCs and ICAM-
1, TCR-MCs are generated at the contact interface, which assemble with kinases and 
adaptors that participate in TCR-proximal signaling. Following the first attachment, the T 
cell continues to spread on the bilayer, with new MCs generated on the edge (red arrows). 
(b) After the full expansion, the T cell begins to contract (black arrows) and MCs 
accumulate at the central region of the interface. During this process, the MCs fuse each 
other to form larger MCs, whereas kinases and adaptors dissociate from TCR-MCs. (c) 
Ten minutes after T cell-bilayer conjugation, TCR-MCs finally accumulate at the center of 
the IS to form ‘c-SMACs’. The c-SMACs contain minimal levels of kinases and adaptors. 
New functional MCs are continuously generated on the peripheral edge, which are 
translocated to the c-SMACs to sustain TCR signals, which last for hours (white arrows). 
Taken from [222]. 
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Introduction 
The view that the T cell receptor (TCR) is part of a multimolecular complex that 
associates loosely at the surface of T cells and functions as an activation unit[229], is now 
widely accepted. More recently, the concept that the assembly of the TCR signaling 
machinery takes place in lipid rafts has been put forward[230, 231], and whereas the 
existence of these specialized lipid microdomains seems to be a general assumption, their 
role in the initiation of T cell signaling has been a matter of intense debate. Much of the 
controversy results from the experimental approaches used to differentiate these 
membrane structures and to trail the assemblage of signaling receptors and effectors at 
the cell surface. In this review we describe the current knowledge and the recent 
advances towards the understanding of the principles that dictate the organization of the 
signaling complexes as protein networks in the plasma membrane. 
 
Lipid rafts definition: an overview 
Lipid rafts are membrane microdomains enriched in glycosphingolipids, 
sphingomyelin and cholesterol, embedded in the glycerophospholipid-rich fluid plasma 
membrane. In general, these lipid microdomains can also be designated as GEMs 
(glycolipid-enriched membranes) or DIGs (detergent-insoluble glycolipid domains), so 
called due to their property of insolubility in cold 1% Triton X-100. Non-transmembrane 
proteins with raft affinity undergo lipid modifications which renders them hydrophobic and 
thus able to anchor to the plasma membrane. These modifications could be either a 
covalent linkage to glycosyl-phosphatidylinositol (GPI) in the case of outer leaflet insertion, 
or the attachment of S-palmitoyl fatty acid, possibly added by myristoylation of amino-
terminal glycine residues, for inner leaflet anchoring[232, 233]. A classical example of the 
latter is the Src-family protein tyrosine kinase Lck, which contains a myristoylation site at 
Gly2 and double palmitoylation sites at Cys3 and Cys5[87]. 
The first evidence for the existence of membrane microdomains came from the 
recognition of different levels or degrees of order in the membrane hydrophobic core, 
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detected by fluorescent dyes[234]. Further proof supporting this concept resulted from the 
observation that cholesterol and sphingolipid-rich domains were resistant to non-ionic 
detergent solubilization at low temperatures, and could be isolated as low-density 
fractions on sucrose gradient centrifugation[232, 235]. This is intrinsically related to the 
organizational levels of the lipids in the membrane; the tightly packed saturated lipid acyl 
chains and cholesterol, forming a liquid-ordered (Lo) phase will be more resistant to 
solubilization than the more fluid, liquid-disordered (Ld) phase. The cholesterol 
dependence of lipid rafts in order to form a liquid-ordered phase in the cell membrane has 
been demonstrated in studies using model membranes[236]. However, the principle of 
heterogeneity based on artificial models as well as the correlation of the lipid rafts concept 
with detergent insolubility has created much controversy in the field, leading to very critical 
opinions on the nature and function of lipid rafts[237]. 
 
Visualizing lipid microdomains: from models to live cells 
One property attributed to Triton X-100 is that it can partially solubilize the Lo 
phase, which may lead to loss of selected rafts components, such as weakly associated 
transmembrane receptors[238]. Results obtained by Simons and co-workers suggest that 
the composition of detergent-resistant membranes is both dependent on cell type and 
detergent solubilization properties, raising questions on lipid rafts definition based on a 
Triton X-100 insolubility criterion[239]. Nevertheless, most detergents do not induce 
artifactual ordered domains or promote association of solubilized components with Lo 
microdomains[236], therefore detergent-resistant lipid microdomains can at most diverge 
from “physiological” rafts in that some components may be selectively lost during lysis 
procedures. 
Given that biochemical approaches produce controversial results, characterization 
of the lipid rafts and particularly the dynamics in living cells can best be achieved through 
the usage of advanced microscopy techniques. Contrarily to the immunological synapse, 
which can be readily followed by light microscopy, lipid rafts in resting cells, termed 
elemental rafts, are submicroscopic complexes (26 ± 13 nm) and cannot be visualized by 
classical microscopy methods[240]. However, crosslinking raft-resident proteins induces 
the coalescence of rafts into patches of hundreds of nanometres in diameter that can be 
viewed by fluorescence microscopy[241, 242].  
Several novel technical approaches have been used in the attempt to clarify the 
raft concept by characterizing the size and structure, and the diversity and dynamics of 
these microdomains. Fluorescence resonance energy transfer (FRET) measurements 
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have provided evidence that raft markers exhibit an energy transfer pattern that is 
consistent with cholesterol-dependent clustering in small domains[243-245]. Using 
homotypic FRET, Sharma and colleagues have shown that a fraction of GPI-anchored 
proteins at the plasma membrane can be detected in small (4 nm) and dense clusters of 
as few as 4 GPI protein molecules[246]. 
Techniques such as fluorescence recovery after photobleaching (FRAP) and 
single particle tracking (SPT) were brought into play to address questions concerning the 
diffusion and dynamics of individual raft proteins or lipids. The FRAP technology showed 
that the diffusion rate of the non-raft mutant of influenza hemagglutinin (HA) was superior 
to the rate of lateral diffusion of the wild type molecule[247]. However, a different study 
using a similar approach showed that the dynamics of a set of raft and non-raft proteins 
were comparable, all molecules diffused freely over large areas[248]. One limitation of 
FRAP measurements is that the temporal resolution is below the residence time of a 
protein in the rafts.  
With the SPT technique and the development of single fluorophore imaging[249] it 
is now possible to follow an individual molecule and measure its diffusion coefficient and 
confinement times within certain boundaries, allowing spatial and temporal information on 
the molecule’s behaviour[250-252]. Using total internal reflection fluorescence microscopy 
(TIRF) to track the trajectory of single raft-associated Lck and LAT, as well as the non-raft 
molecule CD2, Douglass and Vale surprisingly observed, in non-activated cells, a much 
larger diffusion coefficient for raft molecules than for CD2[253], although it can be argued 
that the relative immobility of CD2 may be due to its association with the 
cytoskeleton[211]. The fact that any of these proteins can in some circumstances move in 
or out of lipid rafts still hinders any definitive conclusion on the mobility of lipid rafts based 
on protein markers, though.  
 
T cell receptor signaling association with lipid rafts 
Upon productive engagement of the T cell receptor to peptide/MHC complexes 
presented at the surface of antigen presenting cells, co-receptor (CD4 or CD8) binding to 
non-polymorphic regions of MHC molecules results in the approximation of CD4/CD8-
associated Lck to the TCR/CD3 complex. Lck is thus able to phosphorylate tyrosine 
residues within ITAM sequences present in the different CD3 chains, which become 
docking sites for the cytoplasmic kinase ZAP-70. Once ZAP-70 is targeted to the 
membrane, the TCR/CD3 complex is armed with a cocktail of protein tyrosine kinases, 
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also including Fyn, that extensively phosphorylate tyrosine residues in a number of 
receptors and adaptors.  
The fact that several signaling molecules were found in association with lipid raft 
microdomains lead to the assumption that rafts were more than just a structural 
peculiarity. In unstimulated cells, important signaling proteins such as the adaptors 
LAT[254] or PAG[255], or the Src-like kinase Fyn[102] are resident in rafts, whereas most 
transmembrane receptors are found outside these platforms. However, the protein content 
of the rafts as well as the activity of raft-associated proteins changes with cell stimulation. 
Signaling effectors like Lck that are in equilibrium between the two phases can change 
their behaviour or activity upon TCR triggering; while in the resting cell the fraction of Lck 
found in the rafts is in a close and inactive conformation, upon cell activation the 
open/active form of Lck is most abundant in the rafts[103], being able to activate resident 
Fyn[102]. The lipid modifications and consequent localization in lipid rafts seem crucial for 
the effective function of Lck, as a non-acylated form of the kinase failed to phosphorylate 
the TCR/CD3 complex[87].  
A recent study tackling the functional significance of membrane localization on the 
initiation of signal transduction, using mutant molecules engineered to not address to 
rafts, produced intriguing results on the function of the lipid moiety of the molecules. A 
LAT mutant (C26/29A) that cannot be palmitoylated, and a fusion protein consisting of the 
extracellular domain of LAX fused to intracellular LAT (LAX-LAT) were both detected 
outside rafts only. Just the LAX-LAT fusion could rescue T cell function both in vitro, as 
well as and in vivo in transgenic mice expressing LAT mutants in a null background[256]. 
So, whereas raft residency does not seem to be essential for the signaling activity, lipid 
modifications of raft-based molecules possibly tether membrane proteins stably to the 
membrane. 
As many signaling effectors do concentrate in lipid rafts, these membrane 
microdomains are thus considered as signaling platforms where optimal conditions for cell 
activation are met. A further function suggested for lipid rafts is to link the signaling 
machinery with the cytoskeleton. The requirement of cytoskeleton reorganization for 
sustained signaling has been previously demonstrated[257], and the observation that 
filamentous actin and ξ chains are enriched in lipid microdomains following CD48/TCR co-
ligation strengthens that view[258].  
All these findings show or imply that the TCR itself associates with lipid rafts at 
some stage after selective stimulation of T cells, although there is some controversy on 
the kinetics of such an association: the TCR is either induced to associate with lipid 
rafts[230, 259], or it is already resident, at least a small fraction, in a subset of lipid 
rafts[260, 261], these disputes again falling in the general discussion on the correct 
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methodology. However, given that TCR engagement to MHC/peptide should precede all 
changes in cell behavior due to antigen recognition, including membrane and cytoskeleton 
reorganization, it is more appropriate to envision TCR association with lipid rafts from the 
receptor-centered point of view: T cell receptors are constrained to the immunological 
synapse, and lipid rafts/raft resident molecules move to these cellular interfaces[262]. 
Protein-protein interactions can thus be foreseen as the driving forces for redistribution of 
raft-associated proteins, as well as for the lipid phases (Figure 1). 
 
 
CD4
Lck
LAT
Fyn
GPI-linked
CD2
TCR/CD3
Ag
 
Figure 1.  A model for membrane microdomain organization in T cell receptor signaling. 
For simplicity only illustrative molecules are represented. In resting cells, lipid rafts may 
exist as regions of heterogeneous composition and size. Some proteins already partition 
into these domains either by GPI-anchoring or by acylation, as is the case of the Src 
kinases Lck and Fyn as well as several adaptor proteins (eg. LAT). Most transmembrane 
proteins are found outside these platforms. Upon antigen stimulation rafts coalesce 
bringing together the TCR and the signaling machinery. The current view sustains the idea 
that lipid rafts are highly dynamic structures which is probably based on a high diffusion 
rate of lipid rafts resident proteins. This mobility requires the ability of these proteins to 
interact with other proteins. When the proper protein-protein interaction is established this 
results in the creation of a signaling complex.  
 
Dynamics of protein interactions in lipid rafts 
Results mainly from raft patching experiments suggest that the association of the 
TCR with lipid rafts increased when the TCR is crosslinked together with accessory 
proteins such as CD2, CD5, CD9 and CD28[214, 216, 263]. This has been suggested as 
a mechanism of co-stimulation, in the sense that the induced clustering of lipid rafts 
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resulted in increased tyrosine phosphorylation events[214, 263]. Additionally, CD28 co-
stimulation induces the movement of actin cytoskeleton to the TCR engagement site[264].  
Raft-controlled interactions, by their dynamic nature, should facilitate transient 
encounters between raft-resident proteins whereas the interactions of raft with non-raft 
proteins could be limited, because of the physical segregation in different membrane 
phases. This constraint is overcome if protein-protein interactions are prevalent over the 
raft/non-raft separation, and indeed no obstruction on the recruitment of non-raft 
molecules to the ordered lipid phase is evident from current experimental research. The 
co-receptor CD8 exists as a CD8αα homodimer or a CD8αβ heterodimer. Whereas the β 
subunit facilitates raft-association, the α unit provides an extracellular binding site for MHC 
class I and an intracellular motif that binds to Lck. Since CD8αβ, but not CD8αα, partitions 
into rafts, it promotes the association with lipid rafts of a significant fraction of TCR/CD3 
that binds to CD8α/Lck[265]. Therefore, protein-protein interactions can dictate the 
localization at a certain moment of proteins within lipid raft microdomains. 
Recently, Douglass and Vale were able to show that while non-raft CD2 single 
molecules are mainly immobile, Lck and LAT showed abrupt changes from highly mobile 
to a highly immobile state, the latter occurring when they spatially overlapped a signaling 
cluster[253]. Using a series of mutants that interfere either with lipid raft-targeting or with 
protein associations, they concluded that protein-protein interactions are determinant in 
selecting which non-raft molecules are retained or excluded from lipid rafts, rather than 
any type of raft-addressing label. As rafts were not found to be the primary factor in the 
clustering and diffusional immobility of CD2/Lck/LAT clusters, the authors propose that 
highly mobile signaling proteins diffusing in the membrane randomly encounter activated 
signaling complexes, and are captured by the emerging signaling complex provided the 
correct bonds can be established. CD2 and Lck have been shown to interact directly, and 
the recruitment of CD2 to lipid rafts relies on such interactions[208, 209, 266]. However, 
these specific protein interactions were not addressed in the study, so complementary 
work is required, with these and other molecules, before a solid model can be built. 
 
Conclusions and perspectives 
Are lipid rafts central stages where multifactor signaling complexes are assembled, 
or are they platforms that carry the signaling apparatus where it is required, largely 
dependent on protein interactions, as recent advances seem to suggest? If so, what role 
is performed by the lipid content of rafts, is the lipid environment essential for signal 
transduction or is it merely the result of random or facilitated aggregation of proteins that 
are covalently connected to the plasma membrane?  
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Development of more refined techniques that allow a better understanding of 
protein movements within the plasma membrane is thus required. The development of 
new sets of fluorescent lipids, such as polyene-lipids that exhibit a similar distribution in 
respect to the membrane ordered and disordered liquid phases as their natural 
counterparts, will make it possible to trace the movement of individual proteins in 
membrane microdomains of diverse composition[267]. With the appropriate tools, the 
concepts of the immunological synapse and clustering of proteins in lipid rafts 
microdomains will undoubtedly be assessed.  
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ABSTRACT 
 
The MRC OX52 monoclonal antibody is a marker of rat T lymphocytes. We have 
cloned by PCR the rat homologue of CD6, and FACS analysis and immunoprecipitations 
using OX52 in COS7 cells transfected with rat CD6 cDNA showed that CD6 is the cell 
surface molecule recognized by OX52. Immunoprecipitation analysis showed that CD6 
coprecipitated with CD5. CD5 in turn, was coprecipitated equivalently with CD2, CD6 and 
the TCR, but the fraction of CD5 associated with CD6 was highly phosphorylated in 
kinase assays, in marked contrast with the low level of phosphorylation of CD5 associated 
with either TCR or CD2.  Examination of protein kinases associating with these antigens 
showed that, paradoxically, CD2 coprecipitated the highest amount of Lck and Fyn. CD6 
also associated with Lck, Fyn, and ZAP-70, although at lower levels, but additionally 
coprecipitated the Tec family kinase Itk, which is absent from CD2, CD5 and TCR 
complexes. Lck together with Itk was the best combination of kinases effectively 
phosphorylating synthetic peptides corresponding to a cytoplasmic sequence of CD5. 
Overall, our results suggest that CD6 has an important role in the regulation of CD5 
tyrosine phosphorylation, probably due to its unique feature of associating with kinases of 
different families.  
 
  
INTRODUCTION 
 
CD5 is a surface antigen central to the regulation of signal transduction in 
thymocytes, T lymphocytes and B-1a lymphocytes [1]. The mature 67 kDa glycoprotein 
contains an extracellular region composed of three domains of the scavenger receptor 
cysteine-rich (SRCR) superfamily, a single transmembrane segment, and a cytoplasmic 
tail containing several serine/threonine phosphorylation sites and four tyrosine residues 
(numbering of the CD5 amino acid residues indicated in this text refers to the human 
sequence) - Y378, Y429, Y441 and Y463, putative docking sites for SH2 domain-
containing signaling effectors [2].  
Both co-stimulatory [3-5] and inhibitory [6-8] roles have been proposed for CD5, 
and these may correlate with the activity or nature of the effectors that upon stimulation 
bind to phosphorylated tyrosine residues of CD5. In T cells, Lck is the major kinase 
responsible for the phosphorylation of CD5, at residues Y429 and Y463 [9], the former 
being also the principal site of docking of Lck itself [10]. ZAP-70 and CD3-ξ have also 
been shown to bind to CD5, although the exact mode of interaction is not fully understood: 
ZAP-70 does not bind directly to the pseudo-ITAM sequence containing residues Y429 
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and Y441 [11, 12], and moreover, there is no evidence of direct phosphorylation of CD5 
by this kinase. Additionally, CD5 signaling activates a pathway involving 
phosphatidylinositol 3-kinase, whose two SH2 domains bind to phosphorylated Y441 and 
Y463 [5, 11]. 
Regarding the inhibitory effect of CD5, the molecular mechanism remains to be 
elucidated. Two of the tyrosine residues, Y378 and Y441, are within putative ITIMs, but 
the evidence of involvement of these residues in inhibitory effects is very slim. So far, no 
repressors have been shown to bind to Y441, and only in Jurkat T cells the phosphatase 
SHP-1 seems to dock to Y378 [7]. No evidence of such binding was found in B cells [8]. 
Curiously, it is residue Y429 that harbors molecules that down-modulate cellular 
activation, like Ras-GAP and Cbl in thymocytes [8, 13]. 
The exact mode of CD5 phosphorylation remains also to be fully deciphered. CD5 
is rapidly phosphorylated following TCR stimulation [14]. However, as the TCR/CD3 
complex does not include Lck, the interaction between CD5 and Lck is possibly promoted 
in assembled signaling micro-domains, namely lipid rafts. Indeed, crosslinking CD5 with 
the TCR targets both molecules to these specialized domains [15]. Paradoxically, 
stimulation of T cells with antibodies against CD2, a membrane antigen that does 
associate with both Lck [16, 17] and CD5 [18, 19], seems not to induce CD5 
phosphorylation, but rather its dephosphorylation [18].  
Given the complexity of the signaling mechanisms involving CD5, and the 
apparent contradiction between the outcomes of stimulation through the TCR versus CD2, 
we looked for alternative molecules and kinases that might regulate CD5 phosphorylation. 
Here we report on the rat T cell protein, OX52, which appears to have a role in mediating 
the phosphorylation of CD5, making use of its capacity to associate with tyrosine kinases 
of different families. 
  
 
MATERIALS AND METHODS 
 
Antibodies and CD5 Peptide 
Monoclonal Ab [17, 19] used: CD2-OX34, CD5-OX19, OX52 [20], and human 
C3bi-OX21; TCR-R73, and CD28-JJ319 [21], gifts from T. Hünig (University of Würzburg); 
and anti-phosphotyrosine HRP-conjugated-4G10, purchased from Upstate Biotechnology 
(Lake Placid, NY). Polyclonal rabbit anti-sera: anti-CD6 [22], raised against the 
extracellular domain of mouse CD6; anti-CD5, raised against a peptide of amino acids 
451-471 of human CD5, a gift from D. Y. Mason (John Radcliffe Hospital, Oxford); anti-
Lck, raised against a peptide of amino acids 39-64 of murine Lck, a gift from J. Borst (The 
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Netherlands Cancer Institute, Amsterdam); BL90, polyclonal anti-Fyn and BL12 [23], 
polyclonal anti-Itk were gifts from J. Bolen and M. Tomlinson (DNAX Research Institute, 
Palo Alto); polyclonal anti-ZAP-70 from Santa Cruz Biotechnology (Santa Cruz, CA); goat 
anti-mouse peroxidase conjugated was purchased from BD Biosciences (Heidelberg, 
Germany) and rabbit anti-mouse immunoglobulin (RAM) was purchased from Serotec 
(Kidlington). The N-terminal biotinylated peptide, >70% pure, corresponding to the 
sequence AASHVDNEYSQPPRNSRLSAYPALE-OH of rat CD5, was purchased from 
New England Peptide (Fitchburg, MA). 
 
Cells and cell lines 
Cervical lymph node cells were from 12 week old Lewis male rats, Charles River 
Laboratories (Barcelona). Cell lines: W/FU(C58NT) [17], a rat thymoma, from A. 
Conzelmann (University of Fribourg); and COS7 [19],  obtained from the American Type 
Culture Collection (Rockville, MD). Cell lines were maintained in RPMI with 10% FCS, 1 
mM sodium pyruvate, 2 mM L-glutamine, penicillin G (50 U/ml) and streptomycin (50 
µg/ml). 
 
Cell stimulation and detection of tyrosine phosphorylation 
Approximately 1 x 107 rat lymph node cells were used per sample. R73 and/or 
OX52 were added at 10 µg/ml to cells and incubated on ice for 15 min. Cells were washed 
with PBS, resuspended with 20 µg/ml RAM and incubated for 2 min at 37ºC. Cells were 
lysed by the addition of NP-40 lysis buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 1 mM PMSF and 1% (v/v) NP-40) for 30 min on ice. The nuclear pellet was 
removed by centrifugation at 12,000 x g for 10 minutes at 4°C. Cell lysates were 
denatured in 2 x SDS buffer, and subjected to SDS-PAGE. Immunoblotting and detection 
of tyrosine phosphorylation was performed as previously [18], using 4G10-HRP. 
 
Cloning of rat CD6 cDNA 
Total RNA was isolated from Lewis male rat spleen using Trizol (Life 
Technologies, Barcelona). cDNA was obtained using the ThermoScript RT-PCR System 
(Life Technologies) from total RNA primed with oligo(dT). Rat Cd6 was amplified with 
primers designed based on the reported sequence of mouse Cd6 (GenBank U37543). 
The following primers were used: forward primer from 5’ UTR of mouse Cd6 5’-
GCACTAAGCTTGGGCAGGCGTGAGTAGCAGT-3’ and reverse primer containing the 
stop codon sequence of mouse Cd6 5’-
TACGATGACATCGGTGCAGCCTAGCCTCTAGACCCG-3’.  The 2.0 Kb fragment 
obtained in the PCR reaction was then gel purified and cloned into TOPO 2.1-vector 
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(Invitrogen, Groningen). The sequence was confirmed by de-deoxy sequencing. The 
sequence of the 3’ untranslated region was obtained by using 3’RACE (Life Technologies) 
following the manufacturer’s instructions. Based on sequence information from the 
previous PCR, the primers designed were: forward 5’-GCTCCCAGAGACATCCCA-3’ 
(within exon 6) and reverse universal adapter primer. The first strand for this reaction was 
obtained using oligo dT/adapter primer to obtain the 3’ end of the cDNA. 
 
Transfection of COS7 cells 
A truncated form of rat CD6 (M6.1) lacking part of the cytoplasmic domain 
(residues 524 to 665) was used for transient transfection of COS7 cells and was obtained 
as follows: rat CD6 cDNA cloned in TOPO 2.1 vector was used as a template for the 
amplification PCR reaction using as forward primer a sequence derived from 
5’untranslated region of mouse CD6 5’-GCACTAAGCTTGGGCAGGCGTGAGTAGCAGT-
3’ and a reverse primer designed within CD6 cytoplasmic tail 5’-
CTCTTCAAGTCATTCCTCCAAGGGTGGCATCCG-3’, containing a STOP codon. The 
PCR product obtained was blunt-end sub-cloned into the expression vector pEF-BOS 
[24]. The orientation of the insert was confirmed by colony-PCR. Transient transfection in 
COS7 cells was performed as follows: cells were grown in 80 cm2 flasks in C02 incubator, 
37ºC, 5% CO2, until they were 50-75% confluent. Following washing with RPMI a 
transfection mix containing 0.4 mg/ml DEAE-Dextran, 100 µM chloroquine and 1 µg/ml 
DNA, in RPMI, was added to the cells for 2 hrs, at 37ºC, 5% CO2. Cells were washed with 
PBS, and incubated in DMSO, 10% in PBS, for 2 min followed by two washings with PBS. 
Cells expanded for 48 hrs in RPMI/10% FCS + antibiotics, at 37ºC in 5% CO2. COS7 cells 
were detached from flasks 24 hrs post-transfection, with Trypsin-EDTA solution (Sigma-
Aldrich, Sintra), washed with PBS, and replatted in complete RPMI medium. 
 
Flow cytometry 
48 hours after transfection, COS7 cells were removed from flasks with PBS/EDTA 
(0.2 g/L) and resuspended in PBS containing 0.2% BSA and 0.1% NaN3 
(PBS/BSA/NaN3), at a concentration of 1 x 106 cells/ml.  
Staining was performed by incubation of 2 x 105 cells/well with mAbs (20 µg/ml) for 
30 min on ice, in 96-well round-bottom plates (Greiner, Nürtingen). Cytometric analysis 
was as previously described [18].  
 
Cell surface biotinylation and immunoprecipitations 
Cell surface biotinylation, immunoprecipitations and reprecipitations were 
performed as previously described [18]. 
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Immune complex kinase assays 
Kinase assay buffer (30 µl) containing 10 mM MnCl2, 1 mM Na3V04, 1 mM NaF, 
and 50 µCi (185 KBq) of [γ-32P] ATP (>5000 Ci/mmol, Amersham), was added to the 
beads containing the immune complexes, and in vitro kinase reactions were allowed to 
occur for 15 min at 25°C. When indicated, a biotinylated peptide containing the CD5 
pseudo-ITAM sequence (Biot-AASHVDNEYSQPPRNSRLSAYPALE-OH) was also 
included in the reaction mix at a final concentration of 0.5 µg/µl, and in this case incubated 
at 30ºC for 10 min. Reactions were stopped with 30 µl of 2x SDS buffer and boiling for 5 
min, and the products separated by SDS-PAGE. Gels were dried and exposed at –70ºC to 
Biomax MR-1 films. Biotin-labeled CD5 peptide was recovered using avidin beads (Pierce, 
Illinois) and the incorporated [γ-32P]-ATP measured in a Beckman liquid scintillation 
counter. Results are expressed in counts per minute (cpm). 
 
 
RESULTS 
 
Enhanced tyrosine phosphorylation of cellular substrates upon crosslinking the 
TCR with the OX52 antigen 
We have looked for molecules involved in the regulation of CD5 phosphorylation. 
Upon TCR triggering the 67-kDa antigen CD5 becomes tyrosine phosphorylated [14]. 
Using rat lymph node cells, we detected phosphorylation of substrates in cells stimulated 
with the mAb OX52 or an anti-TCR mAb, R73 (Fig. 1). Using a combination of both mAb, 
proteins of 100 kDa, 85 kDa, and 38-40 kDa had an increased level of phosphorylation 
when compared to cells stimulated with R73 or OX52 alone. However, we particularly 
noticed that a protein of 66 kDa phosphorylated upon R73 triggering was also 
phosphorylated upon OX52 crosslinking alone. Co-ligation of OX52 and R73 increased 
the phosphorylation only slightly. We therefore decided to further investigate the OX52 
antigen, and to see whether this molecule was involved in the regulation of CD5 
phosphorylation. 
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Figure 1. Coligation of OX52 antigen and TCR enhances tyrosine phosphorylation. Rat lymph 
node cells were left unstimulated or stimulated with either R73 (10µg/ml), OX52 (10µg/ml), or with 
a combination of both, and cross-linked with RAM. Cells were lysed in 1% NP-40 and equal 
amounts of cleared lysates were resolved on SDS-PAGE, transferred to nitrocellulose membranes 
and immunoblotted with 4G10-HRP. Phosphorylation of a 66-kDa protein is indicated by an arrow. 
 
 
CD5 associates with the OX52 antigen, and is highly phosphorylated in kinase 
assays 
We performed immunoprecipitations on cell lysates from surface biotinylated C58 
cells. Following cell lysis using Brij 96, CD2, CD5, CD28, TCR and the OX52 antigen were 
precipitated using specific antibodies. OX21 was used as a negative control (Fig. 2A). 
Immune complexes were subjected to SDS-PAGE and transferred onto nitrocellulose 
membranes, and biotinylated proteins were detected by streptavidin-peroxidase/enhanced 
chemiluminescence. CD2, the αβTCR chains, CD5 and CD28 could easily be detected at 
their expected sizes in the respective lanes. In the lane of OX52, a broad smear was 
detected above 100 kDa. Common to all lanes, except those of CD28 and OX21, was a 
protein of 66 kDa, presumed to be CD5. To prove that this protein was CD5, we disrupted 
the immune complexes and performed reprecipitations using polyclonal anti-CD5. The 
amount of CD5 precipitating with OX52 was comparable to that associating with either 
CD2 or with the TCR (Fig. 2B). 
In parallel, immunoprecipitates of CD2, CD5, TCR, CD28 and OX52, were 
subjected to in vitro kinase assays. Very strong phosphorylation was detected in both CD5 
and OX52 immunoprecipitations (Fig. 2C). Again, the OX52 precipitate contained a 
protein of molecular weight above 100 kDa, and additionally the 66-kDa protein. 
Conversely, CD5 coprecipitated a high molecular weight phosphoprotein with the same 
mobility as that present in OX52 immune complexes. Reprecipitation of CD5 confirmed 
that OX52 was associated with phosphorylated CD5 (Fig. 2D). 
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Figure 2. CD5 associates at similar 
levels with CD2, TCR and OX52, but is 
highly phosphorylated when 
associating with OX52. A, C58 cells 
were biotinylated, lysed in 1% Brij 96 and 
subjected to immunoprecipitations with 
mAb specific to CD2, TCR, CD5, CD6, 
CD28 and OX21 (negative control). 
Immune complexes were resolved on 
10% SDS-PAGE under non-reducing 
conditions and transferred to 
nitrocellulose. The membrane was 
incubated with streptavidin-HRP and 
visualised by enhanced 
chemiluminescence. B, Biotinylated CD5 
was reprecipitated from the immune 
complexes shown in A, run in SDS-
PAGE and visualised as above (indicated 
by an arrow).  C, In vitro kinase reactions 
were performed in immune complexes of 
the molecules indicated. Following SDS-
PAGE, phosphorylated products were 
visualised by exposure of the dried gel at 
–70ºC to Biomax MR-1 films. Immune 
complexes were disrupted and CD5 (D) 
and CD6 (E) were reprecipitated with the 
use of polyclonal antibodies, subjected to 
SDS-PAGE and exposed to 
autoradiography. 
 
Interestingly, although CD5 did coprecipitate with CD2 and TCR, the fraction of 
CD5 associating with either CD2 or the TCR was not highly phosphorylated. In fact, 
phosphorylated CD5 could hardly be detected in CD2 immunoprecipitations. These data 
mean that in our experimental conditions CD2, TCR and OX52 all coprecipitate CD5 
equivalently, but only the fraction of CD5 associating with OX52 is highly phosphorylated. 
Based on the molecular weight and tissue distribution of OX52 [20], we 
hypothesized that the OX52 antigen was the rat homologue of CD6. Using a polyclonal 
anti-mouse CD6 serum, we attempted to reprecipitate CD6 from the immune complexes. 
Reprecipitation of CD6 yielded a phosphoprotein of 110 kDa present in OX52 immune 
complexes, and to a lesser extent in CD5 immune complexes, but not in those of CD2, 
TCR or CD28 (Fig. 2E).  
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PCR cloning of the rat homologue of CD6 
For the purpose of cloning rat Cd6, we obtained cDNA by RT-PCR from RNA 
isolated from splenocytes of Lewis male rats. Primers were designed based on the cDNA 
sequence of mouse Cd6 (GenBank U37543). The 5’ primer is 17 bases upstream of the 
start codon, and the 3’ primer overlaps with the stop codon. The PCR amplified DNA 
fragments ranging from 1.4 to 2.0 Kb, probably corresponding to different CD6 isoforms 
that result from alternative splicing. We gel-purified the heaviest DNA product, and sub-
cloned it into the vector TOPO 2.1. Sequencing of this product revealed an open reading 
frame of 1998 bases. With this sequence information, the gene-specific primer for 3’-
RACE was designed (see Material and Methods). The 3’-RACE reaction produced a 
fragment that included a further 893 bp from the stop codon until the poly (A) tail.  
The coding sequence of rat Cd6 (GenBank accession no AF488727) corresponds 
to a 665 amino acids long polypeptide (Fig. 3). It has 89% identity with mouse CD6 and 
71% identity with the human molecule (GenBank U34625). Domain 2 shares the highest 
identity, 95%, with the mouse homologue, when compared with domains 1 and 3, which 
have 54% and 88% identity, respectively. The highest level of identity with the human 
sequence (85%) is found for domain 3. 
Analysis of the rat CD6 amino acid sequence reveals only one feature different from the 
mouse sequence, an additional putative N-glycosylation site at position N92. Comparing 
to the human sequence, major differences lie within the cytoplasmic domain. Although all 
tyrosine residues and PKC phosphorylation sites are conserved, only five of the eight 
putative casein kinase II phosphorylation sites are shared among man, rat and mouse 
CD6. One relevant difference between the human and the rodent sequences is that the 
mouse and rat sequences contain three putative SH3-binding sequences, whereas the 
human has only two, the membrane-proximal diproline motif 468PRVP being changed to 
472APPP.  
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Figure 3. Comparison of the predicted amino acid sequence of rat CD6 with mouse and 
human sequences. Identical residues are denoted by asterisks. SRCR domain boundaries and 
the transmembrane region are indicated by arrows. Potential N-glycosylation sites are NG’s. 
Tyrosine residues are highlighted at grey. The following intracellular motifs are indicated: three 
proline-rich sequences in rat and mouse contrasting with only two in human are denoted by PR’s. 
The motifs containing the casein kinase II phosphorylation site consensus sequence are indicated 
by Ck. PKC phosphorylation consensus sequence containing motifs are indicated by KC. The 
accession number of rat CD6 is AF488727 at the database of the National Center of Genome 
Resources. 
 
OX52 is the rat homologue of CD6 
The proof required to assign OX52 as rat CD6 was that this antibody specifically 
recognizes expressed CD6, and we performed these experiments in a non-lymphoid 
system. As the OX52 epitope lies within the extracellular domain, we produced a 
truncated form of rat CD6, which removes part of the cytoplasmic domain (see Material 
and Methods). We transfected the CD6 cDNA into COS7 cells, and 48 hours post-
transfection cells were surface biotinylated, lysed with Brij 96, and subjected to 
immunoprecipitations using the OX52 mAb. As control, we used COS7 cells transfected 
with the empty vector. OX52 mAb was able to precipitate a labeled protein expressed only 
in the CD6 transfected cells, not in the control cells (Fig. 4A). Moreover, we additionally 
used a polyclonal antibody raised against the extracellular domain of mouse CD6 to 
immunoprecipitate the expressed rat CD6. Given the high homology between the rat and 
mouse molecules, it was not surprising that this anti-serum precipitated a protein with the 
same mass as that precipitated by OX52.  
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The identity of OX52 as rat CD6 was also confirmed by FACS analysis. OX52 mAb 
did not detect any proteins on the surface of mock-transfected COS7 cells. However, in 
CD6 transfected cells, a sub-population was clearly positive for staining with OX52 (Fig. 
4B). 
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homologue of CD6. (A) COS7 cells 
were transiently transfected with cDNA 
containing a truncated form of rat CD6 
(M6.1) lacking most of the cytoplasmic 
domain, inserted in pEF-BOS, or 
transfected with the empty vector (pEF-
Bos). 48 hours post-transfection cells 
were biotinylated and lysed in Brij 96. 
OX52 mAb and polyclonal anti-mouse 
CD6 antiserum were used to 
immunoprecipitate the expressed rat 
CD6. As negative control (Neg), we used 
the OX19 mAb. Immune complexes were 
separated by SDS-PAGE and transferred 
to nitrocellulose. Membranes were 
incubated with streptavidin-HRP and 
biotinylated CD6 visualised by enhanced 
chemiluminescence. (B) Rat CD6 
expression was analysed by flow 
cytometry. Both mock-transfected (upper 
histogram), as well as rat CD6 (M6.1 
cDNA)-transfected COS7 cells (lower 
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the surface proteins and the kinases, except ZAP-70, were also detected using other 
detergents such as NP-40 and Triton X-100 (data not shown). CD6 could coprecipitate 
Lck, Fyn and Itk, in all detergents, whereas ZAP-70 associations were lost when using 
other detergents than Brij 96.  
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Figure 5. CD6 associates with Src kinases Lck and Fyn, with ZAP-70 and with the Tec family 
kinase Itk. C58 cells were lysed in Brij 96 and the indicated surface proteins immunoprecipitated. 
Immune complexes were subjected to kinase reactions, following which the reaction products were 
denatured, and Lck, Fyn, ZAP-70 and Itk reprecipitated using specific polyclonal Abs. Precipitates 
were ran on SDS-PAGE, transferred to nitrocellulose and the 32P incorporation detected by 
autoradiography. 
 
Lck, together with Itk, efficiently phosphorylates CD5 peptides 
The previous data suggested that a kinase or a combination of kinases associating 
with rat CD6 has the capacity to induce a high level of phosphorylation of tyrosine 
residues within the CD5 cytoplasmic domain. Therefore, we decided to test the 
phosphorylation efficiency of individual or combinations of kinases towards a synthetic 
peptide comprising two tyrosine residues within the ITAM-like motif of CD5. C58 cells 
were lysed with Triton X-100, and Lck, Fyn, Itk, and Zap-70 were immunoprecipitated, 
either alone or in pairs, using specific polyclonal anti-sera. Kinase assays of the immune 
complexes were performed at 30ºC for 10 min in the presence of the CD5 peptide, 
biotinylated at the N-terminal residue. Phosphorylated peptide was recovered from the 
solution through precipitation with streptavidin beads, and radioactive counts associated 
with the peptide were measured in a β counter. From the upper panel on Figure 6, it can 
be observed that Lck alone is able to efficiently phosphorylate the peptide, whereas Fyn 
has a much lower efficiency, and Itk or ZAP-70 phosphorylate the peptide only residually. 
When testing combinations of pairs of kinases (Fig. 6, lower panel), we observed that the 
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best combination effectively phosphorylating the peptide was that of Lck with Itk. All other 
combinations had a significantly lower capacity of inducing peptide phosphorylation. 
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Figure 6. Lck together with Itk is the most efficient combination for the phosphorylation of 
an exogenous CD5 peptide. C58 cells were lysed in Triton X100 and Lck, Fyn, ZAP-70 and Itk 
immunoprecipitated alone (upper panel) or in pairs (lower panel) using specific polyclonal Abs. As 
negative control, we used rabbit pre-immune serum. Immune complexes were submitted to kinase 
assays in the presence of exogenous biotinylated CD5 peptide. The reaction was 10 min at 30ºC, 
following which the complexes were denatured and the peptide recovered by streptavidin beads. 
Incorporated radioactivity was measured in a β scintillation counter. The results are expressed in 
counts per minute (cpm). 
 
 
DISCUSSION 
 
T cell activation results from a combination of signals delivered by the TCR and 
other signaling molecules. Upon TCR/CD3 stimulation, CD5 is phosphorylated on tyrosine 
residues [14] and binds intracellular SH2 domain-containing signaling effectors. 
Conversely, CD5 triggering augments TCR responses [3, 4]. In the last years, however, in 
vivo studies have challenged the view that CD5 solely mediates activation signals. CD5-
null mice display enhanced reactivity of thymocytes towards antigen and increased 
positive selection, consistent with a down-modulatory role for CD5 [6]. These studies have 
rapidly obtained the support of in vitro data, in T and B-1a cells, showing that CD5 binds 
repressor molecules such as SHP-1, Cbl and Ras-GAP [7, 8, 13, 25].  
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Surface receptors other than the TCR may also exert some of their activities 
through CD5. CD2 falls in this category, firstly because stimulation via CD2 induces the 
dephosphorylation of CD5, possibly through the induction of SHP-1 activity [18], and 
secondly because CD2 synergizes with CD5 in the regulation of thymocyte selection. CD2 
null-mice also display enhanced thymocyte reactivity, an effect highly augmented in the 
CD2/CD5 double knock-out, suggesting that CD2 and CD5 are functionally associated in 
restraining thymocyte activation [26]. It is possible that engagement of different T cell 
antigens to the counter-receptors on APC originate different signals that may converge at 
the level of CD5 and thus regulate CD5 usage in signaling pathways. We propose that, a 
third T cell surface protein, CD6, is involved in the regulation of CD5 phosphorylation.  
The mAb MRC OX-52 was described in 1986 by Mason and co-workers, and was 
found to label an antigen mainly confined to the T cell areas of the lymphoid organs [20]. It 
has since been considered a marker for the T cell population in rat tissues or cell 
suspensions. We proved by cloning, cellular expression, cytometric analysis and 
molecular characterization that this protein is the rat homologue of CD6. 
Having established OX52 as rat CD6, we focused on the role of CD6 in the 
regulation of CD5 phosphorylation. In our assays, equal amounts of CD5 were obtained in 
immunoprecipitations of CD2, TCR and OX52. CD6, on the other hand, could only be 
coprecipitated with CD5 but not with CD2 or with the TCR, suggesting a close interaction 
between CD5 and CD6. Interestingly, whereas CD5 in OX52 immunoprecipitates could be 
highly phosphorylated in kinase assays, the same amount in CD2 precipitates could 
hardly be detected (Fig. 2). 
The obvious explanation, that CD2 did not associate with kinases capable of 
phosphorylating CD5, had to be discarded, since CD2 precipitated the largest amount of 
Lck. The hypothesis that Lck is not responsible for CD5 phosphorylation is equally 
improbable, given the evidence for this activity collected in the past [9, 10, 27]. 
Nevertheless, we tested this hypothesis by incubating Lck directly with a synthetic peptide 
containing the site of phosphorylation in the cytoplasmic domain of CD5, Y429, 
preferentially used by Lck. As expected, Lck efficiently phosphorylated the peptide (Fig. 
6). 
We have used tyrosine phosphatase inhibitors throughout our experiments. 
Nevertheless, it cannot be excluded that phosphatases may play a role in the inhibition of 
phosphorylation of the fraction of CD5 that is coupled to CD2. Most of the phosphatase 
activity associated with CD2 derives from CD45 [28, 29]. CD45 could dephosphorylate 
CD5 directly, or alternatively, dephosphorylate Lck and thus render it inactive [30]. 
Additionally, SHP-1 may as well dephosphorylate Lck at its activating residue Tyr-394 
[31]. 
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Although it remains unclear why CD2-associated CD5 is not readily 
phosphorylated, it appears easier to explain the strong phosphorylation observed in the 
fraction of CD5 that associates with OX52/CD6. Our studies show that tyrosine kinases of 
different families bind to CD6. In fact, rat CD6 coprecipitated Lck, Fyn, ZAP-70 and Itk, 
something not generally observed for the other cell surface proteins studied, CD2, TCR, 
CD5 and CD28. It is conceivable that the capacity of CD6 to induce the phosphorylation of 
CD5 may derive from the fact that it associates with different kinases, which may increase 
each other’s activities. Indeed, Lck and Fyn synergize with ZAP-70 to produce sustained 
responses [32], and a functional Lck is required for Itk phosphorylation and activation to 
occur [33]. Previous studies, where the levels of CD5 phosphorylation observed in Lck-
deficient cells were significantly lower when compared to Lck+ cells, clearly indicated a 
major role for Lck, but nevertheless suggested that other kinases whose activity may 
depend on Lck, potentially have a role in CD5 tyrosine phosphorylation [10]. 
In individual terms, Lck ranked as the most efficient kinase phosphorylating a CD5 
peptide, as can be depicted from Figure 6. Fyn is significantly less efficient, and Itk and 
ZAP-70 phosphorylate the CD5-peptide only residually. However, when we used pairs of 
kinases, the combination of Lck with Fyn was not the most effective. Rather, Lck in 
conjunction with Itk gave the best incorporation of radioactive ATP in the CD5 peptide. 
Moreover, we noticed that the Itk kinase was phosphorylated only in the presence of Lck, 
but not of Fyn or ZAP-70 (not shown). Therefore, Lck and Itk may have a combined role in 
promoting the efficient phosphorylation of CD5, and thus explain the exceptional capacity 
of CD6 in supporting the high level of CD5 phosphorylation observed. Alternatively, an 
independent inhibitory effect of both Fyn and ZAP-70 on Lck, possibly through the 
phosphorylation of the C-terminal inhibitory tyrosine residue of Lck, may exist, thus 
explaining why CD5 is less susceptible to tyrosine phosphorylation in the presence of the 
TCR or CD2.   
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ABSTRACT 
 
The great majority of mammalian genes yield multiple transcripts arising from 
differential mRNA processing, but in very few instances have alternative forms been 
assigned distinct functional properties. We have cloned and characterized a new isoform 
of the accessory molecule CD6 which lacks the CD166-binding domain. The novel 
isoform, CD6∆d3, results from exon 5 skipping and consequently lacks the third 
scavenger receptor cysteine-rich (SRCR) domain of CD6. Differential expression of the 
SRCR domain 3 resulted in a remarkable functional difference: whereas full-length CD6 
targeted to the immunological synapse, CD6∆d3 was unable to localize at the T cell:APC 
interface during antigen presentation. Strikingly, whereas full-length CD6 is the 
predominant polypeptide species in resting cells, CD6∆d3 is markedly up-regulated upon 
activation of T lymphocytes, partially substituting full-length CD6, as evaluated by 
immunoblotting, and by flow cytometry using antibodies recognizing SRCR domains 1 and 
3 of human CD6. Analysis of expression of CD6 variants showed that, the CD6∆d3 
isoform is significantly expressed in a significant number of thymocytes, constituting the 
sole species in a small percentage of cells; suggesting that CD6 switching between full-
length and ∆d3 isoforms may be involved in thymic selection as well. This elegant 
mechanism controlling the expression of the CD166-binding domain may help regulate 
signaling delivered by CD6, through different types of extracellular engagement. 
 
 
INTRODUCTION 
 
T cell receptor recognition of peptide-MHC complexes expressed on antigen 
presenting cells (APC) involves the formation of a tight cell-cell contact area, the 
immunological synapse, where individual proteins are selectively partitioned [1, 2]. The 
model of synapse formation predicts an initial stabilization of the contact by engaged 
integrins, which anchor the region of the contact and allow the TCRs to scan MHC-peptide 
complexes [3]. With time, stably engaged TCR complexes coalesce into a central area 
(cSMAC, central supramolecular activation clusters), surrounded by a ring (pSMAC, 
peripheral supramolecular activation clusters) enriched in the integrin LFA-1 [2, 4]. In the 
mature synapse, cSMAC are also enriched in the co-stimulatory molecule CD28 and the 
CD4 or CD8 co-receptors [3, 5]. It has been suggested that the formation of the synapse 
is favoured by receptor-ligand interactions of small auxiliary molecules such as CD2-CD58 
and CD28-CD80 that stabilize the cell contact by the formation of low-affinity interactions, 
in a size dependent-manner. According to this model, the small adhesion pairs cluster at a 
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tight membrane region, thus segregating larger glycoproteins such as CD43 or CD45 [1, 
6].  
CD6 is a 100-130-kDa surface glycoprotein expressed primarily on medullary 
thymocytes and mature T lymphocytes [7]. CD6 has been regarded as a co-stimulatory 
molecule as antibody-mediated CD6 crosslinking can potentiate proliferative T cell 
responses [8-10]. Moreover, a sub-population of CD6 negative T cells displayed lower 
alloreactivity in mixed leukocyte reactions compared to normal CD6+ T cell populations 
[11].  CD6 could additionally play a role in thymocyte maturation, as CD6 antibodies have 
been shown to partially block the adhesion of thymocytes to thymic epithelial cells [12]. 
This observation also provided the first evidence that CD6 had a cell surface ligand. A 
requirement for ligand engagement for costimulatory effects of CD6 was shown by 
inhibition of antigen-specific and CD3 mAb induced T cell responses by soluble CD6 [13, 
14]. Recently, CD6 has been reported to accumulate at the immunological synapse, 
mediating early and late T cell-APC interactions required for immunological synapse 
maturation and cell proliferation [13, 15]. 
Upon CD3 engagement CD6 becomes phosphorylated on tyrosine residues 
suggesting that interactions with SH2 domain-containing intracellular effectors may occur 
[16]. An interaction with the SH2 domain of SLP-76 has been shown to be critical for the 
costimulatory effects of CD6 [17]. The cytoplasmic domain of CD6 is unusually long, and 
contains additionally two well-conserved proline-rich sequences, potential binding sites for 
SH3 domain-containing proteins well-suited for signal transduction [16, 18]. Indeed, the rat 
homologue of CD6 has been shown to associate with protein tyrosine kinases of different 
families, namely Src-family kinases Lck and Fyn, ZAP-70 of the Syk family, and the Tec-
family kinase Itk [19]. CD6 has additionally been shown to associate at the surface of T 
cells with CD3 [13] and with the structurally related receptor CD5 [19, 20]. However, there 
are still no data proposing a functional role for these interactions.  
By contrast, the molecular basis of the interaction between CD6 and the 
extracellular physiological ligand, CD166, has been comprehensively investigated in 
human and murine models [21]. CD166 is a widely expressed glycoprotein containing five 
immunoglobulin superfamily domains, of which the N-terminal domain has been shown to 
bind to the third Scavenger Receptor Cysteine-Rich (SRCR) type domain of CD6, the 
membrane-proximal domain [22, 23]. The residues of CD6 involved in the contact with 
CD166 are located in the E-F loop, a region that in the particular case of the third domain 
of CD6 is most divergent from all known SRCR domains [24]. The resulting interaction 
between CD6 and CD166 is therefore unusual, as most other T cell surface proteins 
mediating cell-cell interactions bind through their N-terminal domains. However, affinity 
and kinetic measurements revealed that, in solution, binding occurs with a Kd of 0.4-
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1.0 µM [14], relatively strong compared to most other leukocyte adhesion pairs, albeit in 
the range of low affinity interactions characteristic of cell surface receptors [25-27]. 
The human, rat and mouse Cd6 genes contain thirteen exons, of which the last six 
code for the cytoplasmic tail. Numerous CD6 isoforms have been reported that result from 
alternative splicing of the exons coding for the cytoplasmic domain [18, 28-30], but no 
specific physiological function has been attributed to any of these isoforms. Exon 7 
contains the sequence coding for the transmembrane domain, and the first six exons code 
for most of the extracellular domain. Alignment of the CD6 extracellular sequence with 
that of the scavenger receptor domain of Mac-2 binding protein, for which a crystal 
structure has been obtained [24], predicts that each scavenger-type domain of CD6 is 
encoded by a single exon, and that removal of each of these exons would result in a 
protein only devoid of the correspondent domain. We have obtained from thymocytes and 
peripheral T cells four alternatively spliced isoforms of human CD6 cDNA lacking 
sequences encoding extracellular exons. In particular, one isoform omits exon 5, whose 
corresponding translated polypeptide lacks the SRCR domain 3. This CD6 isoform, 
CD6∆d3, is up regulated upon activation, paralleling a decline in the expression of full-
length CD6. The failure of CD6∆d3 to bind to the CD6-ligand, CD166, highlights the role of 
domain 3 in addressing CD6 to the immunological synapse, and the down-modulation of 
domain 3 induced upon T cell activation reveals a rare mode of positional control of cell 
surface receptors dependent on alternative mRNA splicing. 
 
 
MATERIALS AND METHODS 
 
Cells and cell lines 
Human primary T cells were isolated from peripheral blood by using the 
RosetteSep human T cell enrichment cocktail (StemCell Technologies, Grenoble, France). 
All cell lines: E6.1, JKHM, B-CLL, J.CaM1 [31], P116 and Raji [32] were maintained in 
RPMI 1640 supplemented with 10% FCS, 1 mM sodium pyruvate, 2 mM L-glutamine, 
penicillin G (50 U/ml) and streptomycin (50 µg/ml). Thymocytes were isolated from human 
thymic biopsy specimens (derived from children under 2 years of age undergoing 
corrective cardiac surgery).  
 
Antibodies and reagents 
Human monoclonal antibodies were OX126 [17], specific for human CD6 domain 3, 
FITC-labeled UMCD6 [9], anti-domain 1 of CD6, from Ancell (Bayport, MN), MEM-98 [33] 
(anti-CD6 domain 1, a kind gift from Václav Hořejší, Academy of Sciences, Prague, Czech 
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Republic), CD166-3A6 [34] (BD Pharmingen, San Diego, CA), CD71 (Dako, Glostrup, 
Denmark) and CD3-OKT3. Polyclonal antibodies: goat anti-mouse peroxidase-conjugated 
was from Molecular Probes Europe (Leiden, The Netherlands), rabbit anti-mouse FITC-
labeled from Dako (Glostrup, Denmark), rabbit anti-mouse Ig, RAM from BD Biosciences 
(Heidelberg, Germany), anti-phosphotyrosine HRP-conjugated-4G10 from Upstate 
Biotechnology (Lake Placid, NY) and Rhodamine Red-X-conjugated anti-mouse IgG 
secondary antibody from Jackson ImmunoResearch Laboratories (WestGrove, PA) were 
also used. 
 
cDNA cloning and plasmids 
Total RNA was isolated from JKHM, E6.1, human PBMC and human thymocytes 
using RNA extraction Kit (Qiagen, Venlo, The Netherlands). cDNA was obtained using the 
ThermoScript reverse transcriptase-polymerase chain reaction (RT-PCR) system (Life 
Tecnologies, Barcelona, Spain) from total RNA primed with oligo(dT). Human Cd6 was 
amplified with primers designed based on the reported sequence (GenBank U34625). The 
following primers were used in the cloning of the isoforms: forward primer spanning the 
initiation codon 5’-CGCGGATCCTCTAGATGTGGCTCTTCTTCGGGATCACTGGAT TG-
3’ and reverse primer in the exon 7 (TM-coding sequence) of human Cd6 5’- 
GGAGCATTAGCTCCCGAGATTCCTTG - 3’. The PCR fragments were cloned into 
pCR2.1-TOPO vector. The sequences were confirmed by de-deoxy sequencing. Human 
CD6FL/pEGFP-N1 was produced by amplifying full-length sequence from the clone 
CD6/pBJ-neo [18] by PCR using as the forward primer 5’- 
CGCGGATCCTCTAGATGTGGCTCTTCTTCGGGATCACTGGATTG-3’ and the reverse 
primer 5’- CTACTAGAATCCGCTGCGCTGATGTCATCG -3’. The PCR product was then 
cloned into the BamHI restriction site of pEGFP-N1 vector (Clontech Laboratories, Palo 
Alto, CA) producing CD6FL/pEGFP-N1. The CD6∆d1/pEGFP-N1 construct was obtained 
by digestion of CD6∆d1/TOPO 2.1 with XhoI and SmaI and the product obtained was 
subcloned into CD6WT/pEGFP cut with the same enzymes. The isoform CD6∆d3 was 
amplified from the vector pCR2.1-TOPO using the primer M13-R from the vector as the 
forward primer, and a reverse primer in the exon 7 of human CD6 including a naturally 
occurring EcoRI restriction site 5’-CTACTAGAATTCCCAGAACGATGGAGG 
GGATGAGGAGCATTAGCTCCCGAGATTCCTTG-3’. The PCR product was inserted in 
the CD6FL/pEGFP-N1 producing CD6∆d3/pEGFP-N1. A cytoplasmic deletion mutant of 
human CD6 fused to GFP was produced by PCR from CD6/pBJ-neo with the forward 
primer 5’-CTCCAGACATGTGGCTCTTCTTCGG-3’ and the reverse primer 5’-
GCCTTCATCCTCTTGAGAATTAAAGGAAAA-3’, terminating just before the first tyrosine 
residue codon of the cytoplasmic domain. The PCR product was cloned into the TOPO 
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cloning site of pcDNA3.1/CT-GFP-TOPO, using GFP Fusion TOPO TA Expression Kits 
(Invitrogen, version I), to produce CD6CY5/pcDNA3.1/CT-GFP-TOPO.  
 
Cellular activation  
Human primary T cells were activated by incubating 3 × 106 cells/ml with 
Phytohemagglutinin (PHA-P) at 5 µg/ml in RPMI, at 37ºC, 5% CO2, or left untreated. After 
72h cells were collected and analyzed by flow cytometry or immunoblotting. For 
phosphotyrosine detection, approximately 5 × 106 cells were used per sample. The 
different mAb used were added at 2-10 µg/ml to cells and incubated on ice for 15 min. 
RAM at 20 µg/ml was then added to cells and incubated at 37ºC for the times indicated. 
No crosslinking was required when cells were stimulated with OKT3. Cells were briefly 
pelleted and lysed for 30 min on ice in NP-40 lysis buffer (10 mM Tris-HCl (pH 7.4), 150 
mM NaCl, 1 mM EDTA, and 1% NP-40), containing 2 mM NaF, 2 mM PMSF and 2 mM 
Vanadate. Nuclei and cellular debris were removed by centrifugation at 12,000 × g for 10 
min at 4ºC. 
 
Immunoblotting and flow cytometry  
Immunoblotting and flow cytometry were performed as described previously [35]. 
 
Cell Transfections 
Primary T lymphocytes (5 × 106 cells) were transiently transfected with 5 µg of 
CD6FL/pEGFP-N1, CD6∆d3/pEGFP-N1 or CD6CY5/pcDNA3.1/CT-GFP-TOPO plasmids 
using the Human T cell Nucleofector kit (Amaxa, Köln, Germany), and T cells were used 
24 h post-transfection.  
 
Conjugate formation and fluorescence analysis  
Raji B cells were incubated with a mix of superantigens (rSEE, SEA, SEB and 
SEC3, 200 ng/ml each, Toxin Technologies, Sarasota, FL) and plated on poly-D-lysine-
coated glass coverslips for 30 min at 37ºC. T cells were added to APCs and then 
incubated at 37ºC for 45 min. Cells were fixed with 4% paraformaldehyde in PBS for 10 
min and washed several times with PBS before analysis. Where indicated, T cells were 
pre-incubated, for 30 min at 4°C, with the mAbs OX126 or UMCD6-FITC, and Raji B cells 
pre-incubated with 3A6 (CD166), all at 10 µg/ml, or left untreated. Immunofluorescence 
and transmission light images were acquired on an Eclipse TE300 inverted microscope 
(Nikon, Melville, NY) equipped with a cooled CCD camera (CoolSNAPFx, Roper 
Scientific, Evry, France). Images were acquired and analyzed using the Metamorph 
software (Roper Scientific). Conjugate formation and synapse localization of CD6 or 
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CD166 were quantified with blind scoring, counting a minimum of 50 productive 
conjugates in each of two or more experiments, and each experiment was observed by 
two to three examiners.  
 
Single-cell Ca2+ and fluorescence video imaging 
Raji cells were prepared and pulsed with Ag as described above and plated on 
glass coverslips mounted on 30-mm petri dishes. T cells were pre-incubated for 30 min at 
4°C with the blocking mAb against d3 of CD6, OX126, at 10 µg/ml or left untreated. The T 
cells were then loaded with 1 µM Fura-2AM (Molecular Probes) in 1 ml of Hepes buffer 10 
mM, pH 7.5 containing 140 nM NaCl, 5 mM KCl, 1 mM CaCl2, 0.5 mM MgCl2, 1 mM 
Na2HPO4 and 1 mg/ml glucose and added to APC at 37°C. After T cells were added, 
Fura-2 fluorescence was followed with a TE300 inverted microscope and the Metafluor 
software (Universal Imaging, West Chester, PA) was used. Averaged Ca2+ responses 
were calculated in cells showing a Ca2+ increase >150 nM. Transmission light images 
were taken every 12 s in turn with fluorescence images. 
 
Phosphotyrosine accumulation measurements at the immunological synapse  
Raji and T cells were prepared as described for conjugate formation. After cells 
were fixed, phosphotyrosines were labeled with the anti-phosphotyrosine, 4G10 at 5µg/ml 
followed by labeling with Rhodamine Red-X-conjugated anti-mouse IgG secondary 
antibody. For synaptic phosphotyrosine signal we calculated a ratio of the signal inside the 
synapse divided by the signal outside the synapse measured on two regions of same 
area. Data were averaged from 40 cells analyzed for each condition. 
 
RNAse Protection Assays (RPA) 
Total RNA from E6.1 cells was analyzed for quantifying the different human CD6 
mRNA species.  The two RPA probes and the regions they span in human Cd6, as well as 
the expected sizes of the protected fragments are shown in figure 3A. Probe 1 cDNA 
template was designed to include 46 bp of exon 1, exon 2, exon 3 and 311bp of exon 4. 
An RPA with this probe could generate three different patterns of bands: one with a band 
sized at 777 bp, the full-length isoform; the other with two bands at 115 and 311 bp 
corresponding to the CD6∆d1 isoform and the third pattern with also two bands of 46 and 
311 bp generated by the CD6∆Ex2d1 isoform. Probe 2 comprises 79 bp of exon 4, exon 
5, exon 6 and 77 bp of exon 7. In the same manner, this probe can give rise to three 
patterns: one band at 525 bp, the full-length isoform; another with two bands at 79 and 
143 bp corresponding to the CD6∆d3 isoform and the last pattern with two bands of 79 
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and 77 bp generated by the CD6∆d3Ex6 isoform. RT-PCR was used to obtain a cDNA 
template for the antisense RNA probe 1 and the fragment was cloned into pCR4-TOPO. 
The cDNA for probe 2 was produced by restriction of the plasmid pBJneo-CD6 with HindIII 
and EcoRI. The fragment was cloned into pDP-20 using the same restriction enzymes.  
Probe 1 and 2 were linearized using NotI and HindIII respectively, purified and complete 
digestion was checked on agarose gel. 32P-radiolabeled UTP (NEN) was incorporated into 
probes by in vitro transcription using T3 polymerase for probe 1 and T7 polymerase for 
probe 2.  
E6.1 cells total RNA (30 µg) was hybridized with excess amounts of each 
riboprobe. After overnight hybridization at 65ºC and at 75ºC, the samples were digested 
with RNAse A/T1 for 90 minutes at 37ºC. As a digestion control (D), of RNAse A/T1, the 
same amount of probes was directly digested. The fragments protected from RNAse 
digestion were resolved on 8% 8M urea denaturing acrylamide gels and visualized using 
X-ray films. pBR322 DNA-MspI digest (New England Biolabs, ) was used as molecular 
weight marker.  
 
 
RESULTS 
 
Four novel human CD6 extracellular isoforms arise from alternative splicing 
Different CD6 isoforms, both from human and mouse, have been described arising 
from alternative splicing of exons coding for sequences within the cytoplasmic domain [18, 
28-30]. Cloning of the rat homologue of CD6 [19] allowed us to notice that an additional 
isoform, CD6∆d3, resulting from alternative splicing of an exon coding the third SRCR 
domain, the CD166-binding domain, was expressed on different tissues of lymphoid origin 
(Castro et al. 2007, unpublished results). We thus investigated whether a similar isoform, 
or eventually additional isoforms, were expressed in human cells as well. 
The first cDNA coding for human CD6 was originally obtained from a peripheral 
blood acute lymphocytic leukemia expression cDNA library [7], although, as was 
acknowledged later, it lacked a substantial portion of the cytoplasmic tail coding 
sequence. In the subsequent work, polymerase chain reaction-based methods were 
unsuccessfully employed to re-clone the entire molecule. This was partly due to the length 
of the first intron (35 kb), but also to the fact that the 5’ coding region contains large GC-
rich sequences. Therefore, the cytoplasmic isoform-coding transcripts that were being 
found by different research groups were grafted onto the original HPB-ALL cDNA 
containing the extracellular coding sequences [18, 30]. All succeeding work addressing 
the function of different mRNA-encoded cytoplasmic isoforms thus contained the same 
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extracellular domain, and no further research on possible extracellular variants of CD6 
has been performed since. 
Having improved amplification efficiency with the use of DMSO and the choice of 
an efficient polymerase, we were successful in obtaining from human peripheral blood 
mononuclear cells (resting and activated), human thymocytes, and the leukemic T cell 
lines JKHM and E6.1, cDNAs coding for the full-length molecule and also several PCR 
products with sizes ranging from 2000 down to 1600 bp (Figure 1A, results shown are 
from amplification using PBMC). We then tested for the existence of extracellular 
isoforms, performing RT-PCR reactions amplifying just the extracellular domain-coding 
sequences. Amplification products of 1200 bp, and 300 bp shorter, were clearly detected 
(Fig. 1A, right lane).  
The several cDNA species obtained from each cell type, displaying distinct mobility 
on agarose gels, were gel-purified and sub-cloned into the TOPO 2.1 vector. Sequencing 
showed that the longest product was full-length CD6 in all cases. Four different isoforms 
lacking extracellular-coding exons were revealed, and confirmed by sequencing (Figure 
1B-C). Alignment, from the N-terminus up to the transmembrane domain, of the 
corresponding amino acid sequences with that of wild-type human CD6 shows that these 
cDNAs code for novel isoforms. The boundaries of the SRCR domains are indicated by 
arrows, according to Hohenester et al. [24] (Figure 1B). The scheme of the structure 
obtained for the five CD6 protein isoforms is shown in Figure 1C.  
The isoform corresponding to CD6∆d3, that we had previously identified in rat, 
lacking just exon 5 which codes for the SRCR domain 3, was acknowledged. A further 
mRNA species skipped exons 5 and 6, the latter coding for a linker between the 
membrane proximal SRCR domain and the transmembrane stretch. Two additional 
isoforms were unveiled, one missing exon 3 which codes for the SRCR domain 1, and 
one other lacking exons 2 and 3. These isoforms are referred to as CD6∆d3 (GenBank 
accession no. DQ786329), CD6∆d3Ex6 (GenBank accession no. DQ786330), CD6∆d1 
and CD6∆Ex2d1, respectively, and were obtained from the tissues and cell lines indicated 
in Figure 1C. However, at this stage we did not perform an extensive study to address the 
frequency, or even the existence, of each isoform in all different tissues and cells. 
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Figure 1. Cloning of four novel CD6 isoforms lacking extracellular exons. A) Total RNA from 
human PBMC was used for RT-PCR and amplified from the ATG up to the transmembrane region 
(TM) or the STOP codon. The cDNA products were analyzed on gels, isolated and sequenced. In 
the middle lane the amplification of the full-length cDNA is shown, clearly visible at 2071 bp, and 
additional shorter products between 2000 and 1600 bp. As can be seen on the right hand sided 
lane, products of amplification of the extracellular region were obtained, including the full-length 
isoform of 1200 bp and a smaller band of 900 bp. B) Alignment of CD6FL and smaller extracellular 
isoforms peptide sequences from the N-terminus up to the transmembrane domain. The 
boundaries of the SRCR domains are indicated by arrows, according to Hohenester et al. 
[24].Residues missing in the sequence are indicated by dashed lines. C) Scheme of the structure 
obtained for the extracellular human CD6 protein isoforms and cells where they were found. 
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T cell activation controls expression of the human SRCR domain 3 of CD6 
The previous results suggested that, as in the rat, multiple CD6 polypeptide 
isoforms co-exist in human T cells. Since in rat cells we had observed a partial 
substitution of CD6FL by CD6∆d3 upon cellular stimulation, we compared the expression 
of the putative CD6 extracellular isoforms in resting T cells, and upon cell activation with 
PHA-P, using for detection of CD6 monoclonal antibodies specific for CD6 domain 3, 
OX126, or CD6 domain 1, UMCD6 [22]. In purified resting T lymphocytes, both SRCR 
domains 1 and 3 of CD6 are expressed at similar levels, a result consistent with resting T 
cells expressing mostly CD6FL (Fig. 2A, left panel). In contrast, 3 days following 
stimulation with PHA-P, the expression of domain 3 was significantly down-modulated, 
compared to the relatively unchanged labeling of domain 1 (Fig. 2A, right panel).  
We have also analyzed the changes on CD6 isoform expression upon cell activation by 
immunoblotting. Non-activated human T cells expressed a major CD6 species of 130 kDa. 
However, three days post activation with PHA-P, an additional CD6 isoform with a MW of 
97 kDa was clearly detected by immunoblotting, while the expression of the larger CD6 
species was decreased to a level equivalent to that of the smaller isoform (Fig. 2B). 
Together, the cytometry and western blotting analysis suggest that following activation of 
human T lymphocytes, the expression of full-length CD6 is partially down-regulated with 
the concomitant appearance of the CD6∆d3 isoform.  
 
Human CD6 targeting to the immunological synapse: analysis of binding to CD166 
Using rat CD6, we had established that during antigen presentation, the full-length 
CD6 molecule was translocated to the immunological synapse between T cells and 
antigen presenting cells, provided that the ligand, CD166, was expressed in the APC, and 
that domain 3 of CD6 was present at the surface of the T cell. We proceeded to confirm 
that human CD6 isoforms behaved similarly to those analyzed in rat, regarding 
translocation to the immunological synapse upon antigen recognition. Human T 
lymphocytes were induced to express full-length human CD6 (CD6FL), the CD6∆d3 and 
CD6∆d1 isoforms, or the CD6CY5 mutant, all fused to GFP. Following incubation of T 
cells with superantigen loaded Raji cells, which expressed endogenous CD166 at high 
levels on the surface (not shown), conjugate formation and CD6 translocation to the 
synapse was evaluated in all conditions. Both CD6FL, CD6∆d1 and CD6CY5 localized 
very efficiently to the immunological synapse in approximately 80% of total conjugates, 
whereas CD6∆d3 was typically dispersed throughout the cell surface (Fig. 3A and B).  
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Figure 2. Increased expression of CD6∆d3 in human cells, upon activation. A) Human primary 
T cells isolated from peripheral blood, using the RosetteSep human T cell enrichment cocktail, 
were analyzed by flow cytometry for the expression of CD6 extracellular isoforms by using specific 
antibodies recognizing either domain 1, UMCD6, or domain 3, OX126. The expression is compared 
to the fluorescence of the control secondary antibody FITC-conjugated (left panel). Following 3 
days stimulation with PHA-P, a significant decrease in the level of expression of the isoform lacking 
domain 3 could be detected, as can be seen by using the same antibodies (right panel). PHA-P 
activated cells were gated based on the expression of the activation marker CD71 (not shown). B) 
The expression of CD6 in resting cells, and in cells three days post-activation with PHA-P, was 
analyzed by Western blotting with anti-CD6 MEM-98 mAb. A decrease in the level of the higher 
molecular weight isoform and the appearance of a lower molecular weight species can be seen 
after activation.  
 
In order to test whether non-engineered endogenous CD6 expressed in T 
lymphocytes was still capable of targeting to the synapse, and that this effect was due to 
the binding to endogenous Raji-expressed CD166, we evaluated, through 
immunofluorescence, the localization of CD6 in T:Raji interfaces using blocking, as well as 
non-blocking antibodies. Characteristically, CD6 confined to the synapse in 75% of 
unblocked T cell:Raji conjugates, a figure that did not significantly change when T cells 
had been previously incubated with UMCD6, an antibody recognizing domain 1 of CD6, 
and not able to block CD6-CD166 interactions (Fig. 3C and D). However, when T cells 
had been incubated with the blocking, anti-CD6 domain 3, mAb OX126, CD6 localization 
at the synapse dropped dramatically to residual levels (Fig. 3C and D). Similarly, previous 
incubation of Raji with the CD166 mAb, described to obstruct the interaction with CD6 
[34], resulted in the noticeable reduction of the translocation of CD6 to the synapse (Fig. 
3C and D), in agreement with a previous study using blocking CD166 antibodies in T cell 
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– dendritic cell conjugates [15]. Taken together, the results demonstrate that the direct 
interaction between CD166 and the SRCR domain 3 of CD6 is the driving force for the 
translocation of CD6 to the immunological synapse. 
 
 
Figure 3. Human CD6 localizes at the synapse depending on the binding of the CD6 SRCR 
domain 3 to endogenous CD166 expressed at the surface of Raji cells. A) T cells expressing 
CD6FL-GFP, CD6∆d1-GFP CD6∆d3-GFP, or CD6CY5-GFP (shown in red) were incubated with 
Raji B cells pre-pulsed with 1 µg/ml of a superantigen mix and analyzed for localization at the 
immunological synapse. B) Bar chart representing CD6 accumulation at the immunological 
synapse in T cells expressing the different CD6 isoforms. Results are from three independent 
experiments. C) Antibody blocking interference of CD6-ligand interaction on the localization of CD6 
at the immunological synapse. Prior to incubation with superantigen-pulsed Raji B cells, T 
lymphocytes were incubated with the mAbs UMCD6, recognizing CD6 domain 1 (α-CD6d1), or 
OX126, recognizing CD6 domain 3 (α-CD6d3), or left untreated. Alternatively, Raji B cells were 
treated with anti-CD166 mAb (α-CD166). The localization of CD6 was performed by 
immunolabeling with UMCD6-FITC, or with RAM-FITC in the case of blocking with α-CD6d3. D) 
Quantification of the number of cell conjugates displaying CD6 at the immunological synapse. 
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Blocking CD6-CD166 binding changes CD6 localization and inhibits tyrosine 
phosphorylation but does not affect Ca2+ responses on live T lymphocytes  
When T lymphocytes expressing endogenous CD6 were pre-treated with the 
OX126 blocking antibody and then incubated with Raji B cells, as shown in Figure 3, or 
when using CD6FL/GFP T cells pre-blocked with OX126 (not shown), there was a 
significant decrease in CD6 clustering at the IS: just a few of the conjugates had CD6 
accumulated at the synapse compared to close to 80% obtained without any treatment or 
using irrelevant antibodies. This result suggests that the interaction with CD166, blocked 
by OX126, is necessary to target CD6 to the synapse. This treatment additionally resulted 
in a small reduction, from 87% to 79%, of the number of T cell-APC conjugates actually 
formed (data not shown). Due to the lack of appropriate antigen presenting cells negative 
for the expression of CD166, we used this system where T cells were either pre-incubated 
with the OX126 or left untreated, to further evaluate the role of CD6 in T cell signaling.  
The use of primary T lymphocytes interacting with superantigen-loaded APC, and 
its transient genetic manipulation have proven to be useful tools in the determination of 
critical parameters for T cell activation [36], such as calcium signals and phosphorylation 
of tyrosine residues  quantification. The measured calcium signals of live T cells treated 
with OX126, interacting with CD166-expressing Raji cells, were not significantly different 
from those obtained with untreated T cells (Figure 4).  
 
 
 
Figure 4. Ca2+ responses are not affected by blocking CD6-CD166 binding. Superantigen-
pulsed Raji B cells were allowed to interact with Fura-2 loaded T lymphocytes that express 
endogenous CD6. Intracellular calcium was measured sequentially every 10s in T cells interacting 
with Raji B cells. Black line represents mean values obtained with T cells previously treated for 30 
min at 4ºC with the blocking antibody OX126 and the grey line, the values obtained with untreated 
T cells. 
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Using the same approach, tyrosine phosphorylation was measured with 4G10 (anti 
p-Tyr) immunolabeling in treated and untreated T cells interacting with CD166-expressing 
Raji cells. Figures 5A and 5B show typical conjugates obtained 30 min after cell-cell 
contact. The amount of p-Tyr at the IS was significantly lower in cells treated with OX126 
blocking antibody (Figure 5B) when compared with untreated cells (Figure 5A). To further 
analyze this inhibition, we showed that the majority of OX126 treated cells have low levels 
of p-Tyr at the synapse, with the average mean of 1000 arbitrary units (AU) for p-Tyr 
intensity while the untreated cells have more distributed levels of p-Tyr intensity, with the 
mean of 1500 AU (Figure 5C). Hence, we observed a 33% inhibition of tyrosine 
phosphorylation at the IS when the contact between CD6 and CD166 was blocked and 
consequently CD6 was not clustered at the immunological synapse. 
 
 
Figure 5. Tyrosine phosphorylation inhibition after blocking CD6-CD166 binding. A and B) 
Superantigen-pulsed Raji B cells were allowed to interact with T lymphocytes expressing 
endogenous CD6, either left untreated (A) or pre-incubated for 30 min at 4°C with the blocking mAb 
against d3 of CD6, OX126, at 10 µg/ml (B). After conjugates formed, cells were fixed and 
phosphotyrosines were labeled with the anti-phosphotyrosine, 4G10 at 5µg/ml, followed by 
labelling with Rhodamine Red-X-conjugated anti-mouse IgG secondary antibody. C) The graph 
shows the number of cells presenting different levels of a synaptic accumulation of 
phosphotyrosine above background. The signal represents a ratio of the signal inside the synapse 
divided by the signal outside the synapse measured on two regions of same area. Data were 
averaged from 40 cells analyzed for each condition. 
 
 
CD3 and CD6 co-stimulation enhance the overall tyrosine phosphorylation pattern – 
a role for Lck and ZAP-70 
We followed our initial results obtained with rat CD6, demonstrating that CD6 could 
interact with protein tyrosine kinases of different families: Src-family kinases Lck and Fyn, 
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the Tec-family kinase Itk, and the Syk-family kinase ZAP-70. As CD6 synergized with the 
TCR/CD3 complex in promoting the phosphorylation of the SRCR-family molecule CD5, 
we had shown that Lck together with Itk was the best combination of kinases effectively 
phosphorylating synthetic peptides corresponding to a cytoplasmic sequence of CD5 [19]. 
We have further studied the involvement of tyrosine kinases in human CD6 
signaling using wild type Jurkat cells, as well as Jurkat cells deficient of either Lck or ZAP-
70. As shown in Figure 6, in wild type Jurkat cells, JKHM, CD6 crosslinking could enhance 
the phosphorylation of CD5 (68 KDa, under reducing conditions). CD3 stimulation as well 
could promote CD5 phosphorylation, however, the effect was greatly improved with a 
combination of CD6 and CD3 antibodies. 
 
 
Figure 5. Tyrosine phosphorylation pattern after CD3 and CD6 crosslinking. JKHM, J.CaM1 
and P116 were left unstimulated or stimulated with CD3 (2µg/ml), CD6 (10µg/ml) or a 
combination of both and were crosslinked with RAM. Cells were lysed in 1% NP-40 and equal 
amounts of cleared lysates were resolved on SDS-PAGE, transferred to nitrocellulose membranes 
and immunoblotted with 4G10-HRP. 
 
Apart from CD5 phosphorylation, the CD3 + CD6 stimulation resulted in the high 
level of phosphorylation of a cellular protein ~40 kDa, which we identified as Linker for 
Activation of T cells (LAT). Using the same protocol in J.CaM1 cells (Lck deficient) and 
P116 cells (ZAP-70 deficient), we noticed that CD6 signaling was greatly impaired in both 
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instances. In ZAP-70 deficient cells, no increased phosphorylation could be observed 
following CD3, CD6 or CD3 + CD6 stimulation. In Lck deficient cells, however, some 
phosphorylation of CD5 could be obtained, but with a long delay of 2 minutes, in the CD3 
and CD3 + CD6 stimulations. No phosphorylation of LAT was observed, though.  
 
Quantification of specific mRNA CD6 species using RNAse Protection Assays 
While initially setting-up the experimental polymerase chain reaction based-
methods for cloning CD6 extracellular-coding mRNA isoforms, we noticed that the 
frequency of cDNA clones corresponding to CD6∆d1 exceeded, and were easier to obtain 
than, CD6∆d3 cDNA clones. We thus compared the amounts of the different extracellular 
isoform-coding CD6 transcripts from resting E6.1 Jurkat cells by RNase Protection 
Assays, a powerful tool for detecting and quantifying specific RNAs based on the 
hybridization in solution of a labeled anti-sense probe RNA with the RNA pool being 
tested. Complementary portions of labeled probe and mRNA from the pool form hybrids 
that are resistant to digestion with single stranded-specific RNase T1 and RNase A. 
Two RPA probes were designed, probe 1 to discriminate isoforms CD6∆d1 and 
CD6∆Ex2 and probe 2 to discriminate CD6∆d3 and CD6∆d3Ex6 (Figure 7A). As shown in 
Figure 7B, the unspliced transcripts protected the full-length of both probes, 777 bp for 
probe 1( ) and 525 bp for probe 2 ( ). The higher bands, on top of the full protected 
probes, correspond to the undigested probes. Using probe 2, bands corresponding to the 
splicing of exons 5 and/or 6 were absent. The intensity of the RPA bands obtained was 
low, but acceptable for the analysis of endogenous expressed mRNA, and did suggest 
that for non-activated cells there is no major production of CD6∆d3 or CD6∆d3Ex6 
mRNAs. However, in line with our initial cloning assessment, transcripts excluding exon 3 
gave rise to protected fragments of 311 bp (  ) and 115 bp ( ), whereas it was not 
possible to determine if the simultaneously splicing of exons 2 and 3 occurred as the 
fragment (46 bp) was too small to be spotted. Given that we were able to detect, by two 
different methods, the production of mRNA species that lack exon 3, or exons 2 and 3, but 
have no evidence from cytometry analysis (Figure 2) that either resting or activated cells 
can express CD6 proteins lacking domain 1, it is possible that there is a block in the 
translation of these particular transcripts, or that these specific mRNAs are not further 
processed to become messenger RNA, being possibly regulatory RNAs.  
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Figure 7. Quantification of specific mRNA CD6 species using RNAse Protection Assays. A) 
Schematic representation of CD6 extracellular and transmembrane exons. The two probes designed 
for the RPA and the expected protected fragments are indicated. B) Total RNA from E6.1 cells was 
analyzed for quantifying the different human CD6 mRNA species.  RT-PCR was used to obtain a 
cDNA template for the antisense RNA probes.  Probe 1 and 2 were linearized, purified and complete 
digestion was checked on agarose gel. 32P-radiolabeled UTP (NEN) was incorporated into probes by 
in vitro transcription using T3 polymerase for probe 1 and T7 polymerase for probe 2. E6.1 cells total 
RNA (30 µg) was hybridized with excess amounts of each riboprobe. After hybridization at 65ºC and at 
75ºC, the samples were digested with RNAse A/T1 and the protected fragments were resolved on 8% 
8M Urea denaturing acrylamide gels and visualized using X-ray films. The full-length of both probes 
protected the unspliced transcripts, with 777 bp for probe 1 ( ) and with 525 bp for probe 2 ( ). The 
higher bands, on top of the full protected probes, correspond to the undigested probes. Transcripts 
excluding exon 3 gave rise to protected fragments of 311 bp (  ) and 115 bp ( ) and, it was not 
possible to determine if the simultaneously splicing of exons 2 and 3 occurred as the fragment (46 bp) 
was too small to be detected. Unexpectedly, with probe 2 bands corresponding to the splicing of exons 
5 and/or 6 were absent. pBR322 DNA-MspI digest (New England Biolabs) was used as molecular 
weight marker. D represents the digestion control of each probe. 
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However, given that they can be produced, we investigated in other cell types 
whether CD6 polypeptides devoid of domain 1 could be expressed at a given stage. We 
analyzed T lymphocytes from healthy donors, a B-CLL derived line, and human 
thymocytes from four different subjects. Using two color FACS analysis addressing the 
expression of domains 1 and 3 of CD6, in most of the cell populations analyzed we found 
no evidence of cell populations expressing CD6 molecules lacking domain 1, although in 
two of the normal T lymphocyte samples, a minute number of cells (less than 0.5%) 
appeared to be in fact domain 3 positive, and domain 1 negative. Interestingly, a 
significant number of thymocytes from all four different samples were CD6d1+d3-, or had 
the domain 3 expressed at low levels. Therefore, adding to the down-regulation of domain 
3 induced in activated T lymphocytes, the suppression of CD6 domain 3 expression is 
significantly more evident in a considerable number of thymocytes. 
 
Figure 8. FACS analysis of CD6d1 and CD6d3 expression. Human primary T cells, from three 
healthy donors were isolated from peripheral blood, using the RosetteSep human T cell enrichment 
cocktail; human thymocytes (Thy), obtained from four human thymic biopsy specimens; and a B-
CLL derived line were analyzed by flow cytometry for the expression of CD6 extracellular isoforms 
by using specific antibodies recognizing either domain 1, UMCD6, or domain 3, OX126. Most cell 
populations do not express CD6∆d1 isoform, although samples 1 and 2 from T cells have less than 
0,5% that appear to be CD6d1-d3+. All four samples of thymocytes do cells that are CD6d1+d3-. 
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DISCUSSION 
 
The great majority of mammalian genes yield multiple mRNA transcripts arising 
from diverse promoter selection, alternative splicing and/or differential polyadenylation 
[37]. In spite of the frequency and potential impact of this phenomenon, particularly 
relevant in the immune system, the cases in which distinct functional properties have been 
assigned to different mRNA isoforms of the same molecule are scarce. In T lymphocytes, 
just a few examples of naturally occurring alternatively spliced isoforms of transmembrane 
proteins have been reported, and only in three cases with clear distinct functional 
consequences: CTLA4 and CD95 can become transmembrane molecules instead of 
being secreted [38, 39], as a consequence of the inclusion of membrane spanning 
domains following cell stimulation; and CD45, upon T cell differentiation, is produced with 
a shorter N-terminal extracellular domain, which increases the dimerization capacity of the 
molecule [40]. Alongside this general trend, multiple isoforms resulting from alternative 
splicing of cytoplasmic domain-coding exons have been described for CD6, but with no 
distinct functions assigned [18, 28-30]. In this work we describe a rare example of a 
functional consequence resulting from alternative splicing in molecules of the immune 
system: the localization of CD6 with respect to the immunological synapse depends on 
the regulated expression of the CD166-binding domain by means of alternative mRNA 
splicing. 
Targeting of CD6 to the synapse can be driven by simple lateral diffusion and does 
not require cytoskeletal reorganization, as deletion of the cytoplasmic tail did not affect the 
ability of CD6 to localize to the synapse. Therefore, the positioning of CD6 within the 
synapse must be largely determined by molecular interactions established with the 
contacting cell. Human CD6 molecules targeted very efficiently to the immunological 
synapse when expressing the CD166-binding domain, provided that the antigen 
presenting cells expressed the ligand, CD166, and that no blocking using antibodies 
occurred. However, when using T cells expressing CD6∆d3, synaptic localization of that 
isoform could still be attained in a small percentage of conjugates. A putative role for 
domain 2 of CD6, now substituting the positioning of domain 3 in CD6∆d3, or even for the 
membrane juxtaposed stalk region, could be considered, given that previous studies had 
suggested a minor participation of these domains in the binding to CD166 [22, 23]. 
Nevertheless, it is the presence of domain 3 that largely determines CD6 synaptic 
localization, and thus regulation of its expression is the key event establishing the 
positioning of CD6 upon conjugate formation and T cell activation. 
The mode of action of CD6 appears to be significantly different from that of other 
accessory molecules that influence signaling at or near the immunological synapse. CD2 
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binding to its ligand CD58 (CD48 in rodents) contributes to enhanced signaling, as it 
associates with intracellular positive mediators [41]. CD28 and CTLA-4 have devised a 
scheme whereby sequential expression of each molecule, combined with binding to one 
of the alternative ligands, CD80 and CD86 (themselves also sequentially expressed 
during T cell-APC interactions), drives responses from co-stimulation to inhibition [42]. 
Differences in the affinity and avidity of binding determine the selective recruitment of 
CD28 or CTLA-4 to the immunological synapse upon recognition of CD86 or CD80 [43].  
Meanwhile CD6, which was reported to deliver co-stimulatory signals as strongly 
as CD28 [15], mimics CD28 distribution with respect to synaptic localization, in that it is 
recruited to the immunological synapse at the onset of activation, and, according to the 
present study, is excluded from the cellular interface at later stages. However, it may 
achieve this through a completely different mechanism: expressing the SRCR domain 3, 
CD6 is directed to the synapse where it can control signaling; choosing not to express the 
SRCR domain 3, it is no longer restricted to the cellular interface and its regulatory 
function may be diluted.  
The reason why CD6 does not simply switch off its expression is not immediately 
evident. However, the existence of an alternative ligand for CD6 raises new perspectives 
for its overall function [44]. If the new ligand can interact with a different part of CD6, 
switching from full-length to ∆d3 may allow CD6 to shift from the synapse established with 
the APC to either an interaction with a second adjacent cell, or again to the initial 
interface, provided that the second ligand is present. Differential molecular interactions 
could then modulate the behaviour of CD6. A role for domain 1 in the binding to this 
putative alternative ligand is worth consideration, given that domain 1 itself could be, albeit 
very rarely, excluded.  
The apparent steadiness in expression of the alternative CD6 mRNAs in different 
mature sub-populations in the rat may suggest that CD6∆d3 can define small subsets of 
thymocytes and mature T cells (Castro et al. 2007, unpublished results), however, the 
switch to the expression of the shorter isoform observed upon stimulation of T cells is 
undoubtedly a consequence or a product of activation. In the resting state, the majority of 
the cells express mainly the full-length CD6 form; upon productive T cell stimulation, there 
is a partial substitution of the full-length isoform by a substantial number of CD6 molecules 
per cell that no longer express the CD166-binding domain and thus are not restricted to 
the immunological synapse. This type of regulation of splicing is not unique, as it has long 
been known to control the expression of CD45 isoforms [45, 46]. The novel CD6 isoform 
reported here seems to have a more obvious function as it disables the interaction of the 
protein with its ligand. Productive TCR recognition of antigen may signal for the shorter 
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CD6 isoform to be produced, and this may reduce the activity of CD6 at the synapse, 
possibly inducing a different behaviour. 
The expression of the CD6FL isoform seems to be highly favoured in the DP stage 
in the thymus (Castro et al. 2007, unpublished results). Previous observations suggest 
that CD6 can be involved in positive selection where it correlates with the expression of 
CD69 in DP thymocytes [47]. Moreover, an inverse correlation between thymocyte CD6 
expression and the rate of apoptosis has been demonstrated. Our results may be 
indicative of a mechanism of regulation where the expression of CD6FL capable of 
interacting with the ligand, CD166, expressed by thymic epithelial cells, is favoured at the 
double positive stage and bypassed later on during thymic selection.  
Although preliminary, our findings show that the inhibition of CD6-ALCAM binding, 
results in a negligible effect on Ca2+ signals but in a 33% inhibition of tyrosine 
phosphorylation at the IS. Our previous observations on rat CD6 (unpublished results), 
indicating that it can down-modulate calcium signals initiated upon T cell interaction with 
superantigen-primed Raji cells are not in disagreement with the current results. In rat 
CD6+ cells establishing contacts with Raji cells, expressing or not rat CD166, no 
differences in the registered Ca2+ profiles were observed, clearly indicating that the 
localization at the IS is not crucial for CD6 to down-modulate signaling. This may be the 
reason why we don’t see any difference in the Ca2+ profile after blocking CD6 
engagement. It is tempting to speculate that CD6 expression can result in a general 
inhibitory outcome but the engagement of CD6 with ALCAM and subsequent 
accumulation at the synapse, point towards a positive or co-stimulatory function for CD6, 
as demonstrated by our p-Tyr  and crosslinking results and also previous studies [8-11, 
13, 14]. It is possible, however, that the suppression of activation signals is due to the 
overall interference that the soluble reagents cause on the cell-to-cell contact, rather than 
to a very specific effect blocking just the CD6-CD166 ligation.  
Some of the early reports on the co-stimulatory properties of CD6 relied on the use 
of monoclonal antibodies as the source of external stimuli [8-10]. Also, in our experiments 
crosslinking human CD6 together with the TCR, with the use of monoclonal antibodies, we 
observed a very strong phosphorylation of LAT, an important mediator of T cell signaling. 
However, such type of stimulation can very likely induce the indiscriminate aggregation of 
protein tyrosine kinases that associate non-covalently with CD6 [19], possibly originating 
effects very dissimilar from those obtained through physiological stimulation. CD5, a 
highly homologous molecule also expressed in T lymphocytes, was originally accepted as 
a co-stimulatory molecule for equivalent reasons [48-50]. It turned out to be a clear 
inhibitor of T-cell activation and thymocyte selection [51].  
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An inhibitory role for CD6 on thymocyte development has been previously 
suggested [47, 52]. Our earlier unpublished results with rat CD6 provide biochemical 
evidence that CD6 can indeed modulate signals triggered upon antigen recognition. 
Whether this role is intrinsic, or dependent on regulated interactions with other surface 
molecules, is still to be determined. For example, the IgSF surface glycoprotein CD2 can 
transduce mitogenic signals due to its association with the tyrosine kinases Lck and Fyn 
[41], however, through its interaction with the inhibitory molecule CD5 it can also induce or 
amplify a negative response [35, 53]. Regarding CD6, it shares with CD5 the attribute to 
inhibit signaling upon T cell-APC interactions, not requiring ligand binding to do so [54]. 
Since CD5 and CD6 also associate at the surface of T cells and one major effect of CD6 
stimulation is the phosphorylation of CD5 [19], it is feasible that CD5 can integrate or 
transform the signals triggered through CD6. The physiological mode of regulation exerted 
by CD6 on cellular behaviour could therefore depend on the levels of expression, or most 
likely and given that very few T cells do not express CD6, on the isoforms of CD6 
produced at a certain stage of cellular activation or differentiation.  
This interpretation can nevertheless make the case that CD6 assists in T cell 
activation as well: given that, as we suggest, the CD6-associated enzymatic activity is 
kept constant regardless of the cellular localization of CD6, if CD6 localizes to the 
immunological synapse and binds to CD166, these interactions are likely to increase 
cellular adhesion and thus support a stimulatory role for CD6, albeit indirect. 
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ABSTRACT 
In T lymphocytes, lipid rafts are preferred sites for signal transduction initiation and 
amplification. Many cell membrane receptors, such as the T cell receptor, co-receptors, 
and accessory molecules associate within these microdomains upon cell activation. 
However, it is still unclear in most cases whether these receptors interact with rafts 
through lipid-based amino acid modifications, or whether raft insertion is driven by protein-
protein interactions. We have addressed the mechanisms that control the localization of 
rat CD2 at the plasma membrane, and its redistribution induced upon activation. Following 
incubation of rat CD2-expressing cells with radioactive-labeled palmitic acid, or using CD2 
mutants with cysteines 226 and 228 replaced by alanine residues, we found no evidence 
that rat CD2 was subjected to lipid modifications that could favor the translocation to lipid 
rafts, discarding palmitoylation as the principal mechanism for raft addressing. On the 
other hand, using Jurkat cells expressing different CD2 and Lck mutants, we show that 
the association of CD2 with the rafts fully correlates with its capacity to bind to Lck. As 
CD2 physically interacts with both Lck and Fyn, preferentially inside lipid rafts, and 
reflecting the increase of CD2 in lipid rafts following activation, CD2 can mediate the 
interaction between the two kinases and the consequent boost in kinase activity in lipid 
rafts. 
 
 
INTRODUCTION 
 
CD2 is a 45-58 KDa type I integral protein expressed on virtually all T lineage and 
natural killer cells [1]. The extracellular domain of CD2 is composed by two 
immunoglobulin superfamily domains [2], of which the membrane-distal V-like domain is 
involved in the binding to the ligand [3]. Engagement of CD2 to CD58 in humans, or to 
CD48 in rodents, facilitates adhesion between T cells and antigen presenting cells (APC) 
and is proposed to promote the formation of an optimal intercellular membrane spacing 
(~140Å) suitable for TCR-pMHC recognition [4].  
Concomitantly with its function as an adhesion molecule, CD2 has a role in the 
process of signal transduction. It has long been known that stimulation of CD2 with 
combinations of monoclonal antibodies or with the physiological ligand induces T cell 
proliferation in rats and human [5, 6]. Moreover, ligation of CD2 with CD58 augments the 
interleukin-12 (IL-12) responsiveness of activated T cells [7], and can also reverse T cell 
anergy induced by B7 blockage [8].  
The cytoplasmic domain is required for CD2-mediated activation [9-12], but as it 
has no intrinsic enzymatic activity, it depends on physical interactions with other signaling 
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molecules to propagate the stimulus received upon ligand binding. CD2 associates with 
the Src-family tyrosine kinases Lck and Fyn [13-15], and through these kinases couples to 
downstream signal transduction pathways. Proline-rich sequences of the cytoplasmic 
domain of CD2 have also been shown to establish interactions with the SH3 domain of the 
adaptor protein CD2AP [16], and thus connect CD2 to the cytoskeleton, and with the SH3 
domain of CD2BP1 [17], resulting in the down-regulation of activation-dependent CD2 
adhesion. CD2 additionally binds to the GYF domain of CD2BP2, an interaction involved 
in cytokine production following CD2 stimulation [18].  
The T cell plasma membrane contains regions of distinct lipid composition, 
enriched mainly in sphingolipids and cholesterol immersed in a phospholipid-rich 
environment, and termed lipid rafts [19]. In unstimulated cells, key signaling proteins such 
as the adaptors LAT [20] or PAG [21], or the Src kinase Fyn [22], are resident in the rafts, 
whereas most integral proteins are found outside these platforms. Localization and 
targeting of signaling molecules to lipid rafts is largely dependent on post-translational 
acylation modification of proteins, one of the most important being membrane-proximal 
cysteine palmitoylation. These cysteine residues are usually present within a conserved 
motif consisting of cysteines and hydrophobic residues, CVRC in LAT, GCVC in Lck and 
Fyn. 
The composition of rafts-associated proteins may, nevertheless, change upon cell 
stimulation. Membrane compartmentalization and partitioning of essential T cell-activating 
components in lipid rafts were shown to be involved in the initial stages of T cell activation 
[23]. Several co-stimulatory molecules on the T cell surface, such as CD2 [24], CD5, CD9 
[25] and CD28 [26] can up-regulate TCR signals by enhancing the association of the TCR 
with lipid rafts. Also, whereas the fraction of Lck found in the rafts is in a close inactive 
conformation, upon cell activation the open/active form of Lck accumulates in the rafts 
[27], where it activates resident Fyn [22].  
Human CD2 has been shown to translocate to lipid rafts upon CD2-antibody 
crosslinking, or following binding to CD58 during conjugate formation [28], and the shift 
between phases may result in the replacement of CD2BP2 by raft-resident Fyn [29], which 
competes for the same proline-rich sequence of the cytoplasmic tail of CD2. In contrast to 
human CD2 which is reported to be entirely non-raft resident in resting cells [28], mouse 
CD2 contains a CIC motif at the membrane-proximal region that can putatively address 
CD2 to lipid rafts [25]. We have investigated the localization and transition of rat CD2 
between different phases at the T cell surface, and show that a significant fraction of rat 
CD2 is constitutively present in lipid rafts, and that this proportion increases upon CD2-
stimulation. However, membrane-proximal cysteine palmitoylation is not the decisive tag 
addressing rat CD2 to lipid rafts, but rather the interaction with the Src family kinase Lck. 
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MATERIALS AND METHODS 
 
Cells and transfections 
Splenocytes were obtained by maceration of spleens from 3-months old Wistar male rats 
in ice cold PBS. The rat thymoma cell line W/FU(C58NT)D [30], referred to in the text as 
C58 cells, was given by A. Conzelmann (University of Fribourg, Switzerland).  
Jurkat E6.1 cells [31] were obtained from A. Weiss (UCSF, CA); E6.1 cells expressing full-
length rat CD2, E6.1-CD2(CY whole) (referred to in this text as E6.1-CD2), or expressing 
CD2 cytoplasmic deletion mutants, E6.1-CD2(CY 6), (CY 40), (CY 66), (CY 81) and (CY 
97), that possess respectively the first 6, 40, 66, 81 and 97 amino acids of the cytoplasmic 
tail [12, 32] were kindly provided by M. Puklavec (University of Oxford, UK). 
pKG5-CD2-2C, a plasmid where the codons for Cys226 and Cys228 are mutated to encode 
alanine residues, was constructed by PCR using pRCD2-11, a plasmid containing the 
cDNA sequence of full-length rat CD2 [12], as template with the forward primer 5’-
GGGGCGCTGTTTATTTTCGCTATCGCCAAGAGGAAAAAACGGAAC-3’ and the reverse 
primer 5’-GTTCCGTTTTTTCCTCTTGGCGATAGCGAAAATAAACAGCGCCCC-3’. The 
changed codons are underlined. The PCR product was digested with Dpn I and used to 
transform competent cells. CD2 positive mutants were digested with Bam HI and replaced 
the equivalent restriction fragment containing wild type CD2 subcloned in pKG5. pKG5-
CD2-2C was used for transfecting E6.1 cells to handle E6.1-CD2(CIC/AIA). Briefly, cells 
at 1.0 x 107 cells/ml in ice cold PBS were transferred into 0.4 cm electroporation cuvettes, 
mixed at 4ºC with plasmid at a final concentration of 0.1 mg/ml, and pulsed with 0.62 kV 
and 25 µF using a Gene Pulser II electroporator from Bio-Rad (Hercules, CA). Cells were 
transferred to culture flasks containing RPMI with 10% FCS, 1 mM sodium pyruvate, 2 
mM L-glutamine, penicillin G (50 U/ml) and streptomycin (50 µg/ml), all from Invitrogen 
(Barcelona, Spain). After forty-eight hours, the selection antibiotic was added to the 
cultures (G418 at 1 mg/ml). Following antibiotic selection, cells were analyzed for 
expression by flow cytometry and immunoblotting.  
The Lck deficient J.CaM1 cell line [33] was transfected with pRCD2-11, and G418-
resistant cells that expressed high levels of rat CD2 were selected and named J.CaM1-
CD2. To generate J.CaM1/Lck(KD)-CD2 cells, the newly obtained J.CaM1-CD2 cells were 
co-transfected with pSRα-Lck-KD, a plasmid containing Lck cDNA carrying a mutation at 
the ATP-binding site (K273A) [34]. J.CaM1 cells reconstituted with wild-type Lck, 
J.CaM1/Lck(WT), and with an Lck molecule having Cys3 mutated to Ala3, 
J.CaM1/Lck(C3A) [35], were obtained from P. Kabouridis (Queen Mary, University of 
London, UK), and transfected with pRCD2-11, to handle J.CaM1/Lck(WT)-CD2 and 
J.CaM1/Lck(C3A)-CD2 cells, respectively. 
97 
Chapter II - Research work 
 
 
Antibodies 
The mAbs used were rat CD2-OX55 [6] and rat CD2-OX34 [36]. Polyclonal antibodies and 
conjugates were: rabbit anti-LAT, from Upstate Biotechnology; rabbit anti-Lck, raised 
against a peptide of amino acids 39-64 of murine Lck, a gift from J. Borst (The 
Netherlands Cancer Institute, Amsterdam); BL90, polyclonal anti-Fyn, a gift from J. Bolen 
and M. Tomlinson (DNAX Research Institute, Palo Alto, CA); goat anti-mouse peroxidase 
conjugated, purchased from Molecular Probes (Eugene, OR); and goat anti-rabbit 
peroxidase conjugated from Zymed (San Francisco, CA). 
 
Metabolic labeling of cellular proteins with [3H]palmitate 
Aliquots of 1.5 × 107 cells were collected from culture, resuspended in 1.5 ml RPMI 
complete medium supplemented with 300 µCi/ml [3H]palmitic acid and incubated for 16 h 
at 37ºC. Cells were harvested and lysed in lysis buffer (10 mM Tris.Cl pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1 mM PMSF and 1% (v/v) Triton X-100).  The nuclear pellet was 
removed by centrifugation at 12,000 × g for 10 min at 4°C and the lysate run on SDS-
PAGE under non-reducing conditions. Immunoprecipitations were performed by 
incubating the lysate with antibodies (5 µg IgG or 2 µl anti-serum) and 100 µl of 10% 
protein A Sepharose CL-4B beads (Amersham Biosciences), for 90 min at 4°C by end-
over-end rotation. The beads containing the immune complexes were washed three times 
in 1 ml lysis buffer, denatured and loaded on an SDS-PAGE gel. The gel was soaked for 
30 min in fixing solution (25:65:10 isopropanol/H2O/acetic acid) and additionally treated for 
30 min with “Amplify” (Amersham Biosciences), dried and exposed to film for 6 weeks. 
 
Flow cytometry 
Cells were washed and resuspended in PBS containing 0.2% BSA and 0.1% NaN3 
(PBS/BSA/NaN3), at a concentration of 1 × 106 cells/ml. Staining was performed by 
incubation of 5 × 105 cells/well with mAbs (20 µg/ml) for 15 min on ice, in 96-well round-
bottom plates (Greiner, Nürtingen). Cytometric analysis was as previously described [37]. 
 
Sucrose gradient centrifugation 
Approximately 1.5 × 108 cells were used per sample. Cells were washed, resuspended in 
1 ml RPMI medium and maintained at 37ºC for 15 min. Cells were then washed twice with 
ice-cold phosphate-buffered saline (PBS) and lysed for 30 min on ice in 1 ml MBS buffer 
(25 mM MES, 150 mM NaCl, pH 6.5), containing 1% Triton X-100, 1 mM PMSF and 
cocktail protease inhibitors (1 mM AEBSF, 0.8 µM aprotinin, 50 µM bestatin, 15 µM E-64, 
20 µM leupeptin and 10 µM pepstatin A, Calbiochem, La Jolla, CA). The lysates were 
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homogenized by brief sonication for ten pulses on ice, using a Heat Systems/Ultrasonics 
sonicator (model W-375) equipped with a microtip and set to 50% duty cycle, output 3. To 
obtain the rafts fraction, cell lysates were mixed with an equal volume of 85% sucrose in 
MBS buffer and transferred to the bottom of Sorvall ultracentrifuge tubes. The samples 
were then overlaid with 6 ml of 35% sucrose followed by 2 ml of 5% sucrose. After 
centrifugation at 200,000 × g for 17 h at 4°C in a TST41.14 swing-out rotor (Sorvall), 
10 fractions of 1 ml were collected from the bottom of the tube and analyzed by Western 
blotting. The fractions are labeled from the top of the gradient. 
 
Western blotting  
Proteins were separated by SDS-PAGE in non-reducing conditions and then transferred 
to Hybond-C-extra membranes by electroblotting. Membranes were blocked in TBS, 0.1% 
(v/v) Tween 20 (TBS-T), containing 5% (w/v) non-fat dried milk, probed with unconjugated 
primary antibody for 1 hour and revealed with HRP-conjugated goat anti-mouse or goat 
anti-rabbit IgG (1:20,000 dilution). Immunoblots were developed using ECL–plus reagents 
(Amersham Biosciences, Carnaxide, Portugal) and exposed to CL-XPosure films (Pierce, 
Rockford, IL). 
 
Densitometry 
Densitometric analyses were performed on autoradiographs of the SDS-PAGE gels, using 
a GS-800 Densitometer (BIO-RAD) and Quantity One software. All densitometry values 
obtained were calculated from non-saturated signals. 
 
Capping and immunofluorescence microscopy 
All procedures were performed at 4ºC unless otherwise described. Cells were washed in 
RPMI, resuspended at 2 × 106 cells/ml in RPMI/5% FCS and incubated for 10 min with the 
mAbs OX34 at 5 µg/ml. Cells were washed twice with PBS containing 0,2 % BSA, 
followed by incubation with  RAM-Alexa 568 conjugate (Molecular Probes, Leiden, The 
Netherlands) for 10 min. After washing, cells were incubated with Cholera-toxin subunit B 
Alexa 488 conjugate (Molecular Probes, Leiden, The Netherlands) for another 10 min, and 
washed again. Cells were resuspended in RPMI/5% FCS and incubated for 15 min at 
37ºC to induce antibody capping. For fixation, cells were treated with 4% para-
formaldehyde in PBS for 30 min at RT. Fixed cells were plated onto glass coverslips and 
mounted in Vectashield media (Vector Laboratories, Burlingame, CA). Stained 
preparations were observed with a Zeiss Axioskop microscope, and images acquired with 
a SPOT2 camera (Diagnostic Instruments). Images were processed with Photoshop 6.0 
(Adobe Systems). The percentage of co-localization represents the counts of CD2 caps 
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that also had GM1 caps, with the mean and standard deviation of counts of at least 40 
cells from different experiments. 
  
Cell activation 
For lipid rafts analysis, approximately 1.7 × 108 cells were used per sample. Cells were 
washed and resuspended in 1 ml RPMI medium containing OX34 at a 1:100 dilution of 
ascitic fluid. After 5 min incubation on ice, cells were crosslinked with RAM at 20 µg/ml 
and maintained at 37ºC for 15 min. Cells were then washed twice with ice-cold phosphate-
buffered saline (PBS), lysed and fractionated by sucrose gradient centrifugation as 
described above.  
 
Immunoprecipitations and in vitro kinase assays 
Immunoprecipitations, in vitro kinase assays, and reprecipitation of phosphorylated 
substrates were performed as previously described [13]. 
 
 
RESULTS 
 
A significant proportion of CD2 associates with plasma membrane lipid rafts in 
resting rat T cells and in a rat thymoma cell line 
Previous work has shown that in human resting T lymphocytes the transmembrane 
glycoprotein CD2 is virtually absent from membrane lipid rafts, as defined based on a 
Triton X-100 insolubility criterion [28]. However, in mouse cells a considerable fraction of 
CD2 molecules are raft resident [25]. We have investigated the membrane localization of 
the rat homologue of CD2 in resting primary cells as well as in the rat thymoma cell line 
C58. Non-activated splenocytes or C58 cells were solubilized in a lysis buffer containing 
1% Triton X-100, and the lysates were subjected to sucrose gradient centrifugation. The 
localization of the molecules within or outside lipid rafts was evaluated by immunoblotting 
with the monoclonal antibody OX55, using as marker for the rafts fractions 
immunoblottings for the resident palmitoylated molecule LAT [20]. As measured by 
densitometry of immunoblots in different experiments, between 7 and 15% of rat CD2 is 
constitutively confined to the rafts in unstimulated splenocytes, and the majority of CD2 
molecules are recovered from the “soluble” phase (Fig. 1). Using non-stimulated C58 
cells, we could observe that CD2 is over represented in the rafts (approximately 75%), 
compared to the non-raft fractions.  
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Figure 1. CD2 associates with lipid rafts in resting rat T cells and in a rat thymoma cell line. 
Approximately 1.5 x 108 cells rat splenocytes and a rat thymoma cell line, C58 cells, were lysed 
and total cell lysates fractionated by sucrose density centrifugation as described in Material and 
Methods. Fractions were recovered, and numbered 1 to 9 from the top of the gradient. Equal 
volumes of each fraction were separated by SDS polyacrilamide gel electrophoresis (SDS-PAGE) 
and immunoblotted with OX55 (α-CD2), followed by horseradish peroxidase-labeled goat anti-
mouse. LAT was visualized with a polyclonal antibody followed by horseradish peroxidase-labeled 
goat anti-rabbit. The preferential distribution of LAT into the rafts allows for the identification of raft 
fractions. Densitometry of the bands reveal that in the experiment shown, 15% of rat CD2 
molecules from splenocytes were localized in lipid rafts, as were approximately 75% of CD2 from 
C58 cells. 
 
Rat CD2 targeting to lipid rafts is not fully determined by palmitoylation of Cys226 
and Cys228  
The difference in raft-localization between human and mouse CD2 has been 
attributed to two membrane-juxtaposed cysteine residues, present in the mouse amino 
acid sequence and absent from the human molecule, that could be palmitoylated and thus 
address the molecule to lipid rafts. We examined whether the membrane-juxtaposed 
cysteine residues Cys226 and Cys228, also present in rat CD2, might have a role in 
targeting the molecule to the rafts, using a mutant where these residues were replaced by 
alanines. The mutant CD2(CIC/AIA) was stably expressed in E6.1 Jurkat cells, and 
surface expression levels were confirmed by flow cytometry (not shown). E6.1-
CD2(CIC/AIA) cells, as well as E6.1 cells expressing full-length rat CD2, E6.1-CD2, were 
lysed in 1% Triton-based lysis buffer, lysates were subjected to sucrose gradient 
separation, and analyzed by immunoblotting. As can be seen in Figure 2A, wild-type CD2 
is largely concentrated in lipid rafts (74% as measured by densitometry), however 
CD2(CIC/AIA) is still able to localize very significantly to the rafts (49%), indicating that the 
cysteines 226 and 228 are not fully accountable for the lipid raft-targeting of rat CD2. 
We next examined whether rat CD2 could in fact be palmitoylated in the cysteine 
residues. In these studies we used E6.1-CD2 cells, and cells expressing a cytoplasmic 
deletion mutant, E6.1-CD2(CY6), containing only the first six amino acids of the 
cytoplasmic domain, but still retaining the two cysteine residues. Cells were incubated in 
medium containing [3H]palmitate, for 16 hrs at 37ºC. Following cell lysis, rat CD2 was 
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immunoprecipitated from E6.1-CD2 and E6.1-CD2(CY6) cells, and samples from the 
lysates as well as from the immunoprecipitates were run on SDS-PAGE under non-
reducing conditions, since the presence of 2-mercaptoethanol is recognized to interfere 
with S-ester and hydroxyester linkages, as can be the case for the covalent linkage of 
palmitate with the cysteine residues [38]. As a positive control for the experiment, we 
immunoprecipitated Lck, previously shown to incorporate [3H]palmitate [39].  
Fluorography analysis of radiolabeled products in SDS-PAGE showed that a 
number of cellular proteins did incorporate [3H]palmitate, as can be seen in the lysate 
lanes (Fig. 2B). Lck was easily detected in the respective lane. However, we were not 
able to confirm that rat CD2 could be subjected to lipid modification, as no labeled protein 
bands could be perceived in the lanes of rat CD2. The failure to detect palmitoylated rat 
CD2 could not be attributable to a low cellular expression of the molecule, or to a low 
affinity of the antibodies. As seen in Figure 2C, rat CD2 immunoprecipitated from E6.1-
CD2 and E6.1-CD2(CY6) cells is clearly evident by immunoblotting. Moreover, rat CD2 
was well expressed at the cell surface as confirmed by FACS analysis (not shown).  
 
Figure 2. Analysis of the role of 
Cys226 and Cys228 in raft 
targeting of rat CD2. A) E6.1-
CD2 cells, expressing rat CD2, or 
E6.1-CD2(CIC/AIA), expressing a 
rat CD2 mutant where Cys226 and 
Cys228 are mutated to alanine 
residues, were lysed in 1% Triton 
X-100-containing buffer and 
lysates fractionated by sucrose 
density centrifugation. Equivalent 
amounts of each fraction were 
resolved by 10% SDS-PAGE and 
immunoblotted with OX55, and 
with a LAT polyclonal. B-C) E6.1-
CD2 and E6.1-CD2(CY6) Jurkat 
cells were labeled with 
[3H]palmitate for 16 h, lysed in 
Triton X-100 and 
immunoprecipitated with OX34 
(α-rat CD2), or with Lck sera, as 
indicated. Immunoprecipitates 
and cell lysates were separated 
on 10% SDS-PAGE under non-
reducing conditions and analyzed 
by fluorography (B), or western 
blotting with OX34 (C).  
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A physical association of rat CD2 with Lck is sufficient for the raft targeting of CD2  
To determine the molecular basis for the constitutive presence of a large fraction of 
rat CD2 in the rafts, we focused on the cytoplasmic domain, determining which segments 
could play a role. We used previously characterized cells where rat CD2 mutants are 
expressed in E6.1 Jurkat cells [12, 13, 32, 40]. E6.1 Jurkat cells stably expressing 
cytoplasmic domain deletion mutants of rat CD2 possessing 97, 81, 66, 40 and 6 amino 
acids of the cytoplasmic region were used. All CD2 variants were expressed at similar 
levels at the cell membrane (not shown). The location of each mutant was analyzed 
following sucrose gradient centrifugation and subsequent immunoblotting of rat CD2 with 
OX55. As shown in Figure 3, the deletion mutants CD2(CY97), CD2(CY81), CD2(CY66), 
and CD2(CY40) are mostly raft-resident like the full-length molecule, whereas rat 
CD2(CY6) is totally excluded from lipid rafts. This suggests that the first 40 N-terminal 
amino acids of CD2 cytoplasmic tail are sufficient for the localization of CD2 in lipid rafts. 
Also, the fact that E6.1-CD2(CY6) does not address to lipid rafts while still possessing the 
two membrane-proximal cysteine residues further strengthens the argument that these 
residues do not serve as anchors for the raft lipids. 
 
Figure 3. Analysis of raft 
localization of different rat CD2 
cytoplasmic deletion mutants. 
E6.1 Jurkat cells stably expressing 
different rat CD2 cytoplasmic tail 
deletion mutants were lysed, 
separated by sucrose gradient 
density centrifugation and the 
collected fractions analyzed by 
immunoblotting for the localization 
of CD2, Lck and LAT. The mutants 
analyzed were E6.1-CD2(CY 97), 
E6.1-CD2(CY 81), E6.1-CD2(CY 
66), E6.1-CD2(CY 40) and E6.1-
CD2(CY6), expressing the 
membrane proximal 97, 81, 66, 40 
or 6 amino acid residues, 
respectively. All mutants except 
E6.1-CD2(CY6) still partition within 
lipid rafts fractions. 
 
As the pattern of association of rat CD2 mutants with lipid rafts correlated entirely 
with the pattern of binding to the tyrosine kinase Lck [13], we raised the possibility that the 
interaction between rat CD2 and lipid rafts could be mediated via Lck. Moreover, as seen 
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from Figure 3, all CD2 mutants except CD2(CY6) are in general confined to the same 
fractions as Lck. To test this hypothesis, rat CD2 was stably expressed in the Lck deficient 
J.CaM1 cell line and its inclusion in the membrane fractions analyzed. Supporting our 
prediction, rat CD2 expressed in J.CaM1 cells localizes to the “soluble” fractions, whereas 
the kinase is absent in these cells as expected (Fig. 4A). Further evidence that Lck could 
couple rat CD2 to lipid rafts was obtained through co-capping experiments. Capping of rat 
CD2 molecules, labeled by Alexa Fluor 568-conjugated antibodies, was visualized by 
fluorescence microscopy, in red, and the localization of rafts detected by Alexa Fluor 488 
(green) conjugated to Cholera-toxin subunit B that binds to raft-imbedded GM1. In E6.1-
CD2 cells, capping of CD2 induced very clear co-capping of GM1 labeled rafts in the 
majority of cells, nearly 80% (Fig. 4B and C). By contrast, in the Lck-deficient J.CaM1-
CD2 cells, co-capping was always less well-defined in the fewer cells (32.5%) where we 
could observe some co-localization of CD2 and GM1. 
Figure 4. Lck is required for the 
translocation of CD2 into lipid rafts. A) 
Sucrose density centrifugation and 
immunoblotting with OX55 confirm the 
exclusion of most rat CD2 from the raft 
fractions of J.CaM1-CD2, an Lck-
deficient cell line stably expressing rat 
CD2. Immunoblots of Lck attest the lack 
of expression of Lck in these cells, and 
LAT immunoblots confirm that these cells 
display normal raft behavior. B-C) 
Analysis of co-capping of rat CD2 
molecules with lipid rafts in Jurkat E6.1-
CD2 and J.CaM1-CD2 cells. Rat CD2 
was labeled with OX34 followed by RAM-
Alexa Fluor 568, and the raft marker 
GM1 was detected by Cholera-toxin 
subunit B Alexa 488 conjugate. Cells 
were incubated at 37ºC for 15 minutes to 
induce capping. After fixation, cells were 
visualized by fluorescence microscopy 
(B). GM1 co-capped very clearly with 
CD2 in nearly 80% of E6.1-CD2 cells. By 
contrast, in J.CaM1-CD2 cells, co-
capping was less well-defined and 
detected in approximately 32.5% of cells, 
as assessed from three independent 
counts of different experiments (data 
shown as mean counts ± SE).  
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Our hypothesis that Lck couples CD2 to the rafts was further strengthened when 
J.CaM1-CD2 cells were reconstituted with Lck, and targeting of CD2 to the lipid rafts 
fractions, co-localizing with the re-expressed Lck, was by large restored (Fig. 5A). In order 
to determine whether a functional Lck kinase was required for addressing CD2 to the 
rafts, we transfected J.CaM1-CD2 cells with an Lck cDNA encoding a mutation at the 
ATP-binding site (K273A), and so referred to as Kinase Defective (KD). J.CaM1/Lck(KD)-
CD2 cells were lysed, subjected to sucrose gradients, SDS-PAGE and immunoblotting 
with OX55. As can be seen in the respective panels in Figure 5A, both Lck(KD) as well as 
rat CD2 still localize in lipid rafts, discarding the Lck activity as required for the lipid raft-
CD2 localization.  
It was apparent that the gross majority of rat CD2 molecules would localize with 
Lck when a physical interaction could be established, and that the site of co-localization 
were lipid rafts, as that is the membrane phase where Lck resides in Jurkat cell lines. We 
thus inquired whether CD2 would still localize in the rafts if Lck was excluded, and for this 
we used J.CaM1 cells reconstituted with an Lck mutant which has had cysteine 3 replaced 
by an alanine residue. Lck contains a double palmitoylation site at Cys3 and Cys5 [41], 
and in contrast to an Lck mutant C5A or the double mutant C3,5A, which are mainly or 
exclusive cytoplasmatic, respectively, Lck(C3A) confines to the plasma membrane. 
However, as can be seen in the lower panel of Figure 5A, it no longer addresses to the 
lipid raft fractions, neither does exogenous rat CD2 expressed in these cells, thus proving 
that CD2 homing to lipid rafts is dependent on a physical association with Lck.  
It did not become clear, however, whether in J.CaM1/Lck(C3A)-CD2 cells rat CD2  
associated with “soluble” phase Lck(C3A), and through this association was dragged out 
of lipid rafts, or whether it was free and kept out from the rafts by default, with the 
theoretical possibility of being recruited through the association of another raft resident 
molecule. We tested these hypothesis through the analysis of molecular associations of 
rat CD2, expressed in J.CaM1/Lck(WT)-CD2 as well as in J.CaM1/Lck(C3A)-CD2 cells, 
thus addressing the interaction with raft-resident Lck versus raft-excluded Lck molecules.  
Non-activated cells were lysed in Triton X-100 lysis buffer, Lck or CD2 were 
immunoprecipitated from the lysates, and immune complexes were subjected to in vitro 
kinase assays. CD2 immunoprecipitates from J.CaM1/Lck(C3A)-CD2 cells displayed very 
little kinase activity, when compared to CD2 immunoprecipitates from J.CaM1/Lck(WT)-
CD2 (Fig. 5B). Since raft-resident Lck(WT) and raft-excluded Lck(C3A) displayed 
comparable kinase activities and autophosphorylation efficiency, also indicating that no 
major differences on the activity of the kinase depend on its localization, this suggested 
that in non-activated cells the association between CD2 and Lck is preferentially held in 
the rafts, and that association in the “soluble” phase is much reduced. 
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Given that the T cell specific Src-like kinase Fyn has also been shown to contribute 
to some of the CD2-associated kinase activity, we tested whether Fyn could also 
associate with CD2 in J.CaM1/Lck(WT)-CD2 and J.CaM1/Lck(C3A)-CD2 cells. The 
primary CD2 immune complexes were disrupted by heat and SDS, and Fyn as well as Lck 
were re-precipitated. As can be seen from the lower panels of Figure 5B, both Lck and 
Fyn are clearly present in CD2 complexes from J.CaM1/Lck(WT)-CD2 cells, but absent 
from CD2 immunoprecipitates from J.CaM1/Lck(C3A)-CD2 cells, indicating that in non-
activated cells CD2 associates with both kinases mostly within lipid rafts. 
 
 
Figure 5. CD2 localization in lipid rafts is dependent on a physical association with Lck but 
independent of the kinase activity. A) J.CaM1-CD2 cells expressing either Lck(WT), Lck(KD), a 
kinase defective mutant carrying a mutation at the ATP binding site, or Lck(C3A), an Lck mutant 
which has cysteine 3 replaced by an alanine but still localizes to the plasma membrane were 
analyzed for CD2 rafts localization. Cell lysates were fractionated on sucrose gradients, separated 
by SDS-PAGE, and immunoblotted with CD2, Lck and LAT antibodies. As can be seen in the Lck 
detection, the mutation on cysteine 3, Lck(C3A), results in the nearly total exclusion of the kinase 
from the rafts, whereas Lck(WT) and Lck(KD) still confine to the rafts. CD2 partitioning in the 
different fractions follows the same pattern as Lck. B) J.CaM1/Lck(WT)-CD2 and 
J.CaM1/Lck(C3A)-CD2 cells were lysed and Lck and CD2 were immunoprecipitated. Immune 
complexes were subjected to kinase assays, run on SDS-PAGE and exposed to autoradiography. 
On lower panels, Lck and Fyn were reprecipitated from the original CD2 immunoprecipitations and 
exposed to autoradiography. IP, immunoprecipitation; Rep, reprecipitation.  
 
 
The traffic of CD2 in the membrane of rat T cells upon CD2 activation  
We established that rat CD2 localizes to lipid rafts dependently of its association 
with Lck and that within rafts also interacts with Fyn, both protein tyrosine kinases deeply 
involved in signal transduction in T cells. Thus, we investigated whether upon cell 
activation CD2 could shift through different membrane microenvironments, and what 
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would be the role of CD2 reallocation in the regulation of kinase activity in the different 
membrane phases.  
Splenocytes from 3-month old Wistar rats were stimulated through CD2 crosslinking for 15 
min at 37ºC, or left unstimulated, cells were lysed in Triton-based lysis buffer and lysates 
subjected to sucrose gradient. The different recovered fractions were analyzed for the 
presence of CD2, Lck and Fyn. In resting cells, the majority of CD2 molecules, but also of 
Lck, are outside lipid rafts, whereas virtually all Fyn resides in the rafts (Fig. 6A and B). 
Following CD2 stimulation, the proportion of Lck and Fyn in and outside rafts remained 
unchanged, however a significant fraction of CD2 was translocated to lipid rafts. 
Quantification of the immunoblots by densitometry indicates that the percentage of CD2 in 
the rafts increased over 4 fold, from 8 to 36% (Fig. 6B).   
In order to analyze the kinase activity associated with CD2 in the different 
fractions, we selected fraction 2 as representative of rafts, fraction 9 as a “soluble” 
fraction, and also a control fraction 6, where no CD2, Lck or Fyn are present (selected 
fractions are indicated by arrows on Fig. 6A). CD2 was immunoprecipitated from fractions 
2, 6 and 9, both from resting as well as from activated cells, and immune complexes 
subjected to in vitro kinase assays. Immune complexes of Lck were processed in parallel. 
As can be seen in Figure 6C, phosphoproteins of 55-60 kDa were present in CD2 immune 
complexes already in resting cells, and were better defined in the rafts than in the 
“soluble” fraction, with no signal in the control fraction 6. Upon cellular activation, 
increased phosphorylation of the CD2-associated 55-60 kDa proteins was detected in the 
rafts and the soluble fractions. These phosphoproteins corresponded mostly to 
phosphorylated Lck and also Fyn, as can be seen in the reprecipitations of the kinases 
from the original CD2 immunoprecipitates. 
Careful analysis of the kinase assays suggested that CD2 could precipitate more 
active Lck and Fyn from the rafts fraction than the “soluble” one. Whereas more Fyn is 
expected to associate with CD2 in the rafts, given that 99% of Fyn is raft-resident, the fact 
that more active Lck was also co-precipitated with CD2 from the rafts fraction clearly 
confirms that the association of CD2 and Lck is favored within lipid rafts, despite the fact 
that the majority of CD2 and Lck are not resident in lipid rafts, neither in resting nor in 
activated cells.  
In resting cells, the kinase activity of Lck reflects the proportion of the protein in 
and out of rafts, however there is a clear enhancement of the activity of raft-based Lck 
upon CD2 stimulation that does not require any translocation of Lck to the rafts (Fig. 6D, 
compare to Fig. 6A and B). Interestingly, Fyn, which is not known for associating 
specifically to Lck, co-precipitates with Lck only in rafts, and displays higher activity 
following CD2 stimulation, as can be seen in the lower panel of Figure 6D. This suggests 
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that Lck and Fyn may interact in lipid rafts of activated cells, and that this association may 
be mediated by CD2. 
 
 
Figure 6. Rat CD2 redistribution and molecular associations upon CD2 stimulation. A) Rat 
splenocytes were stimulated through CD2 for 15 min at 37ºC, or left unstimulated. Lysates were 
fractioned by sucrose gradient centrifugation and the recovered fractions were analyzed for the 
presence of CD2, Lck and Fyn. B) Densitometric analysis of the immunoblots illustrated in A. Table 
shows densitometry values of CD2, Lck and Fyn subcellular distributions, representing the 
proportion of the total amount of each molecule detected in the raft and soluble fractions. C-D) In 
vitro kinase assays were performed in immune complexes of CD2 (C), and Lck (D), prepared from 
the fractions indicated by arrows on A. Following SDS-PAGE, phosphorylated products were 
visualized by exposure of dried gels at -70ºC to CL-Xposure films. Immune complexes were 
disrupted, and Lck and Fyn were reprecipitated, subjected to SDS-PAGE and exposed to 
autoradiography. Ip, immunoprecipitation; Rep, reprecipitation. 
 
DISCUSSION 
It is increasingly clear that lipid rafts play an important role in T cell signaling, since 
the assembly of the TCR signaling machinery takes place within this membrane micro-
environment enriched in glycosphingolipids, sphingomyelin and cholesterol [23, 42, 43]. 
Moreover, crosslinking the TCR with accessory proteins such as CD2, CD5, CD9 and 
CD28 readily increases the association of the TCR with lipid rafts [24-26]. The 
conventional view is that the TCR and other signaling molecules translocate to these 
platforms that facilitate signal transduction mechanisms. However, given that MHC-
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engaging T cell receptors that originate activation and signaling, together with accessory 
molecules binding to the respective counter receptors, are polarized towards the sites of 
cell contact with antigen presenting cells, a fairer assessment is that lipid rafts coalesce 
into the interface of TCR-antigen recognition [44, 45]. 
Therefore, rather than considering individual TCRs or other signaling molecules 
being cumulatively trapped by the raft, depending on certain characteristics such as 
intrinsic affinity for the raft lipids or interactions with raft-peripheral proteins, a TCR-
centered perspective should ponder instead how the whole of the raft is captured at the 
sites of antigen recognition. There are currently many open theoretical possibilities, but a 
simple one advances that lipid rafts need not be fairly large or complex structures: 
homotypic FRET studies have shown that some individual rafts can form high density 
clusters of nanometer size (4–5 nm), containing as few as 4 GPI-anchored molecules [46]. 
Moreover, Douglass and Vale showed that the raft associated molecule LAT, as well as 
Lck, had a much larger diffusion coefficient than non-raft CD2, suggesting that lipid rafts 
can be highly mobile and diffuse to the TCR-activation spots [47]. They also suggest that, 
as Lck and LAT change from a highly mobile to a motionless state when they encounter a 
signaling cluster, it is possible that protein-protein interactions, rather than any sort of raft-
addressing labels, can play a major role in establishing specific interactions between raft 
and non-raft proteins. In this paper we demonstrate that the association of rat CD2 with 
membrane lipid rafts is in fact mostly determined by the physical interaction established 
with the protein tyrosine kinase Lck.  
CD2 has been shown to associate to both Lck and Fyn protein tyrosine kinases 
[14, 15], and deletion of the cytoplasmic tail eliminates these interactions and abolishes 
CD2-mediated signaling [12, 48]. However, given that our results, using several mutant 
molecules of CD2 and Lck and different cells lines, show an absolute correlation between 
the capacity of rat CD2 to interact with raft-resident Lck and to be found in lipid rafts, we 
can conclude that it is Lck, and not Fyn, that retains CD2 at the rafts. It is however unlikely 
that Lck is responsible for the actual co-transport of CD2 to the rafts. There is little 
evidence that in non-activated cells CD2 and Lck interact outside lipid rafts, both in 
experiments where mutated Lck was excluded from the rafts (Fig. 5B), as well as from the 
analysis of associations of the different fractions of physiological cells (Fig. 6). Moreover, 
whereas there is an increase of 4.5 fold of CD2 into the rafts upon CD2-induced 
activation, there is no net shift of Lck to the rafts (Fig. 6 A and B). Furthermore, Yang and 
Reinherz [28] have shown that the recruitment of activated CD2 to the rafts does not 
require the cytoplasmic tail, and hence, any association with Src-like kinases. Therefore, it 
is plausible that following TCR-antigen recognition and CD2 engagement to its ligand and 
upon an encounter with a lipid raft, transitory interactions mediated through the CD2 
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ectodomain with a raft resident receptor may allow for a transient overlap of the raft with 
CD2 complexes and induce raft-resident Lck to dock to the cytoplasmic domain of CD2.  
Interestingly, when in the rafts, CD2 seems to bind equally well to Fyn and to Lck, 
and upon activation, more phosphorylated Lck and Fyn can be recovered from CD2 
immune complexes (Fig. 6C). This may simply reflect the increment of CD2 in rafts with 
the consequent increased association of CD2 with the kinases, although an enhancement 
in the activity of the kinases may have to be considered. Regardless of that, CD2 
stimulation clearly induces a functional association between Lck and Fyn (Fig. 6 D). Lck 
and Fyn bind to non-overlapping sequences of CD2 [14, 29], but other CD2 partners 
compete for these sequences. The CD2 proline-rich motif PPPPGHR is complexed with 
the GYF domain of CD2BP2, but only outside lipid rafts, as upon translocation, the SH3 
domain of Fyn displaces CD2BP2 [29]. The penultimate CD2 proline motif PPLPRPR has 
been reported to associate to the SH3 domains of both Lck and CD2BP1 [14, 49], and so 
it is possible that the association between CD2 and Lck may be similarly regulated and 
confined to lipid rafts as well. As the amounts of Lck and Fyn, in and outside the rafts, 
remain unchanged following activation, the increase of the phospho-Fyn signal co-
precipitated with Lck (Fig. 6 D – bottom panel) has to be due to an increase in the amount 
of Fyn associating with Lck, or to the phosphorylation of Fyn induced by Lck [22]. 
Conversely, the augmented Lck signal in the raft fraction of activated cells can be caused 
by an increase in the phosphorylation of Lck, possibly catalyzed by Fyn (Fig. 6 D – middle 
panel). Therefore, a central role of CD2 in the reorganization of lipid rafts upon cellular 
activation could be the facilitation of the association between Lck and Fyn. 
What can then be the role of the two membrane proximal cysteine residues? The 
physical segregation in different membrane phases could be easily overcome if proteins, 
such as rat CD2, should have a lipid raft insertion motif. For example, CD8 can exist as a 
CD8αβ heterodimer, with the β subunit facilitating raft-association and the α unit providing 
an extracellular binding site for MHC class I and an intracellular motif that binds to Lck 
[50]. Since CD8αβ, and not the CD8αα homodimer, partitions into rafts, it can induce the 
association with lipid rafts of a significant fraction of the T cell receptor. It is possible that 
rat CD2 may have a similar role, such as linking cytoskeleton orientation with lipid raft 
organization. However, we were not able to prove that the membrane proximal cysteine 
residues are indeed palmitoylated, although the level of association of mutant CD2 with 
the rafts tends to be lower than the wild type molecule. It is also possible that CD2 may 
establish protein-protein interaction with yet other raft-resident molecules to strengthen 
raft localization. The determination of the function of these two amino acid residues will no 
doubt require further investigation. 
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An immune response requires numerous receptor-mediated signals to be delivered 
to T cells and this coordinated activation in response to foreign antigen will guarantee 
antigen-specific T cell clonal development and differentiation. The specificity of the 
response lies on the recognition of the foreign peptide in the context of an MHC molecule 
by the T cell receptor, however, the modulation and fine-tuning of the T cell receptor 
signals, hence, the specific developmental program and cellular behaviour, is achieved by 
the integration of signals provided by accessory receptor-ligand interactions. The intricate 
assimilation of all these signals still remains a daunting challenge that needs to be 
clarified before any possible medical benefits from predicting T cell behaviour can be 
anticipated. Progress in the clarification of this area of research has been accomplished 
by studies on accessory receptors behaviour and on the internal molecular interactions 
triggered by these numerous receptors engaged during T cell activation, such as the ones 
described in this thesis. 
CD6, a 105-130 kDa type I cell surface glycoprotein, is one of these accessory 
receptors, whose expression is largely restricted to thymocytes and mature T lymphocytes 
[1]. Although several studies point towards a role for CD6 as a costimulatory molecule in T 
cell activation, given that antibody-mediated CD6 engagement can potentiate proliferative 
T cell responses [2-4], its exact function has not yet been elucidated. In this thesis we 
present data showing that CD6 can exert its function via association with CD5, inducing 
CD5 tyrosine phosphorylation, also implying CD6 in the regulation of CD5 function. The 
long cytoplasmic domain of CD6 is well fitted for signal transduction as, apart from 
numerous tyrosine residues, it contains two well-conserved proline-rich sequences, 
potential binding sites for SH3-containing proteins [5, 6]. 
 We have demonstrated that the rat homologue of CD6 is able to associate with 
protein tyrosine kinases of different families, namely Lck and Fyn from the Src-family, 
ZAP-70 of the Syk-family and the Tec-family kinase Itk, and it is therefore reasonable to 
envisage that the ability of CD6 to induce CD5 phosphorylation derives from the CD6-
associated kinases. We have shown that Lck together with Itk is the most efficient 
combination for the phosphorylation of an exogenous CD5 peptide containing the ITAM-
like motif. Since we have found that Itk alone was unable to phosphorylate a CD5 peptide 
and that Lck was able to phosphorylate Itk, we propose that rather than having a 
synergistic effect, the kinases regulate each others activities. Lck phosphorylates the 
activation loop tyrosine of the Itk kinase domain and activates Itk kinase activity by 
inducing autophosphorylation events [7] which probably renders Itk capable of regulating 
the activity of Lck. These suggestion is in conformity with a more downstream role of Itk 
observed in T cell activation [8]. However, until now, there are no established functional 
roles for these interactions. 
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The immune system has always been an attractive model to study the complexity 
of biological regulation, as it is one system that has intricate developmental pathways and 
demands well fine-tuned responses. In such a system where cellular functions are 
regulated in a tissue, temporal or stimuli-dependent manner the generation of alternative 
mRNA transcripts and proteins encoded from a single gene may have an extreme 
importance. In fact, a mechanism that contributes to one further level of regulation of 
immune responses is alternative splicing. This is a crucial and ubiquitous mechanism for 
generating protein diversity and regulating protein expression which is widespread and 
has particular prevalence in the immune system. Several immunologically relevant genes 
have been found to undergo alternative splicing; however, understanding how this large 
number of proteins and protein isoforms regulate the function of the immune system is still 
a crucial challenge. 
One of the molecules that has long been known to be alternatively spliced is CD6; 
different CD6 isoforms, both from human and mouse, have been described arising from 
alternative splicing of exons coding for sequences within the cytoplasmic domain [5, 9-11], 
but until now no specific physiological function has been attributed to any of these 
isoforms. Cloning of the rat homologue of CD6 [12] allowed us to notice that an additional 
isoform, CD6∆d3, resulting from alternative splicing of an exon coding for the third SRCR 
domain, the CD166-binding domain, was expressed on different tissues of lymphoid origin 
(Castro et al. 2007, unpublished results). Subsequently, we have identified in human T 
lineage cells four novel CD6 extracellular isoforms that arise from alternative splicing. The 
work performed with these isoforms, and presented in this thesis, led us to the 
demonstration of a rare example of a functional role of an alternatively spliced isoform, the 
CD6∆d3 isoform. 
The concentration of CD6 at the immunological synapse depends on the 
alternative splicing regulated expression of SRCR domain 3, the CD166-binding domain. 
Furthermore, we have shown that upon human T lymphocyte stimulation, the expression 
of full-length CD6 is partially down-regulated and there is a switch to the expression of the 
shorter CD6∆d3 isoform which without doubt represents a product of activation. Another 
molecule of the immune system that has a similar type of regulation by alternative splicing 
is CD45 [13, 14], however the CD6∆d3 isoform described in this thesis illustrates a more 
evident function as it controls the interaction with the ligand. Upon TCR stimulation, 
instructions for the production of CD6∆d3 are generated and as a consequence the 
activity of CD6 at the immunological synapse is reduced along with a possible change of 
behaviour.  
The preliminary results presented here on Ca2+ signals and tyrosine 
phosphorylation at the synapse after blocking CD6-CD166 binding or crosslinking studies 
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together with our previous unpublished results from rat CD6, where we show that the 
expression of CD6 but not its localization in terms of the synapse can down-modulate 
Ca2+ signals, led us to hypothesize that although CD6 expression may result in a general 
inhibitory outcome, the engagement of CD6 and consequent accumulation at the synapse 
does not preclude the possibility of a positive co-stimulatory role for CD6.  
 
The role of CD6 as a modulator of antigen-induced signals still waits clarification 
as it may be dependent on interactions with other surface molecules, like has been 
observed for CD2. This surface glycoprotein belongs to the immunoglobulin superfamily 
and is expressed on all T lineage and natural killer cells [15]. Stimulation of CD2, either 
alone, or in synergistic combination with the T cell receptor, has long been known to 
transduce mitogenic stimulation in T cells [16-18]. However, as CD2 also interacts with 
CD5 [19], positive signaling of CD2 can potentiate the CD5 inhibitory effect in thymocyte 
selection and T cell activation, as demonstrated in vitro [20, 21] or in vivo, using the 
CD2/CD5 double-knockout mouse [21]. The stimulatory properties of CD2 can be 
attributable to its cytoplasmic domain as clearly demonstrated by structural and functional 
studies on human and rat CD2 [17, 22-24] and consequent association with the tyrosine 
kinases Lck and Fyn, [25-27]. Through these associations it is connected to downstream 
signaling pathways. 
The work presented in this thesis further establishes another role for the 
association of CD2 with Lck, since we have found, using several CD2 and Lck mutants 
and different cell lines, that the interaction of CD2 with Lck is required for the localization 
of rat CD2 in lipid rafts. There are still many speculative models for the function and 
behavior of lipid rafts, but current knowledge supports a TCR-centered perspective, where 
the small and highly dynamic rafts and raft-associated proteins [28, 29] are continuously 
moving until they encounter a signaling cluster and the proper protein-protein interactions 
are created. Our observations also strengthens this view, as we demonstrate that the 
localization of rat CD2 within lipid rafts is mostly dictated by the physical interaction of 
CD2 with Lck, rather then by any sort of raft-targeting signal such as the two membrane-
proximal cysteines. Moreover, our results indicate that Lck and CD2 do not interact 
outside of lipid rafts in non-activated cells, this together with the fact that human CD2 does 
not require the cytoplasmic tail to be recruited to rafts upon activation [30], led us to the 
postulation of the following model: upon TCR and CD2 engagement, interaction of CD2 
extracellular domain with a raft-resident receptor may allow CD2 cytoplasmic tail to 
transiently interact with raft-resident Lck and therefore become captured to the rafts. 
When in the rafts, CD2 associates equally well with Lck and Fyn. Additionally, we 
observed for the first time a functional interaction between Lck and Fyn in lipid rafts upon 
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CD2 crosslinking, suggesting that this association may be mediated by CD2. Therefore, 
the interactions of CD2 with Lck and Fyn and consequently the interaction between both 
kinases may be favored in lipid rafts. Consistently, CD2-associated molecules, such as 
CD2BP2, compete with the SH3 domain of Fyn but only outside rafts [31], and it is 
possible that another partner, CD2BP1, may also compete with Lck [26, 32] within rafts. 
Moreover, as activation of Fyn in lipid rafts has been shown to be achieved by Lck [33] 
and that phosphorylation of Lck may possibly be catalyzed by Fyn, CD2-mediated 
interaction of both kinases may act to boost kinase activity in lipid rafts. 
Further studies should aim at questions that remain regarding the role of the two 
membrane proximal cysteines, that despite the fact that we were not able to detect 
palmitoylation of amino acid residues, when mutated induced a slightly lowered level of 
association of the mutant CD2 with the rafts. Progress towards the understanding of the 
basic mechanisms that control the integration of complex processes such as TCR 
signaling, immunological synapse formation and rafts dynamics will only be achieved 
through the use of appropriate tools to characterize the behaviour of as many molecules 
as possible.  
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